[{"conditions":["Head and Neck Cancer"],"countries":["Canada","United States"],"enrollment":16,"has_results":false,"interventions":["DRUG: imatinib mesylate"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT00045669","official_title":"A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas","phases":["PHASE2"],"primary_completion":"2004-01","sponsor":"University Health Network, Toronto","start":"2002-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Imatinib Mesylate in Treating Patients With Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00045669"},{"conditions":["Adenoid Cystic Carcinoma","Squamous Cell Carcinoma","Sinonasal Carcinoma","Sinonasal Undifferentiated Carcinoma","Mucoepidermoid Carcinoma","Schneiderian Carcinoma","Myoepithelial Carcinoma","Esthesioneuroblastoma","Melanoma"],"countries":["United States"],"enrollment":45,"has_results":false,"interventions":["RADIATION: Proton radiation therapy","RADIATION: Intensity-modulated radiotherapy"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT01586767","official_title":"A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy","phases":["NA"],"primary_completion":"2022-10-17","sponsor":"Massachusetts General Hospital","start":"2011-07-12","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy","url":"https://clinicaltrials.gov/study/NCT01586767"},{"conditions":["Cancer of Breast"],"countries":["United States"],"enrollment":58,"has_results":true,"interventions":["DRUG: Rapamycin"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT02642094","official_title":"Aging Mammary Stem Cells and Breast Cancer Prevention","phases":["PHASE2"],"primary_completion":"2022-03-01","sponsor":"LuZhe Sun","start":"2016-07","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Aging Mammary Stem Cells and Breast Cancer Prevention","url":"https://clinicaltrials.gov/study/NCT02642094"},{"conditions":["Septic Shock"],"countries":[],"enrollment":26,"has_results":false,"interventions":["OTHER: Local cerebral oxygen saturation"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT02706379","official_title":"The Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain in Septic Shock Patients","phases":["NA"],"primary_completion":"2016-04","sponsor":"Southeast University, China","start":"2015-06","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain","url":"https://clinicaltrials.gov/study/NCT02706379"},{"conditions":["Salivary Gland Cancers"],"countries":["Italy"],"enrollment":26,"has_results":false,"interventions":["DRUG: Axitinib"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT02857712","official_title":"Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract","phases":["PHASE2"],"primary_completion":"2018-10","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2014-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14","url":"https://clinicaltrials.gov/study/NCT02857712"},{"conditions":["Ewing Sarcoma","Myxoid Liposarcoma","Sarcoma,Soft Tissue","Desmoplastic Small Round Cell Tumor","Extraskeletal Myxoid Chondrosarcoma","Angiomatoid Fibrous Histiocytoma","Clear Cell Sarcoma","Primary Pulmonary Myxoid Sarcoma","Myoepithelial Tumor","Sclerosing Epithelioid Fibrosarcoma","Fibromyxoid Tumor"],"countries":["United States"],"enrollment":50,"has_results":false,"interventions":["DRUG: Seclidemstat","DRUG: Cyclophosphamide","DRUG: Topotecan"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT03600649","official_title":"Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas","phases":["PHASE1"],"primary_completion":"2025-09","sponsor":"Salarius Pharmaceuticals, LLC","start":"2018-06-04","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","url":"https://clinicaltrials.gov/study/NCT03600649"},{"conditions":["Parotid Neoplasm","Parotid Cancer"],"countries":["Italy"],"enrollment":100,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Multiparametric Magnetic Resonance Imaging","DIAGNOSTIC_TEST: Fine Needle Aspiration Cytology","DIAGNOSTIC_TEST: Clinical Evaluation","DIAGNOSTIC_TEST: Final Histopathological Diagnosis"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT03849482","official_title":"Accuracy of Multiparametric Magnetic Resonance Imaging Versus Fine Needle Aspiration Cytology in the Preoperative Work-Up of Parotid Gland Neoplasms","phases":[],"primary_completion":"2021-12-31","sponsor":"Davide Di Santo","start":"2019-01-24","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Multiparametric Magnetic Resonance Imaging Versus Fine Needle Aspiration Cytology for Parotid Gland Neoplasms","url":"https://clinicaltrials.gov/study/NCT03849482"},{"conditions":["Epithelioid Sarcoma (Ex-US Only)","Spindle Cell Sarcoma","Sinonasal Carcinoma","Small Cell Carcinoma of the Ovary Hypercalcemic Type","Thoracic Sarcoma","Poorly Differentiated Chordoma","ATRT","Malignant Rhabdoid Tumor of Kidney","Malignant Rhabdoid Tumor of Ovary","Malignant Rhabdoid Tumor","Myxoid Spindle Cell Sarcoma","Epithelioid Malignant Peripheral Nerve Sheath Tumor","Chondrosarcoma","Renal Cell Carcinoma","Myoepithelial Carcinoma","Synovial Sarcoma","Renal Medullary Carcinoma","Malignant Mesothelioma","Desmoplastic Small Round Cell Tumor (DSRCT)","Intramedullary Spinal Cord Schwannomatosis"],"countries":[],"enrollment":null,"has_results":false,"interventions":["DRUG: Tazemetostat"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT03874455","official_title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","phases":[],"primary_completion":"","sponsor":"Epizyme, Inc.","start":"","status":"NO_LONGER_AVAILABLE","study_type":"EXPANDED_ACCESS","title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03874455"},{"conditions":["Ewing Sarcoma","Myxoid Liposarcoma","Desmoplastic Small Round Cell Tumor","Extraskeletal Myxoid Chondrosarcoma","Angiomatoid Fibrous Histiocytoma","Clear Cell Sarcoma","Myoepithelial Tumor","Low Grade Fibromyxoid Sarcoma","Sclerosing Epithelioid Fibrosarcoma"],"countries":["United States"],"enrollment":10,"has_results":false,"interventions":["DRUG: Seclidemstat"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT05266196","official_title":"A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)","phases":["PHASE1","PHASE2"],"primary_completion":"2025-12","sponsor":"Salarius Pharmaceuticals, LLC","start":"2022-01-15","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)","url":"https://clinicaltrials.gov/study/NCT05266196"},{"conditions":["Synovial Sarcoma","Soft Tissue Sarcoma"],"countries":["United States"],"enrollment":49,"has_results":false,"interventions":["DRUG: CFT8634"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT05355753","official_title":"A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors","phases":["PHASE1"],"primary_completion":"2023-12-19","sponsor":"C4 Therapeutics, Inc.","start":"2022-03-25","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors","url":"https://clinicaltrials.gov/study/NCT05355753"},{"conditions":["Adipocytic Neoplasm","Liposarcoma","Atypical Fibroxanthoma","Angiomatoid Fibrous Histiocytoma","Fibrosarcoma NOS","Myxofibrosarcoma","Angiosarcoma","Osteosarcoma, Extraskeletal","Dedifferentiated Liposarcoma","Myxoid Liposarcoma","Pleomorphic Liposarcoma","Myxoid Pleomorphic Liposarcoma","Low Grade Fibromyxoid Sarcoma","Sclerosing Epithelioid Fibrosarcoma","Malignant Tenosynovial Giant Cell Tumor of Soft Tissue","Epithelioid Hemangioendothelioma","Glomus Tumor","Inflammatory Leiomyosarcoma","Leiomyosarcoma","Ossifying Fibromyxoid Tumor, Malignant","Myoepithelioma","Synovial Sarcoma","Epithelioid Sarcoma","Perineurioma, Malignant","Clear Cell Sarcoma","Extraskeletal Myxoid Chondrosarcoma","Granular Cell Tumor, Malignant","Melanotic Malignant Nerve Sheath Tumor","Malignant Peripheral Nerve Sheath Tumor","Perivascular Epithelioid Tumor, Malignant","Intimal Sarcoma","Myoepithelial Carcinoma","Undifferentiated Sarcoma","Pleomorphic Sarcoma, Undifferentiated","Round Cell Sarcoma, Undifferentiated","NTRK-Rearranged Spindle Cell Neoplasm","Phosphaturic Mesenchymal Tumor, Malignant","Round Cell Sarcoma","Well Differentiated Liposarcoma","Giant Cell Tumor of Soft Parts NOS","Low Grade Myofibroblastic Sarcoma","Dermatofibrosarcoma Protuberans, Fibrosarcomatous"],"countries":["United States"],"enrollment":139,"has_results":false,"interventions":["PROCEDURE: Surgical resection","RADIATION: Proton beam radiation therapy","DRUG: Pazopanib","DRUG: Ifosfamide","DRUG: Doxorubicin","DRUG: Selinexor"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT06239272","official_title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","phases":["PHASE1","PHASE2"],"primary_completion":"2034-06","sponsor":"St. Jude Children's Research Hospital","start":"2024-03-27","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","url":"https://clinicaltrials.gov/study/NCT06239272"},{"conditions":["Myoepithelioma"],"countries":["Italy"],"enrollment":33,"has_results":false,"interventions":["OTHER: Clinical data review"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT06244420","official_title":"Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis","phases":[],"primary_completion":"2024-12-31","sponsor":"Istituto Ortopedico Rizzoli","start":"2024-01-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis","url":"https://clinicaltrials.gov/study/NCT06244420"},{"conditions":["Neuroblastoma","Rhabdomyosarcoma","Synovial Sarcoma","Peripheral Nerve Sheath Tumors","Clear Cell Sarcoma","Alveolar Soft Part Sarcoma","Desmoplastic Small Round Cell Tumor","Chordoma","Rhabdoid Tumor","Epithelioid Sarcoma","Myoepithelial Tumor","Osteosarcoma","Ewing Sarcoma","Wilms Tumor"],"countries":["United States"],"enrollment":27,"has_results":false,"interventions":["DEVICE: Miltenyi CliniMACS Prodigy ® system","DRUG: Zoledronic acid"],"names_myoepithelial":true,"names_skin_adnexal":false,"nct_id":"NCT06625190","official_title":"Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors","phases":["PHASE1","PHASE2"],"primary_completion":"2030-02","sponsor":"University of Florida","start":"2026-02-11","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06625190"},{"conditions":["Otorhinolaryngologic Disease","Otorhinolaryngologic Neoplasm","Pharyngeal Neoplasm","Polymyositis","Speech Disorder"],"countries":["United States"],"enrollment":570,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00001167","official_title":"Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx","phases":[],"primary_completion":"","sponsor":"National Institutes of Health Clinical Center (CC)","start":"1979-08","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Ultrasound Evaluation of Tongue Movements in Speech and Swallowing","url":"https://clinicaltrials.gov/study/NCT00001167"},{"conditions":["Radiation Injuries","Xerostomia"],"countries":["United States"],"enrollment":20,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00001523","official_title":"Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation","phases":[],"primary_completion":"","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","start":"1996-05","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation","url":"https://clinicaltrials.gov/study/NCT00001523"},{"conditions":["Lymphoma","Salivary Gland Disease","Sjogren's Syndrome","Xerostomia"],"countries":["United States"],"enrollment":560,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00001852","official_title":"Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome","phases":[],"primary_completion":"","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","start":"1999-04-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome","url":"https://clinicaltrials.gov/study/NCT00001852"},{"conditions":["Head and Neck Cancer"],"countries":["South Africa","United States"],"enrollment":32,"has_results":false,"interventions":["DRUG: paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00002632","official_title":"PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES","phases":["PHASE2"],"primary_completion":"2002-05","sponsor":"Eastern Cooperative Oncology Group","start":"1995-05-30","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00002632"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["DRUG: cisplatin","DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003182","official_title":"A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma)","phases":["PHASE1","PHASE2"],"primary_completion":"","sponsor":"Hope Cancer Institute, Inc.","start":"1997-03","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00003182"},{"conditions":["Drug/Agent Toxicity by Tissue/Organ","Head and Neck Cancer","Radiation Toxicity"],"countries":["United States"],"enrollment":46,"has_results":false,"interventions":["DRUG: amifostine trihydrate","DRUG: cisplatin","DRUG: paclitaxel","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003251","official_title":"A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer","phases":["PHASE1","PHASE2"],"primary_completion":"","sponsor":"University of Illinois Chicago","start":"1997-12","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00003251"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":22,"has_results":false,"interventions":["DRUG: cisplatin","DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003264","official_title":"Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2002-02","sponsor":"Fox Chase Cancer Center","start":"1997-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00003264"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":7,"has_results":false,"interventions":["DRUG: Antineoplaston therapy (Atengenal + Astugenal)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003489","official_title":"Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"1998-04-03","sponsor":"Burzynski Research Institute","start":"1996-05-06","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00003489"},{"conditions":["Bladder Cancer","Breast Cancer","Head and Neck Cancer","Lung Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["Canada","Puerto Rico","United States"],"enrollment":109,"has_results":false,"interventions":["DRUG: docetaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003565","official_title":"A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients","phases":["PHASE2"],"primary_completion":"2006-01","sponsor":"Alliance for Clinical Trials in Oncology","start":"1998-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Docetaxel in Treating Patients With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00003565"},{"conditions":["Head and Neck Cancer","Lung Cancer","Neurotoxicity","Ovarian Cancer"],"countries":["United States"],"enrollment":2,"has_results":false,"interventions":["DRUG: cisplatin","DRUG: dimesna","DRUG: paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003569","official_title":"Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol","phases":[],"primary_completion":"2003-06","sponsor":"Roswell Park Cancer Institute","start":"1998-03","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel","url":"https://clinicaltrials.gov/study/NCT00003569"},{"conditions":["Head and Neck Cancer"],"countries":["South Africa","United States"],"enrollment":230,"has_results":false,"interventions":["DRUG: methotrexate","DRUG: paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003592","official_title":"Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE3"],"primary_completion":"2000-08","sponsor":"Eastern Cooperative Oncology Group","start":"1999-04-22","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00003592"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":16,"has_results":false,"interventions":["DRUG: gemcitabine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003744","official_title":"Gemcitabine for Advanced Salivary Cancer: A Phase II Study","phases":["PHASE2"],"primary_completion":"2004-05","sponsor":"Dana-Farber Cancer Institute","start":"1998-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery","url":"https://clinicaltrials.gov/study/NCT00003744"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":75,"has_results":false,"interventions":["DRUG: temoporfin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00003856","official_title":"A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy","phases":["PHASE2"],"primary_completion":"","sponsor":"Quintiles, Inc.","start":"1998-10","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT00003856"},{"conditions":["Bladder Cancer","Breast Cancer","Colorectal Cancer","Gastric Cancer","Head and Neck Cancer","Kidney Cancer","Leukemia","Lung Cancer","Melanoma (Skin)","Ovarian Cancer","Prostate Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: tanespimycin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004065","official_title":"A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol","phases":["PHASE1"],"primary_completion":"2005-03","sponsor":"Memorial Sloan Kettering Cancer Center","start":"1999-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer","url":"https://clinicaltrials.gov/study/NCT00004065"},{"conditions":["Advanced Adult Primary Liver Cancer","Anaplastic Thyroid Cancer","Bone Metastases","Carcinoma of the Appendix","Distal Urethral Cancer","Fallopian Tube Cancer","Gastrinoma","Glucagonoma","Inflammatory Breast Cancer","Insulinoma","Liver Metastases","Localized Unresectable Adult Primary Liver Cancer","Lung Metastases","Male Breast Cancer","Malignant Pericardial Effusion","Malignant Pleural Effusion","Metastatic Gastrointestinal Carcinoid Tumor","Metastatic Parathyroid Cancer","Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter","Newly Diagnosed Carcinoma of Unknown Primary","Occult Non-small Cell Lung Cancer","Pancreatic Polypeptide Tumor","Primary Peritoneal Cavity Cancer","Proximal Urethral Cancer","Pulmonary Carcinoid Tumor","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adrenocortical Carcinoma","Recurrent Adult Primary Liver Cancer","Recurrent Anal Cancer","Recurrent Bladder Cancer","Recurrent Breast Cancer","Recurrent Carcinoma of Unknown Primary","Recurrent Cervical Cancer","Recurrent Colon Cancer","Recurrent Endometrial Carcinoma","Recurrent Esophageal Cancer","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer","Recurrent Gastric Cancer","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Islet Cell Carcinoma","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Pancreatic Cancer","Recurrent Parathyroid Cancer","Recurrent Prostate Cancer","Recurrent Rectal Cancer","Recurrent Renal Cell Cancer","Recurrent Salivary Gland Cancer","Recurrent Small Intestine Cancer","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Thyroid Cancer","Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter","Recurrent Urethral Cancer","Recurrent Vaginal Cancer","Recurrent Vulvar Cancer","Skin Metastases","Small Intestine Adenocarcinoma","Somatostatinoma","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Adrenocortical Carcinoma","Stage III Bladder Cancer","Stage III Cervical Cancer","Stage III Colon Cancer","Stage III Endometrial Carcinoma","Stage III Esophageal Cancer","Stage III Follicular Thyroid Cancer","Stage III Gastric Cancer","Stage III Malignant Testicular Germ Cell Tumor","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Ovarian Epithelial Cancer","Stage III Pancreatic Cancer","Stage III Papillary Thyroid Cancer","Stage III Prostate Cancer","Stage III Rectal Cancer","Stage III Renal Cell Cancer","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Vaginal Cancer","Stage III Vulvar Cancer","Stage IIIA Anal Cancer","Stage IIIA Breast Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Anal Cancer","Stage IIIB Breast Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Adrenocortical Carcinoma","Stage IV Anal Cancer","Stage IV Bladder Cancer","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Endometrial Carcinoma","Stage IV Esophageal Cancer","Stage IV Follicular Thyroid Cancer","Stage IV Gastric Cancer","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Pancreatic Cancer","Stage IV Papillary Thyroid Cancer","Stage IV Prostate Cancer","Stage IV Rectal Cancer","Stage IV Renal Cell Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IVA Cervical Cancer","Stage IVA Vaginal Cancer","Stage IVB Cervical Cancer","Stage IVB Vaginal Cancer","Stage IVB Vulvar Cancer","Thyroid Gland Medullary Carcinoma","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer","Urethral Cancer Associated With Invasive Bladder Cancer","WDHA Syndrome"],"countries":["United States"],"enrollment":15,"has_results":false,"interventions":["BIOLOGICAL: recombinant interleukin-12","BIOLOGICAL: ABI-007/carboplatin/trastuzumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004074","official_title":"A Phase I Trial of Herceptin and Interleukin-12","phases":["PHASE1"],"primary_completion":"2009-02","sponsor":"National Cancer Institute (NCI)","start":"1999-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu","url":"https://clinicaltrials.gov/study/NCT00004074"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":14,"has_results":false,"interventions":["DRUG: Trastuzumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004163","official_title":"Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas","phases":["PHASE2"],"primary_completion":"2001-09","sponsor":"Dana-Farber Cancer Institute","start":"1999-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00004163"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: therapeutic autologous lymphocytes"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004178","official_title":"Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma","phases":["PHASE1"],"primary_completion":"2000-12","sponsor":"Roger Williams Medical Center","start":"1998-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gene Therapy in Treating Patients With Cancer","url":"https://clinicaltrials.gov/study/NCT00004178"},{"conditions":["Breast Cancer","Cervical Cancer","Head and Neck Cancer","Prostate Cancer","Sarcoma"],"countries":["Canada"],"enrollment":null,"has_results":false,"interventions":["DRUG: EF5","OTHER: flow cytometry","OTHER: fluorescent antibody technique","OTHER: immunohistochemistry staining method","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004261","official_title":"A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas","phases":["PHASE1"],"primary_completion":"2002-06","sponsor":"University Health Network, Toronto","start":"1999-12","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma","url":"https://clinicaltrials.gov/study/NCT00004261"},{"conditions":["Breast Cancer","Colorectal Cancer","Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Gastric Cancer","Head and Neck Cancer","Liver Cancer","Lung Cancer","Metastatic Cancer","Ovarian Cancer","Pancreatic Cancer","Testicular Germ Cell Tumor"],"countries":["United States"],"enrollment":24,"has_results":false,"interventions":["BIOLOGICAL: CEA RNA-pulsed DC cancer vaccine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00004604","official_title":"A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen","phases":["PHASE1"],"primary_completion":"2001-06","sponsor":"Duke University","start":"1997-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Biological Therapy in Treating Patients With Metastatic Cancer","url":"https://clinicaltrials.gov/study/NCT00004604"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":12,"has_results":false,"interventions":["DRUG: paclitaxel","DRUG: semaxanib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00005647","official_title":"A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck","phases":["PHASE1"],"primary_completion":"2002-12","sponsor":"Case Comprehensive Cancer Center","start":"2000-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00005647"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":24,"has_results":false,"interventions":["BIOLOGICAL: trastuzumab","DRUG: tipifarnib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00005842","official_title":"A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer","phases":["PHASE1"],"primary_completion":"2004-02","sponsor":"National Cancer Institute (NCI)","start":"2000-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer","url":"https://clinicaltrials.gov/study/NCT00005842"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":31,"has_results":false,"interventions":["DRUG: Taxotere","PROCEDURE: Surgery","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00006107","official_title":"Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)","phases":["PHASE1"],"primary_completion":"2003-07-17","sponsor":"Dana-Farber Cancer Institute","start":"2000-07-14","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00006107"},{"conditions":["Cervical Cancer","Fallopian Tube Cancer","Head and Neck Cancer","Lung Cancer","Malignant Mesothelioma","Ovarian Cancer","Pancreatic Cancer","Primary Peritoneal Cavity Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: SS1(dsFv)-PE38 immunotoxin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00006981","official_title":"Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days","phases":["PHASE1"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"2000-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Immunotoxin Therapy in Treating Patients With Advanced Cancer","url":"https://clinicaltrials.gov/study/NCT00006981"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: capecitabine","DRUG: cisplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00010023","official_title":"A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System","phases":["PHASE1"],"primary_completion":"2007-08","sponsor":"NYU Langone Health","start":"2000-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00010023"},{"conditions":["Bladder Cancer","Breast Cancer","Carcinoma of Unknown Primary","Esophageal Cancer","Gastric Cancer","Head and Neck Cancer","Lung Cancer","Melanoma (Skin)","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Sarcoma"],"countries":["United States"],"enrollment":35,"has_results":false,"interventions":["BIOLOGICAL: filgrastim","DRUG: docetaxel","DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00014456","official_title":"A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2005-10","sponsor":"Dartmouth-Hitchcock Medical Center","start":"2000-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00014456"},{"conditions":["Head and Neck Cancer"],"countries":["Belgium","Italy","Netherlands"],"enrollment":21,"has_results":false,"interventions":["DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00017498","official_title":"Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck","phases":["PHASE2"],"primary_completion":"2003-04","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","start":"2001-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00017498"},{"conditions":["Head and Neck Cancer","Oral Complications","Radiation Toxicity"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: cevimeline hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00017511","official_title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region","phases":["PHASE3"],"primary_completion":"2003-03","sponsor":"Daiichi Sankyo","start":"2001-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00017511"},{"conditions":["Anal Cancer","Cervical Cancer","Esophageal Cancer","Head and Neck Cancer","Penile Cancer","Vulvar Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: human papillomavirus 16 E7 peptide","BIOLOGICAL: synthetic human papillomavirus 16 E6 peptide"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00019110","official_title":"VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER","phases":["PHASE1"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"1995-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer","url":"https://clinicaltrials.gov/study/NCT00019110"},{"conditions":["Colorectal Cancer","Endometrial Cancer","Head and Neck Cancer","Liver Cancer","Lung Cancer","Melanoma (Skin)","Pancreatic Cancer","Testicular Germ Cell Tumor","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: aldesleukin","BIOLOGICAL: ras peptide cancer vaccine","BIOLOGICAL: sargramostim","DRUG: DetoxPC"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00019331","official_title":"Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors","phases":["PHASE2"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"1997-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00019331"},{"conditions":["Head and Neck Cancer","Thromboembolism"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: acetylsalicylic acid","DRUG: alvocidib","DRUG: clopidogrel bisulfate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00020189","official_title":"A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","phases":["PHASE2"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"2000-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00020189"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":75,"has_results":false,"interventions":["DRUG: entinostat"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00020579","official_title":"A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas","phases":["PHASE1"],"primary_completion":"2008-04","sponsor":"National Institutes of Health Clinical Center (CC)","start":"2001-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma","url":"https://clinicaltrials.gov/study/NCT00020579"},{"conditions":["Esophageal Cancer","Extrahepatic Bile Duct Cancer","Gastric Cancer","Head and Neck Cancer","Liver Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: capecitabine","DRUG: carboplatin","DRUG: epirubicin hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00021047","official_title":"A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients","phases":["PHASE1","PHASE2"],"primary_completion":"","sponsor":"National Institutes of Health Clinical Center (CC)","start":"2001-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor","url":"https://clinicaltrials.gov/study/NCT00021047"},{"conditions":["Head and Neck Cancer","Non-melanomatous Skin Cancer"],"countries":["United Kingdom"],"enrollment":460,"has_results":false,"interventions":["PROCEDURE: adjuvant therapy","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00021125","official_title":"A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients","phases":["PHASE3"],"primary_completion":"","sponsor":"Medical Research Council","start":"2000-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Radiation Therapy in Treating Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00021125"},{"conditions":["Head and Neck Cancer","Lung Cancer"],"countries":["United States"],"enrollment":29,"has_results":false,"interventions":["BIOLOGICAL: filgrastim","DRUG: cisplatin","DRUG: paclitaxel","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00021333","official_title":"Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung","phases":["PHASE2"],"primary_completion":"2006-04","sponsor":"Fox Chase Cancer Center","start":"1999-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer","url":"https://clinicaltrials.gov/study/NCT00021333"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: carboplatin","DRUG: cisplatin-e therapeutic implant","DRUG: paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00022217","official_title":"A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse","phases":["PHASE2"],"primary_completion":"","sponsor":"Matrix Pharmaceutical","start":"2000-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00022217"},{"conditions":["Head and Neck Cancer","Oral Complications of Radiation Therapy","Radiation Toxicity"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: iseganan HCl oral solution","PROCEDURE: management of therapy complications"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00022373","official_title":"A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy","phases":["PHASE3"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"2000-12","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00022373"},{"conditions":["Graft vs Host Disease","Sjogren's Syndrome"],"countries":["United States"],"enrollment":10,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00023491","official_title":"Assessment of the Potential of Hematopoietic Stem Cells to Transdifferentiate Into Salivary Gland and Oral Mucosal Epithelial Cells in Adult Bone Marrow Transplant Patients","phases":[],"primary_completion":"","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","start":"2001-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells","url":"https://clinicaltrials.gov/study/NCT00023491"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":39,"has_results":false,"interventions":["DRUG: hydroxyurea","DRUG: fluorouracil","BIOLOGICAL: bevacizumab","RADIATION: radiation therapy","BIOLOGICAL: filgrastim","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00023959","official_title":"A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer","phases":["PHASE1"],"primary_completion":"2010-03","sponsor":"National Cancer Institute (NCI)","start":"2001-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00023959"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":60,"has_results":false,"interventions":["DRUG: gefitinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00024089","official_title":"A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","phases":["PHASE2"],"primary_completion":"2006-03","sponsor":"National Cancer Institute (NCI)","start":"2001-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00024089"},{"conditions":["Breast Cancer","Colorectal Cancer","Gallbladder Cancer","Gastric Cancer","Head and Neck Cancer","Liver Cancer","Ovarian Cancer","Pancreatic Cancer","Testicular Germ Cell Tumor"],"countries":["United States"],"enrollment":14,"has_results":false,"interventions":["BIOLOGICAL: TRICOM-CEA(6D)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00027534","official_title":"A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA","phases":["PHASE1"],"primary_completion":"2007-10","sponsor":"Michael Morse, MD","start":"2002-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer","url":"https://clinicaltrials.gov/study/NCT00027534"},{"conditions":["Adenocarcinoma of the Colon","Adenocarcinoma of the Gallbladder","Adenocarcinoma of the Pancreas","Adenocarcinoma of the Rectum","Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Cholangiocarcinoma of the Gallbladder","Diffuse Adenocarcinoma of the Stomach","Intestinal Adenocarcinoma of the Stomach","Male Breast Cancer","Mixed Adenocarcinoma of the Stomach","Ovarian Endometrioid Adenocarcinoma","Paget Disease of the Breast With Intraductal Carcinoma","Paget Disease of the Breast With Invasive Ductal Carcinoma","Recurrent Adult Primary Liver Cancer","Recurrent Breast Cancer","Recurrent Colon Cancer","Recurrent Gallbladder Cancer","Recurrent Gastric Cancer","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Pancreatic Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Salivary Gland Adenocarcinoma","Stage II Malignant Testicular Germ Cell Tumor","Stage II Pancreatic Cancer","Stage III Colon Cancer","Stage III Gastric Cancer","Stage III Malignant Testicular Germ Cell Tumor","Stage III Pancreatic Cancer","Stage III Rectal Cancer","Stage III Salivary Gland Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Gastric Cancer","Stage IV Pancreatic Cancer","Stage IV Rectal Cancer","Stage IV Salivary Gland Cancer","Thyroid Gland Medullary Carcinoma","Unresectable Gallbladder Cancer"],"countries":["United States"],"enrollment":48,"has_results":false,"interventions":["BIOLOGICAL: recombinant fowlpox-CEA(6D)/TRICOM vaccine","BIOLOGICAL: sargramostim","BIOLOGICAL: recombinant fowlpox GM-CSF vaccine adjuvant"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00028496","official_title":"Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas","phases":["PHASE1"],"primary_completion":"2005-11","sponsor":"National Cancer Institute (NCI)","start":"2001-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer","url":"https://clinicaltrials.gov/study/NCT00028496"},{"conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Diffuse Astrocytoma","Adult Ependymoblastoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Adult Myxopapillary Ependymoma","Adult Oligodendroglioma","Adult Pilocytic Astrocytoma","Adult Primary Hepatocellular Carcinoma","Adult Subependymoma","Advanced Adult Primary Liver Cancer","Advanced Malignant Mesothelioma","Male Breast Cancer","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Brain Tumor","Recurrent Adult Primary Liver Cancer","Recurrent Anal Cancer","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Bladder Cancer","Recurrent Breast Cancer","Recurrent Cervical Cancer","Recurrent Colon Cancer","Recurrent Esophageal Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Malignant Mesothelioma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Pancreatic Cancer","Recurrent Prostate Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage II Esophageal Cancer","Stage II Pancreatic Cancer","Stage III Esophageal Cancer","Stage III Pancreatic Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Anal Cancer","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Bladder Cancer","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Esophageal Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Pancreatic Cancer","Stage IV Prostate Cancer","Stage IV Rectal Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Stage IVA Cervical Cancer","Stage IVB Cervical Cancer","Unspecified Adult Solid Tumor, Protocol Specific","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":75,"has_results":false,"interventions":["DRUG: erlotinib hydrochloride","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00030498","official_title":"Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction","phases":["PHASE1"],"primary_completion":"2007-07","sponsor":"National Cancer Institute (NCI)","start":"2001-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction","url":"https://clinicaltrials.gov/study/NCT00030498"},{"conditions":["Advanced Adult Primary Liver Cancer","Carcinoma of the Appendix","Estrogen Receptor-negative Breast Cancer","Extensive Stage Small Cell Lung Cancer","Gastrointestinal Stromal Tumor","HER2-negative Breast Cancer","Metastatic Gastrointestinal Carcinoid Tumor","Ovarian Sarcoma","Ovarian Stromal Cancer","Progesterone Receptor-negative Breast Cancer","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Primary Liver Cancer","Recurrent Anal Cancer","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor","Recurrent Breast Cancer","Recurrent Cervical Cancer","Recurrent Colon Cancer","Recurrent Endometrial Carcinoma","Recurrent Esophageal Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer","Recurrent Gastric Cancer","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Recurrent Pancreatic Cancer","Recurrent Prostate Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Recurrent Small Cell Lung Cancer","Recurrent Small Intestine Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Small Intestine Adenocarcinoma","Small Intestine Leiomyosarcoma","Small Intestine Lymphoma","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Anal Cancer","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Endometrial Carcinoma","Stage IV Esophageal Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Gastric Cancer","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Ovarian Germ Cell Tumor","Stage IV Pancreatic Cancer","Stage IV Prostate Cancer","Stage IV Rectal Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Stage IVA Cervical Cancer","Stage IVB Cervical Cancer","Triple-negative Breast Cancer","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer","Unspecified Adult Solid Tumor, Protocol Specific","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":41,"has_results":false,"interventions":["DRUG: 7-hydroxystaurosporine","DRUG: irinotecan hydrochloride","OTHER: diagnostic laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00031681","official_title":"A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)","phases":["PHASE1"],"primary_completion":"2011-01","sponsor":"National Cancer Institute (NCI)","start":"2001-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)","url":"https://clinicaltrials.gov/study/NCT00031681"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":144,"has_results":false,"interventions":["DRUG: ixabepilone","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00033618","official_title":"A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck","phases":["PHASE2"],"primary_completion":"2007-01","sponsor":"National Cancer Institute (NCI)","start":"2002-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00033618"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: docetaxel","DRUG: irinotecan hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00040807","official_title":"Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma","phases":["PHASE2"],"primary_completion":"2005-04","sponsor":"Eastern Cooperative Oncology Group","start":"2002-11-19","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00040807"},{"conditions":["Adult Solid Tumor","Breast Cancer","Head and Neck Cancer","Kidney and Urinary Cancer","Male Reproductive Cancer","Thorax and Respiratory Cancer"],"countries":[],"enrollment":0,"has_results":false,"interventions":["DRUG: Hypericum perforatum","DRUG: docetaxel","OTHER: placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00041171","official_title":"Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors","phases":["PHASE3"],"primary_completion":"","sponsor":"Alliance for Clinical Trials in Oncology","start":"","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery","url":"https://clinicaltrials.gov/study/NCT00041171"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: vorinostat"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00045006","official_title":"Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies","phases":["PHASE1"],"primary_completion":"2005-12","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2001-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer","url":"https://clinicaltrials.gov/study/NCT00045006"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":8,"has_results":false,"interventions":["DRUG: EF5","OTHER: bioluminescence","OTHER: flow cytometry","OTHER: immunohistochemistry staining method","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00049140","official_title":"Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer","phases":["PHASE2"],"primary_completion":"2004-10","sponsor":"David M. Brizel, MD","start":"2002-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00049140"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":26,"has_results":false,"interventions":["DRUG: docetaxel","DRUG: thalidomide"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00049296","official_title":"Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles","phases":["PHASE1"],"primary_completion":"2004-12","sponsor":"Case Comprehensive Cancer Center","start":"2002-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Thalidomide and Docetaxel in Treating Patients With Advanced Cancer","url":"https://clinicaltrials.gov/study/NCT00049296"},{"conditions":["Head and Neck Cancer","Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","Head and Neck Neoplasms","Carcinoma of the Head and Neck"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["GENETIC: Allovectin-7®"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00050388","official_title":"Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","phases":["PHASE3"],"primary_completion":"","sponsor":"Vical","start":"","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase II Trial of Allovectin-7® for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00050388"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":23,"has_results":false,"interventions":["DRUG: Celecoxib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00052611","official_title":"Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study","phases":["PHASE2"],"primary_completion":"2005-03","sponsor":"Dana-Farber Cancer Institute","start":"2002-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia","url":"https://clinicaltrials.gov/study/NCT00052611"},{"conditions":["Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity"],"countries":["United States"],"enrollment":45,"has_results":false,"interventions":["DRUG: erlotinib hydrochloride","DRUG: docetaxel","OTHER: laboratory biomarker analysis","OTHER: pharmacological study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00055770","official_title":"A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE1","PHASE2"],"primary_completion":"2006-12","sponsor":"National Cancer Institute (NCI)","start":"2002-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00055770"},{"conditions":["Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity"],"countries":["United States"],"enrollment":58,"has_results":false,"interventions":["BIOLOGICAL: bevacizumab","DRUG: erlotinib hydrochloride","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00055913","official_title":"A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck","phases":["PHASE1","PHASE2"],"primary_completion":"2007-09","sponsor":"National Cancer Institute (NCI)","start":"2003-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00055913"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":27,"has_results":false,"interventions":["DRUG: cisplatin","DRUG: ixabepilone"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00057850","official_title":"Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE1","PHASE2"],"primary_completion":"2003-07","sponsor":"National Cancer Institute (NCI)","start":"2002-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00057850"},{"conditions":["Head and Neck Cancer","Lung Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: celecoxib","PROCEDURE: adjuvant therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00058006","official_title":"Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers","phases":["PHASE2"],"primary_completion":"2006-12","sponsor":"Northwestern University","start":"2002-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT00058006"},{"conditions":["Colorectal Cancer","Head and Neck Cancer","Metastatic Cancer"],"countries":["Germany"],"enrollment":27,"has_results":false,"interventions":["DRUG: boronophenylalanine-fructose complex","DRUG: sodium borocaptate","PROCEDURE: conventional surgery"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00062348","official_title":"B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA","phases":["PHASE1"],"primary_completion":"2007-12","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","start":"2003-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases","url":"https://clinicaltrials.gov/study/NCT00062348"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":46,"has_results":false,"interventions":["DRUG: perifosine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00062387","official_title":"A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer","phases":["PHASE2"],"primary_completion":"2007-01","sponsor":"National Cancer Institute (NCI)","start":"2003-05","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00062387"},{"conditions":["Cervical Cancer","Fallopian Tube Cancer","Head and Neck Cancer","Lung Cancer","Malignant Mesothelioma","Ovarian Cancer","Pancreatic Cancer","Primary Peritoneal Cavity Cancer"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: SS1(dsFv)-PE38 immunotoxin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00066651","official_title":"Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing","phases":["PHASE1"],"primary_completion":"","sponsor":"National Cancer Institute (NCI)","start":"2003-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00066651"},{"conditions":["Head and Neck Cancer","Radiation Toxicity","Xerostomia"],"countries":["Canada","United States"],"enrollment":49,"has_results":true,"interventions":["PROCEDURE: salivary gland transfer","RADIATION: Post-operative radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00068237","official_title":"A Phase II Study Of Submandibular Salivary Gland Transfer To The Submental Space Prior To Start Of Radiation Treatment For Prevention Of Radiation-Induced Xerostomia In Head And Neck Cancer Patients","phases":["PHASE2"],"primary_completion":"2008-01","sponsor":"Radiation Therapy Oncology Group","start":"2003-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00068237"},{"conditions":["Anaplastic Thyroid Cancer","Insular Thyroid Cancer","Metastatic Parathyroid Cancer","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Parathyroid Cancer","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Thyroid Cancer","Recurrent Verrucous Carcinoma of the Larynx","Stage III Follicular Thyroid Cancer","Stage III Papillary Thyroid Cancer","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Larynx","Stage IIIB Non-small Cell Lung Cancer","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Non-small Cell Lung Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVA Basal Cell Carcinoma of the Lip","Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Follicular Thyroid Cancer","Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Lymphoepithelioma of the Oropharynx","Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVA Papillary Thyroid Cancer","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVB Basal Cell Carcinoma of the Lip","Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Follicular Thyroid Cancer","Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Lymphoepithelioma of the Oropharynx","Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVB Papillary Thyroid Cancer","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVC Basal Cell Carcinoma of the Lip","Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Follicular Thyroid Cancer","Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Lymphoepithelioma of the Oropharynx","Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVC Papillary Thyroid Cancer","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Thryoid Gland Nonmedullary Carcinoma","Thyroid Gland Medullary Carcinoma","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["DRUG: gefitinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00068497","official_title":"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)","phases":["NA"],"primary_completion":"2007-12","sponsor":"National Cancer Institute (NCI)","start":"2003-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT00068497"},{"conditions":["Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Salivary Gland Adenoid Cystic Carcinoma","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer"],"countries":["United States"],"enrollment":37,"has_results":false,"interventions":["DRUG: bortezomib","DRUG: doxorubicin hydrochloride","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00077428","official_title":"Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2007-06","sponsor":"National Cancer Institute (NCI)","start":"2004-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00077428"},{"conditions":["Head and Neck Cancer"],"countries":["Canada"],"enrollment":19,"has_results":false,"interventions":["DRUG: erlotinib hydrochloride","PROCEDURE: adjuvant therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00079053","official_title":"A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE1"],"primary_completion":"2008-12-09","sponsor":"NCIC Clinical Trials Group","start":"2004-03-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00079053"},{"conditions":["Head and Neck Cancer"],"countries":["Canada"],"enrollment":34,"has_results":false,"interventions":["DRUG: carboplatin","DRUG: cisplatin","DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00079079","official_title":"A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors","phases":["PHASE2"],"primary_completion":"2008-09-29","sponsor":"NCIC Clinical Trials Group","start":"2003-10-27","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor","url":"https://clinicaltrials.gov/study/NCT00079079"},{"conditions":["Head and Neck Cancer","Radiation Toxicity","Xerostomia"],"countries":["United Kingdom"],"enrollment":84,"has_results":false,"interventions":["PROCEDURE: management of therapy complications","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00081029","official_title":"A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer","phases":["PHASE3"],"primary_completion":"2013-01","sponsor":"Royal Marsden NHS Foundation Trust","start":"2004-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT00081029"},{"conditions":["Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["BIOLOGICAL: PV701"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00081211","official_title":"A Phase I Study Of PV701 In Patients With Head And Neck Squamous Cell Carcinoma","phases":["PHASE1"],"primary_completion":"2004-07","sponsor":"National Cancer Institute (NCI)","start":"2004-04","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00081211"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["DRUG: cisplatin","DRUG: docetaxel","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00084435","official_title":"Adjuvant Chemo-RT With Cisplatin (NSC-119875) and Docetaxel (NSC-628503) After Complete Resection of Locally Advanced (Stage III and IV) Squamous Cell Carcinoma of the Head and Neck (SCCHN)","phases":["PHASE2"],"primary_completion":"2007-01","sponsor":"SWOG Cancer Research Network","start":"2005-07","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00084435"},{"conditions":["Male Breast Cancer","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Breast Cancer","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Gastric Cancer","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Melanoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Ovarian Epithelial Cancer","Recurrent Prostate Cancer","Recurrent Renal Cell Cancer","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Colon Cancer","Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage III Gastric Cancer","Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Melanoma","Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Ovarian Epithelial Cancer","Stage III Renal Cell Cancer","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Breast Cancer","Stage IV Colon Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Gastric Cancer","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Melanoma","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Ovarian Epithelial Cancer","Stage IV Prostate Cancer","Stage IV Renal Cell Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Unspecified Adult Solid Tumor, Protocol Specific","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["DRUG: alvespimycin hydrochloride","OTHER: laboratory biomarker analysis","OTHER: pharmacological study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00089362","official_title":"Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors.","phases":["PHASE1"],"primary_completion":"2008-01","sponsor":"National Cancer Institute (NCI)","start":"2004-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00089362"},{"conditions":["Head and Neck Cancer","Pain"],"countries":["United States"],"enrollment":73,"has_results":false,"interventions":["PROCEDURE: acupuncture therapy","PROCEDURE: standard follow-up care"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00090337","official_title":"Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial","phases":["PHASE3"],"primary_completion":"2007-10","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2003-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00090337"},{"conditions":["High-grade Salivary Gland Carcinoma","High-grade Salivary Gland Mucoepidermoid Carcinoma","Low-grade Salivary Gland Carcinoma","Low-grade Salivary Gland Mucoepidermoid Carcinoma","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Salivary Gland Acinic Cell Tumor","Salivary Gland Adenocarcinoma","Salivary Gland Adenoid Cystic Carcinoma","Salivary Gland Malignant Mixed Cell Type Tumor"],"countries":["Canada"],"enrollment":40,"has_results":true,"interventions":["DRUG: lapatinib ditosylate","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00095563","official_title":"A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands","phases":["PHASE2"],"primary_completion":"2009-02","sponsor":"National Cancer Institute (NCI)","start":"2004-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT00095563"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity"],"countries":["Canada"],"enrollment":21,"has_results":true,"interventions":["DRUG: ispinesib","OTHER: laboratory biomarker analysis","OTHER: pharmacological study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00095628","official_title":"A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2010-07","sponsor":"National Cancer Institute (NCI)","start":"2005-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00095628"},{"conditions":["Chemotherapeutic Agent Toxicity","Head and Neck Cancer","Mucositis","Radiation Toxicity","Xerostomia"],"countries":["United States"],"enrollment":58,"has_results":false,"interventions":["DRUG: Amifostine","DRUG: Carboplatin","DRUG: Paclitaxel","RADIATION: radiation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00095927","official_title":"Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck","phases":["PHASE2"],"primary_completion":"2007-06","sponsor":"Dana-Farber Cancer Institute","start":"2003-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Randomized Amifostine For SCCHN","url":"https://clinicaltrials.gov/study/NCT00095927"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["DRUG: sorafenib tosylate","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00096512","official_title":"Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer","phases":["PHASE2"],"primary_completion":"2006-05","sponsor":"National Cancer Institute (NCI)","start":"2004-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00096512"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":88,"has_results":false,"interventions":["DRUG: lapatinib ditosylate","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00098631","official_title":"A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)","phases":["PHASE2"],"primary_completion":"2006-12","sponsor":"National Cancer Institute (NCI)","start":"2004-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00098631"},{"conditions":["Colorectal Cancer","Head and Neck Cancer","Kidney Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["Germany","Netherlands"],"enrollment":70,"has_results":false,"interventions":["BIOLOGICAL: CNGRC peptide-TNF alpha conjugate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00098943","official_title":"Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor","phases":["PHASE1"],"primary_completion":"2007-11","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","start":"2004-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"NGR-TNF in Treating Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00098943"},{"conditions":["Diabetes Mellitus","Sarcoidosis","Dental Caries","Sjorgren's Syndrome","Cystinosis","Head and Neck Neoplasms"],"countries":["United States"],"enrollment":264,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00100204","official_title":"Salivary Proteomics in Disease and Health","phases":[],"primary_completion":"","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","start":"2004-12-21","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Salivary Proteins in Disease and Health","url":"https://clinicaltrials.gov/study/NCT00100204"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":9,"has_results":false,"interventions":["DRUG: Capecitabine","DRUG: Oxaliplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00101075","official_title":"Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers","phases":["PHASE2"],"primary_completion":"2007-03","sponsor":"Dana-Farber Cancer Institute","start":"2004-10","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Title XELOX FOR SALIVARY GLAND CANCERS","url":"https://clinicaltrials.gov/study/NCT00101075"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Pancreatic Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Colon Cancer","Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Pancreatic Cancer","Stage III Rectal Cancer","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IIIB Non-small Cell Lung Cancer","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Colon Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Pancreatic Cancer","Stage IV Rectal Cancer","Stage IV Renal Cell Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":66,"has_results":false,"interventions":["DRUG: erlotinib hydrochloride","BIOLOGICAL: cetuximab","BIOLOGICAL: bevacizumab","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00101348","official_title":"A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma","phases":["PHASE1","PHASE2"],"primary_completion":"2007-10","sponsor":"National Cancer Institute (NCI)","start":"2005-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT00101348"},{"conditions":["Mucositis","Solid Tumors","Stomatitis","Head and Neck Cancer","Squamous Cell Carcinoma"],"countries":[],"enrollment":188,"has_results":true,"interventions":["DRUG: Placebo","DRUG: palifermin","DRUG: cisplatin chemotherapy","RADIATION: Radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00101582","official_title":"Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)","phases":["PHASE3"],"primary_completion":"2007-09","sponsor":"Swedish Orphan Biovitrum","start":"2005-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00101582"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":53,"has_results":false,"interventions":["BIOLOGICAL: monoclonal antibody RAV12"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00101972","official_title":"A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma","phases":["PHASE1"],"primary_completion":"2008-05","sponsor":"MacroGenics","start":"2004-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT00101972"},{"conditions":["Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["DRUG: lapatinib ditosylate","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00114283","official_title":"A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck","phases":["PHASE2"],"primary_completion":"2006-10","sponsor":"National Cancer Institute (NCI)","start":"2005-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00114283"},{"conditions":["High-grade Salivary Gland Mucoepidermoid Carcinoma","Recurrent Salivary Gland Cancer","Salivary Gland Acinic Cell Tumor","Salivary Gland Adenocarcinoma","Salivary Gland Poorly Differentiated Carcinoma","Stage IVA Salivary Gland Cancer","Stage IVB Salivary Gland Cancer","Stage IVC Salivary Gland Cancer"],"countries":["United States"],"enrollment":35,"has_results":false,"interventions":["BIOLOGICAL: trastuzumab","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00126607","official_title":"Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2007-05","sponsor":"National Cancer Institute (NCI)","start":"2005-07","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00126607"},{"conditions":["Head and Neck Neoplasms"],"countries":["Australia"],"enrollment":50,"has_results":false,"interventions":["DRUG: Biotene (mouth care)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00138827","official_title":"A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy","phases":["PHASE4"],"primary_completion":"","sponsor":"St George Hospital, Australia","start":"1999-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Mouth Care Regimes During Radiotherapy","url":"https://clinicaltrials.gov/study/NCT00138827"},{"conditions":["Head and Neck Cancer"],"countries":["France"],"enrollment":296,"has_results":false,"interventions":["DRUG: Ethyol"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00158691","official_title":"A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas","phases":["PHASE3"],"primary_completion":"","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","start":"2001-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas","url":"https://clinicaltrials.gov/study/NCT00158691"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":27,"has_results":false,"interventions":["DRUG: Ethyol (drug)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00167908","official_title":"Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT","phases":["PHASE2"],"primary_completion":"","sponsor":"Washington University School of Medicine","start":"2001-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00167908"},{"conditions":["Head and Neck Cancer"],"countries":["Canada"],"enrollment":42,"has_results":false,"interventions":["PROCEDURE: radiation treatment and surgery","PROCEDURE: radiation alone"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00168116","official_title":"To Evaluate the Effects of Transfer of Submandibular Salivary Gland to the Submental Region (Outside the Radiation Field) on Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure","phases":["PHASE2"],"primary_completion":"2009-05","sponsor":"AHS Cancer Control Alberta","start":"2000-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure","url":"https://clinicaltrials.gov/study/NCT00168116"},{"conditions":["Cancer","Head and Neck Cancer"],"countries":["Canada"],"enrollment":220,"has_results":false,"interventions":["PROCEDURE: Submandibular gland Transfer","DRUG: Salagen"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00168181","official_title":"A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients","phases":["PHASE3"],"primary_completion":"","sponsor":"Alberta Health services","start":"2002-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT00168181"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":95,"has_results":false,"interventions":["COMBINATION_PRODUCT: Medpulser Electroporation with Bleomycin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00198263","official_title":"An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer","phases":["PHASE4"],"primary_completion":"2008-09","sponsor":"Inovio Pharmaceuticals","start":"2004-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00198263"},{"conditions":["Mouth Diseases","Mouth Ulcers","Oral Mucositis","Head and Neck Cancer"],"countries":["Canada","United States"],"enrollment":110,"has_results":false,"interventions":["DRUG: RK-0202"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00230191","official_title":"Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region","phases":["PHASE2"],"primary_completion":"","sponsor":"RxKinetix","start":"2003-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Safety and Efficacy of RK0202 in Oral Mucositis","url":"https://clinicaltrials.gov/study/NCT00230191"},{"conditions":["Uterine Cancer"],"countries":["United States"],"enrollment":30,"has_results":true,"interventions":["DRUG: Ifosfamide","DEVICE: Radiation Therapy","DRUG: Cisplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00231842","official_title":"A Pilot Phase II Trial of Adjuvant Radiation Therapy \"Sandwiched\" Between Ifosfamide in Patients With Mixed Mesodermal Tumors","phases":["PHASE2"],"primary_completion":"2011-07","sponsor":"Montefiore Medical Center","start":"2003-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus","url":"https://clinicaltrials.gov/study/NCT00231842"},{"conditions":["Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Mixed Tumor, Mesodermal"],"countries":["United States"],"enrollment":12,"has_results":true,"interventions":["DRUG: Paclitaxel","DRUG: Carboplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00322881","official_title":"A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer","phases":["PHASE2"],"primary_completion":"2008-04","sponsor":"Dana-Farber Cancer Institute","start":"2006-04","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer","url":"https://clinicaltrials.gov/study/NCT00322881"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":42,"has_results":true,"interventions":["DRUG: eribulin mesylate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00337129","official_title":"Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2008-08","sponsor":"National Cancer Institute (NCI)","start":"2006-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00337129"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":4,"has_results":true,"interventions":["BIOLOGICAL: filgrastim","BIOLOGICAL: pegfilgrastim","DRUG: cisplatin","DRUG: docetaxel","DRUG: fluorouracil","PROCEDURE: conventional surgery","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00352118","official_title":"Phase II Pilot Study of TPF (Docetaxel, Cisplatin, and 5-FU) Induction Chemotherapy Followed by Concurrent Cisplatin and Reduced Dose Radiation in Locally Advanced Head and Neck Cancer","phases":["PHASE2"],"primary_completion":"2008-04","sponsor":"Masonic Cancer Center, University of Minnesota","start":"2006-03","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00352118"},{"conditions":["Parotid Salivary Dysfunction"],"countries":["United States"],"enrollment":17,"has_results":false,"interventions":["GENETIC: Gene Transfer","DRUG: AdhAQP1"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00372320","official_title":"Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of AdhAQP1, an Adenoviral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction","phases":["PHASE1"],"primary_completion":"2014-03-19","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","start":"2006-09-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00372320"},{"conditions":["Head and Neck Cancer"],"countries":["Canada"],"enrollment":100,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00375180","official_title":"Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients Prior to, on Completion of and Six Weeks After Oncology Treatment","phases":[],"primary_completion":"2012-01","sponsor":"AHS Cancer Control Alberta","start":"2006-11","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT00375180"},{"conditions":["Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Advanced Adult Primary Liver Cancer","Carcinoma of the Appendix","Gastrointestinal Stromal Tumor","Metastatic Gastrointestinal Carcinoid Tumor","Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Primary Liver Cancer","Recurrent Anal Cancer","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esophageal Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Extrahepatic Bile Duct Cancer","Recurrent Gallbladder Cancer","Recurrent Gastric Cancer","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Non-small Cell Lung Cancer","Recurrent Pancreatic Cancer","Recurrent Rectal Cancer","Recurrent Salivary Gland Cancer","Recurrent Small Intestine Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Small Intestine Adenocarcinoma","Small Intestine Leiomyosarcoma","Small Intestine Lymphoma","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Anal Cancer","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Colon Cancer","Stage IV Esophageal Cancer","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Gastric Cancer","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Pancreatic Cancer","Stage IV Rectal Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Unresectable Extrahepatic Bile Duct Cancer","Unresectable Gallbladder Cancer"],"countries":["United States"],"enrollment":43,"has_results":false,"interventions":["DRUG: cetuximab","DRUG: erlotinib hydrochloride","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00397384","official_title":"A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer","phases":["PHASE1"],"primary_completion":"2013-06","sponsor":"National Cancer Institute (NCI)","start":"2007-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT00397384"},{"conditions":["Head and Neck Cancer","Parotid Gland Cancer","Thyroid Gland Cancer","Melanoma","Stage IV Head and Neck Cancer"],"countries":["United States"],"enrollment":13,"has_results":false,"interventions":["DRUG: Cisplatin","DRUG: Docetaxel","DRUG: Bevacizumab","DRUG: Erlotinib","RADIATION: Radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00405405","official_title":"A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2010-06","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","start":"2006-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00405405"},{"conditions":["Xerostomia"],"countries":["Israel"],"enrollment":10,"has_results":false,"interventions":["BEHAVIORAL: hypnosis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00408759","official_title":"Phase 2 Study of Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients","phases":["PHASE2"],"primary_completion":"","sponsor":"Bnai Zion Medical Center","start":"2006-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT00408759"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":3,"has_results":true,"interventions":["DRUG: Amifostine","PROCEDURE: Intensity- Modulated Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00409331","official_title":"A Phase II Study To Assess The Efficacy of Amifostine for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment With Intensity- Modulated Radiation Therapy (IMRT) for Parotid Salivary Sparing","phases":["PHASE2"],"primary_completion":"2009-01","sponsor":"M.D. Anderson Cancer Center","start":"2006-12","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment","url":"https://clinicaltrials.gov/study/NCT00409331"},{"conditions":["Solid Tumor","Lymphoma"],"countries":["Denmark","United Kingdom","United States"],"enrollment":121,"has_results":false,"interventions":["DRUG: oral belinostat"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00413075","official_title":"Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2011-08","sponsor":"Valerio Therapeutics","start":"2006-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma","url":"https://clinicaltrials.gov/study/NCT00413075"},{"conditions":["Tumor"],"countries":["United States"],"enrollment":35,"has_results":false,"interventions":["DRUG: belinostat","DRUG: 5-Fluorouracil (5-FU)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00413322","official_title":"A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2008-03","sponsor":"Valerio Therapeutics","start":"2005-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00413322"},{"conditions":["Head and Neck Cancer","Long-term Effects Secondary to Cancer Therapy in Adults","Oral Complications of Radiation Therapy","Radiation Toxicity"],"countries":[],"enrollment":20,"has_results":false,"interventions":["PROCEDURE: adjuvant therapy","PROCEDURE: management of therapy complications","PROCEDURE: quality-of-life assessment","RADIATION: intensity-modulated radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00415025","official_title":"Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT)","phases":[],"primary_completion":"","sponsor":"University of Wisconsin, Madison","start":"2004-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00415025"},{"conditions":["Xerostomia","Mouth Dryness","Nasopharyngeal Cancer"],"countries":["China"],"enrollment":100,"has_results":false,"interventions":["PROCEDURE: Acupuncture","OTHER: Standard Care"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00430378","official_title":"Acupuncture for Prevention of Radiation-Induced Xerostomia","phases":["NA"],"primary_completion":"2021-05-27","sponsor":"M.D. Anderson Cancer Center","start":"2007-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Acupuncture for Prevention of Radiation-Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT00430378"},{"conditions":["Oral Mucositis","Xerostomia","Weight Loss","Head and Neck Cancer"],"countries":["Israel"],"enrollment":35,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00431925","official_title":"Can Cytokines Predict the Severity of Acute Mucositis and the Need for PEG During Chemo-Radiation Treatment to Head and Neck Cancer?","phases":[],"primary_completion":"","sponsor":"Hadassah Medical Organization","start":"","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?","url":"https://clinicaltrials.gov/study/NCT00431925"},{"conditions":["Thyroid Cancer"],"countries":["Switzerland"],"enrollment":202,"has_results":false,"interventions":["DRUG: Radioiodine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00439478","official_title":"The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer","phases":[],"primary_completion":"","sponsor":"University Hospital, Basel, Switzerland","start":"2004-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Dental Safety Profile of High-Dose Radioiodine Therapy","url":"https://clinicaltrials.gov/study/NCT00439478"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["DRUG: capecitabine","DRUG: oxaliplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00448552","official_title":"Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine","phases":["PHASE2"],"primary_completion":"2007-04","sponsor":"University of Miami","start":"2004-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00448552"},{"conditions":["Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Squamous Cell Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage IV Hypopharyngeal Squamous Cell Carcinoma","Stage IV Laryngeal Squamous Cell Carcinoma","Stage IV Laryngeal Verrucous Carcinoma","Stage IV Lip and Oral Cavity Squamous Cell Carcinoma","Stage IV Major Salivary Gland Carcinoma","Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IV Oral Cavity Verrucous Carcinoma","Stage IV Oropharyngeal Squamous Cell Carcinoma","Tongue Carcinoma","Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary"],"countries":["United States"],"enrollment":6,"has_results":false,"interventions":["DRUG: Cediranib Maleate","OTHER: Laboratory Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00458978","official_title":"Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients","phases":["PHASE2"],"primary_completion":"2013-05","sponsor":"National Cancer Institute (NCI)","start":"2007-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00458978"},{"conditions":["Xerostomia"],"countries":["United States"],"enrollment":54,"has_results":false,"interventions":["DRUG: Cevimeline"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00466388","official_title":"An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma","phases":["PHASE4"],"primary_completion":"2009-06","sponsor":"American Academy of Otolaryngology-Head and Neck Surgery Foundation","start":"2007-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT00466388"},{"conditions":["Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Thyroid Cancer","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage I Follicular Thyroid Cancer","Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Papillary Thyroid Cancer","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Adenoid Cystic Carcinoma of the Oral Cavity","Stage II Basal Cell Carcinoma of the Lip","Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage II Follicular Thyroid Cancer","Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage II Lymphoepithelioma of the Nasopharynx","Stage II Lymphoepithelioma of the Oropharynx","Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage II Mucoepidermoid Carcinoma of the Oral Cavity","Stage II Papillary Thyroid Cancer","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity"],"countries":["United States"],"enrollment":15,"has_results":false,"interventions":["DRUG: HPPH","DRUG: photodynamic therapy","PROCEDURE: conventional surgery"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00470496","official_title":"A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2011-10-28","sponsor":"Roswell Park Cancer Institute","start":"2006-10-19","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00470496"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":400,"has_results":false,"interventions":["GENETIC: gene expression analysis","GENETIC: mutation analysis","GENETIC: polymerase chain reaction","GENETIC: polymorphism analysis","OTHER: flow cytometry","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00482872","official_title":"Familial HNSCC Syndrome and p16 Germline Mutations","phases":[],"primary_completion":"2012-07","sponsor":"Vanderbilt University Medical Center","start":"2004-03","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer","url":"https://clinicaltrials.gov/study/NCT00482872"},{"conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Meningioma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Central Nervous System Germ Cell Tumor","Adult Choroid Plexus Tumor","Adult Diffuse Astrocytoma","Adult Ependymoma","Adult Grade II Meningioma","Adult Grade III Meningioma","Adult Malignant Hemangiopericytoma","Adult Mixed Glioma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pineocytoma","Malignant Neoplasm","Meningeal Melanocytoma","Radiation Toxicity","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Brain Tumor","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity"],"countries":["United States"],"enrollment":11,"has_results":true,"interventions":["DRUG: bevacizumab","DRUG: placebo","PROCEDURE: magnetic resonance imaging","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00492089","official_title":"A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage","phases":["PHASE2"],"primary_completion":"2010-08","sponsor":"National Cancer Institute (NCI)","start":"2007-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00492089"},{"conditions":["Head and Neck Cancer"],"countries":["Canada"],"enrollment":46,"has_results":false,"interventions":["PROCEDURE: Salivary gland transfer","PROCEDURE: Helical Tomotherapy treatment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00497406","official_title":"A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Transfer Procedure and Intensity Modulated Radiation Therapy (Helical Tomotherapy) to Reduce Dryness of Mouth (Xerostomia) in Head and Neck Cancer Patients After Surgery","phases":["NA"],"primary_completion":"2016-10","sponsor":"AHS Cancer Control Alberta","start":"2005-12","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce Xerostomia","url":"https://clinicaltrials.gov/study/NCT00497406"},{"conditions":["Cancer"],"countries":[],"enrollment":0,"has_results":false,"interventions":["DRUG: paclitaxel albumin-stabilized nanoparticle formulation","PROCEDURE: gene expression analysis","PROCEDURE: laboratory biomarker analysis","PROCEDURE: pharmacological study","PROCEDURE: polymerase chain reaction"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00499291","official_title":"Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors","phases":["NA"],"primary_completion":"","sponsor":"Eastern Cooperative Oncology Group","start":"2006-09","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00499291"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":19,"has_results":false,"interventions":["DRUG: cyclophosphamide","DEVICE: Cryoablation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00499733","official_title":"Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer","phases":["EARLY_PHASE1"],"primary_completion":"2010-07","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","start":"2007-06","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer","url":"https://clinicaltrials.gov/study/NCT00499733"},{"conditions":["Mixed Tumor, Mullerian"],"countries":["United States"],"enrollment":23,"has_results":true,"interventions":["DRUG: Carboplatin","DRUG: Paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00502203","official_title":"A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus","phases":["PHASE2"],"primary_completion":"2010-11","sponsor":"M.D. Anderson Cancer Center","start":"2001-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus","url":"https://clinicaltrials.gov/study/NCT00502203"},{"conditions":["Dysphagia","Head and Neck Cancer","Mucositis","Xerostomia"],"countries":["United States"],"enrollment":41,"has_results":true,"interventions":["BEHAVIORAL: exercise intervention","DRUG: amifostine trihydrate","PROCEDURE: therapeutic dietary intervention"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00503776","official_title":"Randomized Pilot Trial of Chemoradiation Plus or Minus Amifostine to Assess Potential Nutritional, Inflammatory and Physical Outcomes Related to Xerostomia, Mucositis and Dysphagia","phases":["PHASE2"],"primary_completion":"2008-08","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2006-01","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia","url":"https://clinicaltrials.gov/study/NCT00503776"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":15,"has_results":true,"interventions":["DRUG: dasatinib","PROCEDURE: pharmacological study","PROCEDURE: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00507767","official_title":"A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma","phases":["PHASE2"],"primary_completion":"2010-02","sponsor":"National Cancer Institute (NCI)","start":"2007-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00507767"},{"conditions":["Salivary Gland Cancer"],"countries":["United States"],"enrollment":37,"has_results":true,"interventions":["DRUG: Gefitinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00509002","official_title":"Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)","phases":["PHASE2"],"primary_completion":"2016-09","sponsor":"M.D. Anderson Cancer Center","start":"2004-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Iressa Study in Patients With Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00509002"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":18,"has_results":true,"interventions":["DRUG: doxorubicin hydrochloride","DRUG: gemcitabine hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00509665","official_title":"A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer","phases":["PHASE2"],"primary_completion":"2011-05","sponsor":"Medical University of South Carolina","start":"2005-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00509665"},{"conditions":["Head and Neck Cancer","Precancerous Condition"],"countries":["Canada","United States"],"enrollment":35,"has_results":true,"interventions":["BIOLOGICAL: cetuximab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00524017","official_title":"Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions","phases":["PHASE2"],"primary_completion":"2011-12","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","start":"2007-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract","url":"https://clinicaltrials.gov/study/NCT00524017"},{"conditions":["Head and Neck Cancer","Psychosocial Effects of Cancer and Its Treatment"],"countries":["Canada","United Kingdom","United States"],"enrollment":1745,"has_results":false,"interventions":["OTHER: questionnaire administration","PROCEDURE: assessment of therapy complications","PROCEDURE: psychosocial assessment and care","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00530049","official_title":"Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure","phases":[],"primary_completion":"2021-12-17","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2007-08-14","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure","url":"https://clinicaltrials.gov/study/NCT00530049"},{"conditions":["Neurocognitive Impairment","Delirium","Esophageal Cancer","Head and Neck Cancer","Lung Cancer"],"countries":["United States"],"enrollment":86,"has_results":false,"interventions":["OTHER: Assessment of therapy complications","OTHER: Neurocognitive assessment","OTHER: Quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00533884","official_title":"Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers","phases":[],"primary_completion":"2010-05","sponsor":"Vanderbilt University Medical Center","start":"2007-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic","url":"https://clinicaltrials.gov/study/NCT00533884"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":130,"has_results":true,"interventions":["DRUG: Fentanyl sublingual spray","DRUG: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00538850","official_title":"A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain","phases":["PHASE3"],"primary_completion":"2010-02","sponsor":"INSYS Therapeutics Inc","start":"2007-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain","url":"https://clinicaltrials.gov/study/NCT00538850"},{"conditions":["Mouth Diseases"],"countries":["United States"],"enrollment":1004,"has_results":false,"interventions":["DEVICE: detection of oral pathology"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00540774","official_title":"Optical Sensor for Photodynamic Detection of Oral Pathology","phases":["NA"],"primary_completion":"2026-03-03","sponsor":"University of California, Irvine","start":"2003-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Optical Sensor for Photodynamic Detection of Oral Pathology","url":"https://clinicaltrials.gov/study/NCT00540774"},{"conditions":["Breast Cancer","Colorectal Cancer","Head and Neck Cancer","Lung Cancer","Prostate Cancer","Solid Tumor"],"countries":["United States"],"enrollment":366,"has_results":false,"interventions":["OTHER: questionnaire administration","OTHER: survey administration","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00544336","official_title":"Assessment of Family Quality of Life Among Families With a Member Who is a Cancer Patient","phases":[],"primary_completion":"2009-02","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2007-08","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Family Quality of Life Among Families With a Member Who is a Cancer Patient","url":"https://clinicaltrials.gov/study/NCT00544336"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":46,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: arginine/omega-3 fatty acids/nucleotides oral supplement","DRUG: cisplatin","PROCEDURE: adjuvant therapy","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00559156","official_title":"Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2011-05","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","start":"2005-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT00559156"},{"conditions":["Obesity","Prostate Cancer"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["OTHER: Bariatric Surgery"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00562341","official_title":"Effect of Lap-Band Induced Weight Loss on Serum PSA Levels, Testosterone, Estrogen and Other Serum Markers","phases":[],"primary_completion":"2009-12-31","sponsor":"Maimonides Medical Center","start":"2007-11","status":"WITHDRAWN","study_type":"OBSERVATIONAL","title":"Effect of Lap-Band Induced Weight Loss on Serum PSA Levels","url":"https://clinicaltrials.gov/study/NCT00562341"},{"conditions":["Breast Cancer","Stomach Neoplasms","Salivary Gland Neoplasms","Thyroid Cancer"],"countries":["United States"],"enrollment":169,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00568438","official_title":"Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples","phases":[],"primary_completion":"2015-12-31","sponsor":"Stanford University","start":"2000-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample","url":"https://clinicaltrials.gov/study/NCT00568438"},{"conditions":["Prostate Cancer"],"countries":["United States"],"enrollment":300,"has_results":false,"interventions":["DRUG: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00588185","official_title":"[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer or Salivary Gland Cancer","phases":["NA"],"primary_completion":"2027-02","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2003-02","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT00588185"},{"conditions":["Neck Squamous Cell Carcinoma of Unknown Primary","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Neck Squamous Cell Carcinoma of Unknown Primary","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Salivary Gland Carcinoma","Recurrent Sinonasal Squamous Cell Carcinoma","Salivary Gland Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Major Salivary Gland Cancer AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Verrucous Carcinoma AJCC v7","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Oral Cavity Cancer AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Verrucous Carcinoma AJCC v7","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Oral Cavity Cancer AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Verrucous Carcinoma AJCC v7","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Oral Cavity Cancer AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7","Tongue Carcinoma"],"countries":["Puerto Rico","South Africa","United States"],"enrollment":403,"has_results":true,"interventions":["BIOLOGICAL: Bevacizumab","DRUG: Carboplatin","DRUG: Cisplatin","DRUG: Docetaxel","DRUG: Fluorouracil","OTHER: Laboratory Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00588770","official_title":"A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer","phases":["PHASE3"],"primary_completion":"2018-06-05","sponsor":"National Cancer Institute (NCI)","start":"2008-08-08","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT00588770"},{"conditions":["Xerostomia"],"countries":["United States"],"enrollment":28,"has_results":false,"interventions":["OTHER: sugar-free chewing gum","OTHER: chewing gum","OTHER: mouth rinse","OTHER: mouth rinse","DRUG: mouth spray","DRUG: mouth spray"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00595933","official_title":"A Comparative Trial of Over-the-counter Dry Mouth Remedies for Dry Mouth After Radiation to the Head and Neck","phases":["PHASE1"],"primary_completion":"2010-06","sponsor":"University of Oklahoma","start":"2005-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Comparing Over-the-counter Dry Mouth Remedies After Radiation","url":"https://clinicaltrials.gov/study/NCT00595933"},{"conditions":["Biochemical Recurrent Prostate Cancer"],"countries":["United States"],"enrollment":20,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Isoflavone"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00596895","official_title":"Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy.","phases":["PHASE2"],"primary_completion":"2007-11","sponsor":"University of Florida","start":"2003-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT00596895"},{"conditions":["Fatigue","Head and Neck Cancer","Psychosocial Effects of Cancer and Its Treatment","Sleep Disorders"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["OTHER: medical chart review","OTHER: questionnaire administration","PROCEDURE: fatigue assessment and management","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00616590","official_title":"Assessment of Insomnia in Patients With Head and Neck Cancer During Treatment","phases":[],"primary_completion":"2012-07","sponsor":"Vanderbilt University","start":"2007-07","status":"WITHDRAWN","study_type":"OBSERVATIONAL","title":"Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00616590"},{"conditions":["Head and Neck Cancer","Radiation Toxicity","Xerostomia"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["OTHER: questionnaire administration","PROCEDURE: electroacupuncture therapy","PROCEDURE: management of therapy complications","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00623129","official_title":"Electroacupuncture for Xerostomia in Head and Neck Patients","phases":["NA"],"primary_completion":"2010-11","sponsor":"Mayo Clinic","start":"2006-02","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00623129"},{"conditions":["Cancer"],"countries":["Switzerland"],"enrollment":60,"has_results":false,"interventions":["DRUG: indinavir sulfate","DRUG: ritonavir","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00637637","official_title":"Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study","phases":["PHASE2"],"primary_completion":"2009-06","sponsor":"Oncology Institute of Southern Switzerland","start":"2007-09","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases","url":"https://clinicaltrials.gov/study/NCT00637637"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":41,"has_results":true,"interventions":["DRUG: cisplatin","DRUG: irinotecan hydrochloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00639769","official_title":"Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2007-05","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2002-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00639769"},{"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"countries":["India"],"enrollment":60,"has_results":false,"interventions":["RADIATION: 3 Dimensional Radiation Therapy","RADIATION: Intensity Modulated Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00652613","official_title":"Phase II Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) vs Intensity Modulated Radiotherapy (IMRT) for Squamous Cell Carcinoma of the Head and Neck (HNSCC)","phases":["PHASE2"],"primary_completion":"2008-03","sponsor":"Tata Memorial Hospital","start":"2005-08","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)","url":"https://clinicaltrials.gov/study/NCT00652613"},{"conditions":["Head and Neck Cancer","Xerostomia"],"countries":["Canada","United States"],"enrollment":196,"has_results":true,"interventions":["DRUG: Pilocarpine","PROCEDURE: ALTENS"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00656513","official_title":"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia","phases":["PHASE2","PHASE3"],"primary_completion":"2014-11","sponsor":"Radiation Therapy Oncology Group","start":"2008-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00656513"},{"conditions":["Head and Neck Cancer"],"countries":["France"],"enrollment":45,"has_results":false,"interventions":["BIOLOGICAL: cetuximab","RADIATION: stereotactic body radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00738868","official_title":"Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2011-05","sponsor":"Centre Oscar Lambret","start":"2007-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery","url":"https://clinicaltrials.gov/study/NCT00738868"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":23,"has_results":false,"interventions":["DRUG: systemic chemotherapy","OTHER: survey administration","PROCEDURE: adjuvant therapy","PROCEDURE: management of therapy complications","PROCEDURE: musculoskeletal complications management/prevention","PROCEDURE: physical therapy","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00751816","official_title":"Head & Neck Cancer Survivorship: Physical and Functional Status","phases":[],"primary_completion":"2009-01","sponsor":"Vanderbilt University","start":"2008-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Head & Neck Cancer Survivorship: Physical and Functional Status","url":"https://clinicaltrials.gov/study/NCT00751816"},{"conditions":["Adenocarcinoma of the Prostate"],"countries":["France"],"enrollment":254,"has_results":false,"interventions":["DRUG: Docetaxel + hormonal treatment (LH-RH agonist)","DRUG: Hormonal treatment (LH-RH agonist)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00764166","official_title":"Non-Metastatic High-Risk Prostate Cancer Patients With Biochemical Relapse Only After Local Treatment. A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel","phases":["PHASE3"],"primary_completion":"2009-11","sponsor":"Assistance Publique - Hôpitaux de Paris","start":"2003-06","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel","url":"https://clinicaltrials.gov/study/NCT00764166"},{"conditions":["Head and Neck Cancer"],"countries":["France"],"enrollment":40,"has_results":false,"interventions":["RADIATION: 3-dimensional conformal radiation therapy","RADIATION: fludeoxyglucose F 18","RADIATION: intensity-modulated radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00809016","official_title":"Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors","phases":["NA"],"primary_completion":"2011-05","sponsor":"Centre Oscar Lambret","start":"2007-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT00809016"},{"conditions":["Mesenchymal Tumor","Carcinosarcoma","Leiomyosarcoma"],"countries":["Germany"],"enrollment":41,"has_results":false,"interventions":["DRUG: PegLiposomal Doxorubicin","DRUG: Carboplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00815945","official_title":"Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors","phases":["PHASE2"],"primary_completion":"2011-11","sponsor":"AGO Study Group","start":"2008-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors","url":"https://clinicaltrials.gov/study/NCT00815945"},{"conditions":["Breast Cancer","Head and Neck Cancer","Lymphedema"],"countries":["United Kingdom"],"enrollment":56,"has_results":true,"interventions":["OTHER: Acupuncture and moxibustion"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00828516","official_title":"Using Acupuncture and Moxibustion to Promote Wellbeing and Improve Quality of Life for Patients With Upper Body Lymphoedema Secondary to Cancer Treatment","phases":["NA"],"primary_completion":"2009-09","sponsor":"East and North Hertfordshire NHS Trust","start":"2008-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema","url":"https://clinicaltrials.gov/study/NCT00828516"},{"conditions":["Head and Neck Cancer","Lymphedema"],"countries":["United States"],"enrollment":55,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00840814","official_title":"Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients","phases":[],"primary_completion":"2012-02","sponsor":"Vanderbilt University","start":"2008-05","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00840814"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":12,"has_results":true,"interventions":["RADIATION: stereotactic radiosurgery"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00851253","official_title":"The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer","phases":["NA"],"primary_completion":"2014-12","sponsor":"Boston Medical Center","start":"2009-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00851253"},{"conditions":["Malignant Salivary Gland Neoplasm","Recurrent Salivary Gland Carcinoma","Salivary Gland Adenoid Cystic Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v7"],"countries":["Canada","United States"],"enrollment":55,"has_results":true,"interventions":["DRUG: Dasatinib","OTHER: Laboratory Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00859937","official_title":"Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors","phases":["PHASE2"],"primary_completion":"2013-01-30","sponsor":"National Cancer Institute (NCI)","start":"2009-03-16","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors","url":"https://clinicaltrials.gov/study/NCT00859937"},{"conditions":["Head and Neck Cancer","Xerostomia"],"countries":["China"],"enrollment":23,"has_results":false,"interventions":["OTHER: Acupuncture"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00862550","official_title":"Randomized Pilot Trial of Acupuncture for Prevention of Radiation-Induced Xerostomia","phases":["NA"],"primary_completion":"2021-03","sponsor":"M.D. Anderson Cancer Center","start":"2009-03","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT00862550"},{"conditions":["Adenoid Cystic Carcinoma","Salivary Gland Cancer"],"countries":["Canada"],"enrollment":14,"has_results":false,"interventions":["DRUG: Sunitinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00886132","official_title":"A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands","phases":["PHASE2"],"primary_completion":"2012-12","sponsor":"University Health Network, Toronto","start":"2007-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands","url":"https://clinicaltrials.gov/study/NCT00886132"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":352,"has_results":false,"interventions":["OTHER: proteomic profiles","OTHER: proteomic profiles"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00896675","official_title":"Proteomic Prediction of Clinical Benefit in HNSCC","phases":[],"primary_completion":"2008-12","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2007-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","url":"https://clinicaltrials.gov/study/NCT00896675"},{"conditions":["Colorectal Cancer","Head and Neck Cancer"],"countries":[],"enrollment":538,"has_results":false,"interventions":["OTHER: immunologic technique","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00896896","official_title":"Immunoreactivity to Cetuximab in Cancer Patients","phases":[],"primary_completion":"2008-10","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2006-11","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Immunoreactivity to Cetuximab in Cancer Patients","url":"https://clinicaltrials.gov/study/NCT00896896"},{"conditions":["Breast Cancer","Colorectal Cancer","Head and Neck Cancer","Lung Cancer","Prostate Cancer"],"countries":["United States"],"enrollment":25,"has_results":false,"interventions":["PROCEDURE: venipuncture","RADIATION: radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00897793","official_title":"A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury","phases":[],"primary_completion":"2010-07","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2006-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer","url":"https://clinicaltrials.gov/study/NCT00897793"},{"conditions":["Head and Neck Cancer"],"countries":["Canada","United States"],"enrollment":351,"has_results":false,"interventions":["OTHER: biologic sample preservation procedure","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898300","official_title":"Establishment of a Head and Neck Cancer Tissue/Specimen Bank","phases":[],"primary_completion":"2010-07","sponsor":"Radiation Therapy Oncology Group","start":"2005-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00898300"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":49,"has_results":false,"interventions":["GENETIC: DNA Microarray analysis","GENETIC: MALDI-TOF mass spectrometry","GENETIC: DNA microarray and MALDI-TOF mass spectrometry"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898430","official_title":"Biomarkers of Survival in HNSCC","phases":[],"primary_completion":"2011-02","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2003-11","status":"TERMINATED","study_type":"OBSERVATIONAL","title":"Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT00898430"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":8000,"has_results":false,"interventions":["OTHER: biologic sample preservation procedure","OTHER: medical chart review"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898638","official_title":"Head and Neck Tumor Tissue Repository and Clinical Database","phases":[],"primary_completion":"2050-12","sponsor":"Vanderbilt University Medical Center","start":"2003-02-13","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants","url":"https://clinicaltrials.gov/study/NCT00898638"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":74,"has_results":false,"interventions":["GENETIC: cytogenetic analysis","GENETIC: gene expression analysis","GENETIC: mutation analysis","GENETIC: polymerase chain reaction","OTHER: immunohistochemistry staining method","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898664","official_title":"Genetic Analysis of Head and Neck Squamous Cell Carcinoma","phases":[],"primary_completion":"2008-04","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2006-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00898664"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":58,"has_results":false,"interventions":["GENETIC: DNA and tissue microarray analysis","GENETIC: reverse transcriptase-polymerase chain reaction","OTHER: mass spectrometry"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898742","official_title":"Molecular Signatures of HNSCC in Response to Targeted Therapies","phases":[],"primary_completion":"2010-06","sponsor":"Vanderbilt-Ingram Cancer Center","start":"2007-04","status":"TERMINATED","study_type":"OBSERVATIONAL","title":"Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00898742"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":30,"has_results":false,"interventions":["OTHER: matrix-assisted laser desorption/ionization time of flight mass spectrometry"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00898911","official_title":"Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors","phases":[],"primary_completion":"2012-04-08","sponsor":"ECOG-ACRIN Cancer Research Group","start":"2008-07-08","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00898911"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":100,"has_results":false,"interventions":["GENETIC: protein expression analysis","GENETIC: proteomic profiling","OTHER: immunoenzyme technique","OTHER: laboratory biomarker analysis","OTHER: liquid chromatography","OTHER: mass spectrometry"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00899769","official_title":"Serum Biomarkers for Head and Neck Cancer","phases":[],"primary_completion":"","sponsor":"Vanderbilt University Medical Center","start":"2005-04","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers","url":"https://clinicaltrials.gov/study/NCT00899769"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":null,"has_results":false,"interventions":["BIOLOGICAL: aldesleukin","BIOLOGICAL: recombinant interleukin-12","BIOLOGICAL: sargramostim","OTHER: immunologic technique","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00899821","official_title":"Head And Neck Cancer Immunotherapy Using Biodegradable Microspheres","phases":["NA"],"primary_completion":"2004-12","sponsor":"NYU Langone Health","start":"2000-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00899821"},{"conditions":["Cancer"],"countries":["United States"],"enrollment":98,"has_results":false,"interventions":["GENETIC: protein expression analysis","OTHER: immunohistochemistry staining method","OTHER: laboratory biomarker analysis","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00900302","official_title":"Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer","phases":[],"primary_completion":"2011-03","sponsor":"OHSU Knight Cancer Institute","start":"2005-04","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer","url":"https://clinicaltrials.gov/study/NCT00900302"},{"conditions":["Esophageal Cancer","Head and Neck Cancer","Lung Cancer","Precancerous Condition"],"countries":["United States"],"enrollment":700,"has_results":false,"interventions":["OTHER: immunohistochemistry staining method","OTHER: laboratory biomarker analysis","OTHER: sputum cytology","PROCEDURE: biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00900419","official_title":"Biomarkers and Dysplastic Respiratory Epithelium","phases":[],"primary_completion":"2028-10-30","sponsor":"University of Colorado, Denver","start":"2001-05-03","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers","url":"https://clinicaltrials.gov/study/NCT00900419"},{"conditions":["Cancer"],"countries":[],"enrollment":241,"has_results":false,"interventions":["GENETIC: gene expression analysis","GENETIC: microarray analysis","GENETIC: mutation analysis","GENETIC: polymerase chain reaction","OTHER: flow cytometry","OTHER: immunoenzyme technique","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00904514","official_title":"Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol","phases":[],"primary_completion":"2007-10","sponsor":"National Institutes of Health Clinical Center (CC)","start":"2007-10","status":"TERMINATED","study_type":"OBSERVATIONAL","title":"Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial","url":"https://clinicaltrials.gov/study/NCT00904514"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":36,"has_results":false,"interventions":["DRUG: sunitinib malate","OTHER: pharmacological study","RADIATION: 3-dimensional conformal radiation therapy","BIOLOGICAL: cetuximab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00906360","official_title":"A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2012-09","sponsor":"National Cancer Institute (NCI)","start":"2008-07","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT00906360"},{"conditions":["Cervical Cancer","Prostate Cancer"],"countries":["United States"],"enrollment":13,"has_results":false,"interventions":["PROCEDURE: Hyperthermia","RADIATION: HDR brachytherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00911079","official_title":"Pilot Study of a Catheter-based Ultrasound Hyperthermia System","phases":["NA"],"primary_completion":"2020-07-23","sponsor":"University of California, San Francisco","start":"2009-12-18","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Pilot Study of a Catheter-based Ultrasound Hyperthermia System","url":"https://clinicaltrials.gov/study/NCT00911079"},{"conditions":["Head and Neck Cancer","Oropharyngeal Cancer","Gastroesophageal Reflux Disease"],"countries":[],"enrollment":0,"has_results":false,"interventions":["DRUG: Dexlansoprazole"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00928161","official_title":"Evaluation and Treatment of Reflux Disease in Patients With Head and Neck Cancer Undergoing Radiation Therapy That Causes Significant Mucositis in the Reflux Field and Xerostomia","phases":["NA"],"primary_completion":"2014-11","sponsor":"M.D. Anderson Cancer Center","start":"2012-11","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT00928161"},{"conditions":["Breast Cancer","Head and Neck Cancer","Lung Cancer","Prostate Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":[],"enrollment":0,"has_results":false,"interventions":["DRUG: docetaxel","DRUG: vandetanib","GENETIC: proteomic profiling","OTHER: laboratory biomarker analysis","OTHER: pharmacological study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00937417","official_title":"Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2009-09","sponsor":"SWOG Cancer Research Network","start":"2008-09","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT00937417"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":55,"has_results":true,"interventions":["BIOLOGICAL: cetuximab","OTHER: placebo","DRUG: sorafenib tosylate","OTHER: laboratory biomarker analysis","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00939627","official_title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","phases":["PHASE2"],"primary_completion":"2013-01","sponsor":"National Cancer Institute (NCI)","start":"2009-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","url":"https://clinicaltrials.gov/study/NCT00939627"},{"conditions":["Recurrent Head and Neck Carcinoma","Recurrent Salivary Gland Carcinoma","Recurrent Skin Carcinoma","Skin Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":48,"has_results":false,"interventions":["DRUG: Erlotinib Hydrochloride","OTHER: Laboratory Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00954226","official_title":"Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2025-04-30","sponsor":"M.D. Anderson Cancer Center","start":"2009-08-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00954226"},{"conditions":["Breast Cancer","Colorectal Cancer","Head and Neck Cancer","Lung Cancer","Lymphoma","Prostate Cancer"],"countries":["France"],"enrollment":1674,"has_results":true,"interventions":["OTHER: Geriatric screening tests","OTHER: Multidimensional geriatric assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00963911","official_title":"Validation of a Screening Tool in Geriatric Oncology","phases":["NA"],"primary_completion":"2010-03-08","sponsor":"Institut Bergonié","start":"2008-08-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Validation of a Screening Tool in Geriatric Oncology","url":"https://clinicaltrials.gov/study/NCT00963911"},{"conditions":["Head and Neck Cancer"],"countries":["Ireland"],"enrollment":40,"has_results":false,"interventions":["OTHER: questionnaire administration","RADIATION: 3-dimensional conformal radiation therapy","RADIATION: radiation therapy treatment planning/simulation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00973947","official_title":"A Prospective Randomised Controlled Clinical Trial Investigating the Benefits of Patient-customised Headrests Versus Standard (Non-patient Specific) Headrests in the Immobilisation of Patients Receiving Radiotherapy for Head and Neck Cancer","phases":["NA"],"primary_completion":"2010-08","sponsor":"Cancer Trials Ireland","start":"2008-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00973947"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":3,"has_results":false,"interventions":["PROCEDURE: blood-oxygen-level-dependent functional magnetic resonance imaging","PROCEDURE: diffusion tensor imaging","PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging","PROCEDURE: functional magnetic resonance imaging","RADIATION: intensity-modulated radiation therapy","RADIATION: radiation therapy treatment planning/simulation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00984074","official_title":"A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy","phases":[],"primary_completion":"2011-12","sponsor":"Abramson Cancer Center at Penn Medicine","start":"2008-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT00984074"},{"conditions":["Adenoma, Pleomorphic","Mixed Salivary Gland Tumor","Salivary Gland Tumor, Mixed","Syringoma, Chondroid"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["RADIATION: Radiation","DRUG: Panitumumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00984217","official_title":"Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies","phases":["PHASE2"],"primary_completion":"2011-08","sponsor":"University of Pittsburgh","start":"2011-08","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies","url":"https://clinicaltrials.gov/study/NCT00984217"},{"conditions":["Hormone Refractory Prostate Cancer","Prostate Cancer"],"countries":["United States"],"enrollment":13,"has_results":false,"interventions":["DRUG: L-377202"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00987753","official_title":"A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks","phases":["PHASE1","PHASE2"],"primary_completion":"2000-09","sponsor":"University of Alabama at Birmingham","start":"1999-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study Evaluating the Safety and Tolerability of L-377202","url":"https://clinicaltrials.gov/study/NCT00987753"},{"conditions":["Head and Neck Cancer"],"countries":["Norway"],"enrollment":58,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT00995319","official_title":"Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area","phases":[],"primary_completion":"2013-01","sponsor":"Norwegian University of Science and Technology","start":"2008-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area","url":"https://clinicaltrials.gov/study/NCT00995319"},{"conditions":["Bladder Cancer","Breast Cancer","Head and Neck Cancer","Lung Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":[],"enrollment":69,"has_results":false,"interventions":["OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01015963","official_title":"A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients","phases":[],"primary_completion":"2013-01","sponsor":"Alliance for Clinical Trials in Oncology","start":"2008-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871","url":"https://clinicaltrials.gov/study/NCT01015963"},{"conditions":["Head and Neck Cancer","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity"],"countries":["United States"],"enrollment":44,"has_results":true,"interventions":["DRUG: lapatinib ditosylate","DRUG: capecitabine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01044433","official_title":"A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2015-09-24","sponsor":"Abramson Cancer Center at Penn Medicine","start":"2009-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT01044433"},{"conditions":["Ankylosing Spondylitis (AS)","Psoriatic Arthritis (PsA","Rheumatoid Arthritis (RA"],"countries":["Croatia","Hungary","Israel","Poland","Romania","Slovakia","Ukraine"],"enrollment":809,"has_results":true,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01078402","official_title":"Evaluation of Clinical Outcome, Treatment Compliance and Tolerability of humIRA (Adalimumab) in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries; EviraEAST - a Multi-country, Multi-Center Post Marketing Observational Study in Routine Clinical Use","phases":[],"primary_completion":"2011-11","sponsor":"AbbVie (prior sponsor, Abbott)","start":"2009-04","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries","url":"https://clinicaltrials.gov/study/NCT01078402"},{"conditions":["Malignancy","Salivary Glands","Tumor"],"countries":["Germany"],"enrollment":54,"has_results":false,"interventions":["RADIATION: carbon ion boost"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01154270","official_title":"Combined Therapy of Malignant Salivary Gland Tumours With IMRT and Carbon Ions: COSMIC","phases":["PHASE2"],"primary_completion":"2011-09","sponsor":"Heidelberg University","start":"2010-06","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC","url":"https://clinicaltrials.gov/study/NCT01154270"},{"conditions":["Mucositis","Oral Complications of Chemotherapy","Oral Complications of Radiation Therapy","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Adenoid Cystic Carcinoma of the Oral Cavity","Stage II Basal Cell Carcinoma of the Lip","Stage II Lymphoepithelioma of the Nasopharynx","Stage II Lymphoepithelioma of the Oropharynx","Stage II Mucoepidermoid Carcinoma of the Oral Cavity","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity"],"countries":["United States"],"enrollment":10,"has_results":false,"interventions":["PROCEDURE: quality-of-life assessment","PROCEDURE: management of therapy complications","DIETARY_SUPPLEMENT: L-lysine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01155609","official_title":"L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study","phases":["NA"],"primary_completion":"2011-12","sponsor":"University of Washington","start":"2010-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01155609"},{"conditions":["Head and Neck Cancer","Mucositis","Oral Complications of Radiation Therapy","Pain"],"countries":["United States"],"enrollment":155,"has_results":true,"interventions":["DRUG: doxepin hydrochloride","OTHER: placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01156142","official_title":"A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy","phases":["PHASE3"],"primary_completion":"2012-05","sponsor":"Alliance for Clinical Trials in Oncology","start":"2010-12","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy","url":"https://clinicaltrials.gov/study/NCT01156142"},{"conditions":["Breast Cancer","Esophageal Cancer","Gastric Cancer","Head and Neck Cancer","Lung Cancer","Ovarian Cancer","Prostate Cancer"],"countries":["United States"],"enrollment":33,"has_results":false,"interventions":["DRUG: Taxotere (Docetaxel)","DRUG: Alimta (Pemetrexed)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01172028","official_title":"Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients","phases":["PHASE1"],"primary_completion":"2014-07","sponsor":"University of Arizona","start":"2005-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT01172028"},{"conditions":["Recurrent Oral Cavity Adenoid Cystic Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Adenoid Cystic Carcinoma","Stage III Major Salivary Gland Cancer AJCC v7","Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Tongue Carcinoma"],"countries":["Canada","United States"],"enrollment":30,"has_results":true,"interventions":["OTHER: Laboratory Biomarker Analysis","DRUG: Vorinostat"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01175980","official_title":"A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)","phases":["PHASE2"],"primary_completion":"2018-06-08","sponsor":"National Cancer Institute (NCI)","start":"2010-08-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma","url":"https://clinicaltrials.gov/study/NCT01175980"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":79,"has_results":false,"interventions":["OTHER: immunohistochemistry staining method","OTHER: laboratory biomarker analysis","OTHER: medical chart review"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01192750","official_title":"Retrospective Analysis of ERCC1 Expression in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Received Cisplatin or Cisplatin and Cetuximab","phases":[],"primary_completion":"2010-10-05","sponsor":"ECOG-ACRIN Cancer Research Group","start":"2010-08-05","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab","url":"https://clinicaltrials.gov/study/NCT01192750"},{"conditions":["Head and Neck Cancer","Ototoxicity","Radiation Toxicity"],"countries":["United Kingdom"],"enrollment":84,"has_results":false,"interventions":["PROCEDURE: adjuvant therapy","PROCEDURE: assessment of therapy complications","PROCEDURE: quality-of-life assessment","RADIATION: 3-dimensional conformal radiation therapy","RADIATION: intensity-modulated radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01216800","official_title":"A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors","phases":["PHASE3"],"primary_completion":"2016-08","sponsor":"Institute of Cancer Research, United Kingdom","start":"2008-08","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors","url":"https://clinicaltrials.gov/study/NCT01216800"},{"conditions":["Head and Neck Cancer"],"countries":["Canada","Saudi Arabia","United States"],"enrollment":252,"has_results":false,"interventions":["DRUG: cisplatin","RADIATION: 3-dimensional conformal radiation therapy","RADIATION: intensity-modulated radiation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01220583","official_title":"A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors","phases":["PHASE2"],"primary_completion":"2026-12-31","sponsor":"Radiation Therapy Oncology Group","start":"2011-01","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery","url":"https://clinicaltrials.gov/study/NCT01220583"},{"conditions":["Recurrent Prostate Cancer"],"countries":["United States"],"enrollment":104,"has_results":false,"interventions":["DRUG: 3 POMx capsules","DRUG: 1 POMx capsule"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01220817","official_title":"Safety and Efficacy of POMx in Men With Prostate Cancer: An 18-Month, Randomized, Double-Blind, Dose-Finding Study of the Effects of Two (2) Doses of Pomegranate Juice Extract Capsules (1 or 3 Capsules/Day) on Rising Prostate Specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer","phases":["PHASE2"],"primary_completion":"2010-05","sponsor":"POM Wonderful LLC","start":"2007-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study","url":"https://clinicaltrials.gov/study/NCT01220817"},{"conditions":["HIV Infection","Recurrent Anal Cancer","Recurrent Breast Cancer","Recurrent Esophageal Cancer","Recurrent Gastric Cancer","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Non-small Cell Lung Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Anal Cancer","Stage IV Breast Cancer","Stage IV Esophageal Cancer","Stage IV Gastric Cancer","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["United States"],"enrollment":17,"has_results":false,"interventions":["DRUG: vorinostat","OTHER: diagnostic laboratory biomarker analysis","OTHER: pharmacological study","DRUG: carboplatin","DRUG: paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01249443","official_title":"A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection","phases":["PHASE1"],"primary_completion":"2016-05","sponsor":"AIDS Malignancy Consortium","start":"2013-11","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection","url":"https://clinicaltrials.gov/study/NCT01249443"},{"conditions":["Breast Cancer","Colorectal Cancer","Esophageal Cancer","Head and Neck Cancer","Lung Cancer"],"countries":["United Kingdom"],"enrollment":500,"has_results":false,"interventions":["OTHER: 18F-fluoromisonidazole","OTHER: fluorescence angiography","OTHER: laboratory biomarker analysis","PROCEDURE: infrared thermography","PROCEDURE: magnetic resonance imaging","PROCEDURE: therapeutic conventional surgery","RADIATION: [18F]-ML-10","RADIATION: fludeoxyglucose F 18","RADIATION: rubidium Rb-82"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01254591","official_title":"Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation","phases":["NA"],"primary_completion":"2013-08","sponsor":"University College London (UCL) Cancer Institute","start":"2006-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01254591"},{"conditions":["Recurrent Colon Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Rectal Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Squamous Cell Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage IVA Colon Cancer AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Verrucous Carcinoma AJCC v7","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVA Oral Cavity Cancer AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Rectal Cancer AJCC v7","Stage IVB Colon Cancer AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Verrucous Carcinoma AJCC v7","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVB Oral Cavity Cancer AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Rectal Cancer AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Verrucous Carcinoma AJCC v7","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","Stage IVC Oral Cavity Cancer AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Tongue Carcinoma"],"countries":["United States"],"enrollment":24,"has_results":false,"interventions":["BIOLOGICAL: Cetuximab","OTHER: Laboratory Biomarker Analysis","DRUG: Lenalidomide"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01254617","official_title":"Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study","phases":["PHASE1"],"primary_completion":"2014-01-29","sponsor":"National Cancer Institute (NCI)","start":"2011-02-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01254617"},{"conditions":["Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Squamous Cell Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage IV Hypopharyngeal Squamous Cell Carcinoma","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma","Stage IVA Laryngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Verrucous Carcinoma","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVA Oral Cavity Verrucous Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Verrucous Carcinoma","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Oral Cavity Verrucous Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Verrucous Carcinoma","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVC Major Salivary Gland Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Oral Cavity Verrucous Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma","Tongue Carcinoma"],"countries":["China","United States"],"enrollment":86,"has_results":true,"interventions":["BIOLOGICAL: Cetuximab","OTHER: Laboratory Biomarker Analysis","DRUG: Temsirolimus"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01256385","official_title":"A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy","phases":["PHASE2"],"primary_completion":"2013-12","sponsor":"National Cancer Institute (NCI)","start":"2010-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy","url":"https://clinicaltrials.gov/study/NCT01256385"},{"conditions":["Head And Neck Cancer"],"countries":["China","United States"],"enrollment":435,"has_results":false,"interventions":["PROCEDURE: Acupuncture - Group 1","PROCEDURE: Acupuncture - Group 2","OTHER: Standard Care","OTHER: Questionnaire"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01266044","official_title":"Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia","phases":["PHASE3"],"primary_completion":"2026-12-31","sponsor":"M.D. Anderson Cancer Center","start":"2011-12-09","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT01266044"},{"conditions":["Breast Cancer","Xerostomia"],"countries":["United States"],"enrollment":58,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01272570","official_title":"Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors: The Role of Aromatase Inhibitors","phases":[],"primary_completion":"2013-08","sponsor":"University of Michigan","start":"2010-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors","url":"https://clinicaltrials.gov/study/NCT01272570"},{"conditions":["Salivary Gland Squamous Cell Carcinoma","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Oral Cavity"],"countries":["United States"],"enrollment":3,"has_results":false,"interventions":["RADIATION: intensity-modulated radiation therapy","DRUG: cisplatin","RADIATION: image-guided adaptive radiation therapy","OTHER: 3'-deoxy-3'-[18F]fluorothymidine","PROCEDURE: positron emission tomography/computed tomography","RADIATION: fludeoxyglucose F 18"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01283178","official_title":"A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)","phases":["PHASE1"],"primary_completion":"2016-03","sponsor":"Virginia Commonwealth University","start":"2011-07","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC","url":"https://clinicaltrials.gov/study/NCT01283178"},{"conditions":["Head and Neck Cancer"],"countries":["United Kingdom"],"enrollment":4,"has_results":false,"interventions":["DRUG: docetaxel","DRUG: everolimus","OTHER: laboratory biomarker analysis","OTHER: pharmacological study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01313390","official_title":"DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE1","PHASE2"],"primary_completion":"2011-04","sponsor":"University College, London","start":"2009-06","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01313390"},{"conditions":["Xerostomia"],"countries":["Sweden"],"enrollment":20,"has_results":false,"interventions":["OTHER: XER2020"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01316393","official_title":"Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients","phases":["PHASE4"],"primary_completion":"2011-05","sponsor":"Camurus AB","start":"2011-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Effects of Mucoprotective Product on Xerostomia","url":"https://clinicaltrials.gov/study/NCT01316393"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Salivary Gland Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":24,"has_results":false,"interventions":["BIOLOGICAL: cetuximab","DRUG: paclitaxel","DRUG: carboplatin","DRUG: erlotinib hydrochloride","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01316757","official_title":"Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.","phases":["PHASE2"],"primary_completion":"2015-04-07","sponsor":"Fox Chase Cancer Center","start":"2011-02-16","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","url":"https://clinicaltrials.gov/study/NCT01316757"},{"conditions":["Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Tongue Cancer"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["DRUG: everolimus","DRUG: erlotinib hydrochloride","PROCEDURE: biopsy","OTHER: laboratory biomarker analysis","OTHER: immunohistochemistry staining method","GENETIC: polyacrylamide gel electrophoresis","OTHER: pharmacological study","RADIATION: external beam radiation therapy","GENETIC: microarray analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01332279","official_title":"A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2011-05","sponsor":"Fox Chase Cancer Center","start":"2011-04","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT01332279"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":13,"has_results":false,"interventions":["DRUG: TLR8 agonist VTX-2337","BIOLOGICAL: cetuximab","OTHER: laboratory biomarker analysis","OTHER: pharmacogenomic studies"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01334177","official_title":"Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)","phases":["PHASE1"],"primary_completion":"2014-06","sponsor":"University of Washington","start":"2011-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck","url":"https://clinicaltrials.gov/study/NCT01334177"},{"conditions":["Squamous Cell Carcinoma of the Head and Neck","Nasopharyngeal Carcinoma","Salivary Gland Cancer","Head and Neck Sarcoma","Paraganglioma of Head and Neck","Chordoma of Head and Neck","Chondrosarcoma of Head and Neck","Angiofibroma of Head and Neck"],"countries":["United States"],"enrollment":19,"has_results":true,"interventions":["RADIATION: stereotactic body radiotherapy","RADIATION: Stereotactic body radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01344356","official_title":"Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors","phases":["PHASE4"],"primary_completion":"2018-05","sponsor":"Mercy Research","start":"2008-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiotherapy for Head and Neck Tumors","url":"https://clinicaltrials.gov/study/NCT01344356"},{"conditions":["Malignant Head and Neck Neoplasm","Malignant Neoplasm","Metastatic Malignant Neoplasm in the Neck","Metastatic Malignant Neoplasm in the Uterine Cervix","Pancreatic Adenocarcinoma","Pancreatic Neuroendocrine Carcinoma","Recurrent Colorectal Carcinoma","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Hypopharyngeal Carcinoma AJCC v7","Stage I Major Salivary Gland Cancer AJCC v7","Stage I Nasopharyngeal Carcinoma AJCC v7","Stage I Oral Cavity Cancer AJCC v6 and v7","Stage I Oropharyngeal Carcinoma AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Hypopharyngeal Carcinoma AJCC v6 and v7","Stage II Major Salivary Gland Cancer AJCC v7","Stage II Nasopharyngeal Carcinoma AJCC v7","Stage II Oral Cavity Cancer AJCC v6 and v7","Stage II Oropharyngeal Carcinoma AJCC v6 and v7","Stage IIA Colorectal Cancer AJCC v7","Stage IIB Colorectal Cancer AJCC v7","Stage IIC Colorectal Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Hypopharyngeal Carcinoma AJCC v7","Stage III Laryngeal Cancer AJCC v6 and v7","Stage III Major Salivary Gland Cancer AJCC v7","Stage III Nasopharyngeal Carcinoma AJCC v7","Stage III Oral Cavity Cancer AJCC v6 and v7","Stage III Oropharyngeal Carcinoma AJCC v7","Stage IIIA Colorectal Cancer AJCC v7","Stage IIIB Colorectal Cancer AJCC v7","Stage IIIC Colorectal Cancer AJCC v7","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVA Hypopharyngeal Carcinoma AJCC v7","Stage IVA Laryngeal Cancer AJCC v7","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Nasopharyngeal Carcinoma AJCC v7","Stage IVA Oral Cavity Cancer AJCC v6 and v7","Stage IVA Oropharyngeal Carcinoma AJCC v7","Stage IVB Colorectal Cancer AJCC v7","Stage IVB Hypopharyngeal Carcinoma AJCC v7","Stage IVB Laryngeal Cancer AJCC v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Nasopharyngeal Carcinoma AJCC v7","Stage IVB Oral Cavity Cancer AJCC v6 and v7","Stage IVB Oropharyngeal Carcinoma AJCC v7","Metastatic or Locally Unresectable Solid Tumor"],"countries":["United States"],"enrollment":590,"has_results":false,"interventions":["BEHAVIORAL: Exercise Intervention","OTHER: Health Telemonitoring","OTHER: Health Telemonitoring","OTHER: Health Telemonitoring","OTHER: Health Telemonitoring","OTHER: Health Telemonitoring","OTHER: Quality-of-Life Assessment","OTHER: Questionnaire Administration","OTHER: Health Telemonitoring"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01365169","official_title":"\"CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial\"","phases":["NA"],"primary_completion":"2027-06-30","sponsor":"M.D. Anderson Cancer Center","start":"2011-05-25","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","url":"https://clinicaltrials.gov/study/NCT01365169"},{"conditions":["Parotid Tumor"],"countries":["China"],"enrollment":70,"has_results":false,"interventions":["PROCEDURE: ADM"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01414790","official_title":"The Use of Human Acellular Dermal Matrix in the Prevention of Infraauricular Depressed Deformities and Frey's Syndrome Following Total Parotidectomy","phases":["PHASE3"],"primary_completion":"2011-01","sponsor":"West China Hospital","start":"2004-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome","url":"https://clinicaltrials.gov/study/NCT01414790"},{"conditions":["Juvenile Idiopahtic Arthritis"],"countries":["Australia","Belgium","Colombia","Czechia","France","Germany","Hungary","Italy","Latvia","Lithuania","Mexico","Netherlands","Norway","Poland","Russia","Serbia","Slovakia","Slovenia","Spain"],"enrollment":109,"has_results":true,"interventions":["DRUG: etanercept"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01421069","official_title":"AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS WHO WERE PREVIOUSLY ENROLLED IN PROTOCOL 0881A1-3338-WW(B1801014)","phases":["PHASE3"],"primary_completion":"2021-02-04","sponsor":"Pfizer","start":"2011-10-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis","url":"https://clinicaltrials.gov/study/NCT01421069"},{"conditions":["Solitary Pulmonary Nodules","Multiple Pulmonary Nodules","Renal Neoplasms","Adrenal Gland Neoplasms","Aortic Aneurysm, Abdominal","Liver Neoplasms","Adnexal and Skin Appendage Neoplasms","Lymphadenopathy","Pancreatic Neoplasms"],"countries":[],"enrollment":520,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT01465425","official_title":"Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of \"National CT Colonography Trial\" Data","phases":[],"primary_completion":"2019-12","sponsor":"American College of Radiology Imaging Network","start":"2011-09","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Extracolonic Findings on Computed Tomography (CT) Colonography","url":"https://clinicaltrials.gov/study/NCT01465425"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Salivary Gland Squamous Cell Carcinoma","Stage 0 Hypopharyngeal Cancer","Stage 0 Laryngeal Cancer","Stage 0 Lip and Oral Cavity Cancer","Stage 0 Nasopharyngeal Cancer","Stage 0 Oropharyngeal Cancer","Stage 0 Paranasal Sinus and Nasal Cavity Cancer","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Nasal Cavity and Paranasal Sinus Cancer","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Oral Cavity Squamous Cell Carcinoma","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":70,"has_results":false,"interventions":["OTHER: placebo","OTHER: laboratory biomarker analysis","OTHER: questionnaire administration","DRUG: chemoprevention","DRUG: chemoprevention","OTHER: placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01469429","official_title":"Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer","phases":["PHASE1","PHASE2"],"primary_completion":"2014-09-17","sponsor":"Ohio State University Comprehensive Cancer Center","start":"2007-09-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.","url":"https://clinicaltrials.gov/study/NCT01469429"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":155,"has_results":false,"interventions":["GENETIC: gene expression analysis","GENETIC: in situ hybridization","OTHER: immunohistochemistry staining method","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01487733","official_title":"Analysis of HPV and Other Biomarkers in Specimens From ECOG Studies in Recurrent or Metastatic Head and Neck Cancer (E1395 and E3301)","phases":[],"primary_completion":"2012-01-22","sponsor":"Eastern Cooperative Oncology Group","start":"2011-12-22","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301","url":"https://clinicaltrials.gov/study/NCT01487733"},{"conditions":["Malignant Salivary Gland Tumors"],"countries":["Saudi Arabia"],"enrollment":120,"has_results":false,"interventions":["DRUG: Cisplatin: 40 mg/m2 weekly during radiation","RADIATION: Radiation: 60-66 Gy in 2 Gy daily fractions"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01488838","official_title":"","phases":["PHASE2"],"primary_completion":"2013-11","sponsor":"King Faisal Specialist Hospital & Research Center","start":"2011-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors","url":"https://clinicaltrials.gov/study/NCT01488838"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Non-small Cell Lung Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":4,"has_results":false,"interventions":["BIOLOGICAL: talactoferrin","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01528137","official_title":"A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC)","phases":["PHASE1"],"primary_completion":"2012-08","sponsor":"Stanford University","start":"2012-05","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01528137"},{"conditions":["Oral Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":370,"has_results":false,"interventions":["OTHER: saliva collection prior to clinically driven oral biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01587573","official_title":"Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma","phases":[],"primary_completion":"2018-09","sponsor":"PeriRx","start":"2012-04","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer","url":"https://clinicaltrials.gov/study/NCT01587573"},{"conditions":["Recurrent Oral Cavity Adenoid Cystic Carcinoma","Recurrent Salivary Gland Carcinoma","Salivary Gland Adenoid Cystic Carcinoma","Stage IVA Major Salivary Gland Cancer AJCC v7","Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVB Major Salivary Gland Cancer AJCC v7","Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7","Stage IVC Major Salivary Gland Cancer AJCC v7","Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7"],"countries":["United States"],"enrollment":16,"has_results":true,"interventions":["DRUG: Akt Inhibitor MK2206","OTHER: Laboratory Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01604772","official_title":"A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma","phases":["PHASE2"],"primary_completion":"2013-10-24","sponsor":"National Cancer Institute (NCI)","start":"2012-07-23","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma","url":"https://clinicaltrials.gov/study/NCT01604772"},{"conditions":["Pleomorphic Adenoma of the Parotid Gland"],"countries":["Egypt"],"enrollment":0,"has_results":false,"interventions":["PROCEDURE: Quadrant parotidectomy","PROCEDURE: Superficial parotidectomy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01607866","official_title":"Quadrant Parotidectomy Versus Superficial Parotidectomy for Treatment of Pleomorphic Adenoma","phases":["PHASE2","PHASE3"],"primary_completion":"2016-07","sponsor":"Mansoura University","start":"2014-06","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Quadrant Versus Superficial Parotidectomy","url":"https://clinicaltrials.gov/study/NCT01607866"},{"conditions":["Recurrent Salivary Gland Cancer","Stage IVA Salivary Gland Cancer","Stage IVB Salivary Gland Cancer","Stage IVC Salivary Gland Cancer"],"countries":["United States"],"enrollment":29,"has_results":true,"interventions":["DRUG: eribulin mesylate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01613768","official_title":"Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers","phases":["PHASE2"],"primary_completion":"2017-08-23","sponsor":"University of Washington","start":"2012-05-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT01613768"},{"conditions":["Head and Neck Cancer"],"countries":[],"enrollment":183,"has_results":false,"interventions":["GENETIC: mutation analysis","GENETIC: polymerase chain reaction","GENETIC: polymorphism analysis","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01619618","official_title":"Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302","phases":[],"primary_completion":"2012-07-01","sponsor":"Eastern Cooperative Oncology Group","start":"2012-06-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial","url":"https://clinicaltrials.gov/study/NCT01619618"},{"conditions":["Head and Neck Neoplasms","Xerostomia","Deglutition Disorders"],"countries":["Belgium"],"enrollment":0,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01621048","official_title":"Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer and Correlation With Dose to Organs at Risk","phases":[],"primary_completion":"2016-12","sponsor":"Universitaire Ziekenhuizen KU Leuven","start":"2012-06","status":"WITHDRAWN","study_type":"OBSERVATIONAL","title":"Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01621048"},{"conditions":["Salivary Gland Malignancy"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["DRUG: Postoperative Radiotherapy and Panitumumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01634880","official_title":"Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies","phases":["PHASE2"],"primary_completion":"2013-03","sponsor":"Athanassios Argiris","start":"2012-07","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies","url":"https://clinicaltrials.gov/study/NCT01634880"},{"conditions":["Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage IV Adenoid Cystic Carcinoma of the Oral Cavity","Stage IV Basal Cell Carcinoma of the Lip","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Lymphoepithelioma of the Oropharynx","Stage IV Mucoepidermoid Carcinoma of the Oral Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity","Stage IVA Colon Cancer","Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Colon Cancer","Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":12,"has_results":false,"interventions":["DRUG: everolimus","BIOLOGICAL: cetuximab","OTHER: pharmacological study","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01637194","official_title":"A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors","phases":["PHASE1"],"primary_completion":"2011-07","sponsor":"Fox Chase Cancer Center","start":"2008-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01637194"},{"conditions":["Prostate Cancer"],"countries":["Italy"],"enrollment":250,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01672411","official_title":"Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates, %p2psa and Prostate Health Index in the Detection of Prostate Cancer and in Predicting Aggressive Disease: a Prospective Study","phases":[],"primary_completion":"2012-12","sponsor":"University Of Perugia","start":"2012-04","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01672411"},{"conditions":["Recurrent Adenoid Cystic Carcinoma of the Salivary Glands","Metastatic Adenoid Cystic Carcinoma of the Salivary Glands","Salivary Gland Cancers","ACC"],"countries":["Canada"],"enrollment":21,"has_results":false,"interventions":["DRUG: Dovitinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01678105","official_title":"A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)","phases":["PHASE2"],"primary_completion":"2015-09","sponsor":"Ontario Clinical Oncology Group (OCOG)","start":"2012-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands","url":"https://clinicaltrials.gov/study/NCT01678105"},{"conditions":["Chemotherapeutic Agent Toxicity","Mucositis","Radiation Toxicity","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Xerostomia"],"countries":["New Zealand","United States"],"enrollment":18,"has_results":true,"interventions":["DIETARY_SUPPLEMENT: selenomethionine","OTHER: placebo","DRUG: cisplatin","RADIATION: radiation therapy","PROCEDURE: quality-of-life assessment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01682031","official_title":"Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2012-04","sponsor":"Roswell Park Cancer Institute","start":"2009-06","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT01682031"},{"conditions":["Prostate Cancer","Adenocarcinoma of the Prostate"],"countries":[],"enrollment":138,"has_results":false,"interventions":["DRUG: histrelin acetate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01697384","official_title":"Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer","phases":["PHASE3"],"primary_completion":"2003-08","sponsor":"Endo USA Inc., a Keenova Therapeutics Company","start":"2000-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01697384"},{"conditions":["Salivary Gland Cancer"],"countries":["Italy"],"enrollment":37,"has_results":false,"interventions":["DRUG: Sorafenib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01703455","official_title":"Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study","phases":["PHASE2"],"primary_completion":"2012-10","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2010-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Activity of Sorafenib in Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT01703455"},{"conditions":["Quality of Life","Adverse Effects","Late Effects","Cancer","Xerostomia"],"countries":["France","Germany","Greece","Israel","Italy","Netherlands","Norway","Poland","Sweden","United Kingdom"],"enrollment":585,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01724333","official_title":"International Validation and Testing of a Supplementary Questionnaire Module for Assessment of Oral and Dental Health in Cancer; the QLQ-OH17","phases":[],"primary_completion":"2014-09","sponsor":"Oslo University Hospital","start":"2012-12","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"International Validation of the QLQ-OH17 for Oral Health","url":"https://clinicaltrials.gov/study/NCT01724333"},{"conditions":["Malignant Lymphoma of Lymph Nodes of Inguinal Region","Malignant Lymphoma of Lymph Nodes of Axillary","Malignant Lymphoma of Lymph Nodes of the Cervix","Carcinoma of Parotid Gland","Colon Rectal Cancer Tubulovillous Adenocarcinoma","Tumor of Soft Tissue of Head, Face and Neck"],"countries":["Netherlands"],"enrollment":35,"has_results":false,"interventions":["PROCEDURE: Surgical resection"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01731379","official_title":"In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study","phases":[],"primary_completion":"2014-01","sponsor":"Philips Healthcare","start":"2012-12","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Optical Detection of Peripheral Nerve Bundles During Surgery","url":"https://clinicaltrials.gov/study/NCT01731379"},{"conditions":["Endometrial Clear Cell Adenocarcinoma","Endometrial Mixed Adenocarcinoma","Endometrial Serous Adenocarcinoma","Grade 3 Endometrial Endometrioid Adenocarcinoma","Malignant Mixed Mesodermal (Mullerian) Tumor"],"countries":["United States"],"enrollment":101,"has_results":true,"interventions":["PROCEDURE: Computed Tomography","DRUG: Indocyanine Green Solution","OTHER: Laboratory Biomarker Analysis","PROCEDURE: Lymph Node Mapping","PROCEDURE: Lymphadenectomy","PROCEDURE: Positron Emission Tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01737619","official_title":"Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer","phases":["NA"],"primary_completion":"2025-04-30","sponsor":"M.D. Anderson Cancer Center","start":"2013-04-03","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer","url":"https://clinicaltrials.gov/study/NCT01737619"},{"conditions":["Psoriatic Arthritis"],"countries":["Australia","Belgium","Canada","Czechia","Germany","Poland","Puerto Rico","Russia","Thailand","United Kingdom","United States"],"enrollment":397,"has_results":true,"interventions":["DRUG: Secukinumab (AIN457)","DRUG: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01752634","official_title":"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis","phases":["PHASE3"],"primary_completion":"2014-05-12","sponsor":"Novartis Pharmaceuticals","start":"2013-04-14","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis","url":"https://clinicaltrials.gov/study/NCT01752634"},{"conditions":["Nasopharyngeal Neoplasms","Salivary Gland Diseases","Bone Marrow Diseases","Mucositis"],"countries":["China"],"enrollment":360,"has_results":false,"interventions":["DRUG: Amifostine every-other-day regimen","DRUG: Amifostine everyday regimen"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01762514","official_title":"A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday","phases":["PHASE2"],"primary_completion":"2019-06","sponsor":"Sun Yat-sen University","start":"2013-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens","url":"https://clinicaltrials.gov/study/NCT01762514"},{"conditions":["Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Male Breast Cancer","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Adult Brain Tumor","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Colon Cancer","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Hypopharyngeal Cancer","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Laryngeal Cancer","Recurrent Lip and Oral Cavity Cancer","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Nasopharyngeal Cancer","Recurrent Non-small Cell Lung Cancer","Recurrent Oropharyngeal Cancer","Recurrent Pancreatic Cancer","Recurrent Paranasal Sinus and Nasal Cavity Cancer","Recurrent Rectal Cancer","Recurrent Renal Cell Cancer","Recurrent Salivary Gland Cancer","Stage IIIA Breast Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Breast Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IIIC Breast Cancer","Stage IV Breast Cancer","Stage IV Non-small Cell Lung Cancer","Stage IV Pancreatic Cancer","Stage IV Renal Cell Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVA Salivary Gland Cancer","Stage IVB Colon Cancer","Stage IVB Salivary Gland Cancer","Stage IVC Salivary Gland Cancer","Tongue Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"countries":["United States"],"enrollment":25,"has_results":true,"interventions":["DRUG: 18F-fludeoxyglucose (18F-FDG)","DRUG: 18F-FPPRGD2"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01806675","official_title":"Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis","phases":["PHASE1","PHASE2"],"primary_completion":"2016-12-07","sponsor":"Sanjiv Sam Gambhir","start":"2013-03-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy","url":"https://clinicaltrials.gov/study/NCT01806675"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":12,"has_results":true,"interventions":["DRUG: PI3K inhibitor BKM120","BIOLOGICAL: cetuximab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01816984","official_title":"A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer","phases":["PHASE1","PHASE2"],"primary_completion":"2018-04","sponsor":"University of Chicago","start":"2013-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01816984"},{"conditions":["Thyroid Cancer"],"countries":["Cyprus"],"enrollment":120,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: thymus honey mouthwash"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01833650","official_title":"A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer","phases":["NA"],"primary_completion":"2024-08-01","sponsor":"Cyprus University of Technology","start":"2018-02-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer","url":"https://clinicaltrials.gov/study/NCT01833650"},{"conditions":["Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Tongue Cancer"],"countries":["United States"],"enrollment":48,"has_results":false,"interventions":["DRUG: carboplatin","DRUG: paclitaxel albumin-stabilized nanoparticle formulation","DRUG: fluorouracil","DRUG: hydroxyurea","PROCEDURE: therapeutic conventional surgery","RADIATION: radiation therapy","RADIATION: hyperfractionated radiation therapy","OTHER: laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01847326","official_title":"Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.","phases":["PHASE1"],"primary_completion":"2024-01-22","sponsor":"University of Chicago","start":"2013-03-26","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT01847326"},{"conditions":["Oropharynx Cancer"],"countries":["France"],"enrollment":132,"has_results":false,"interventions":["RADIATION: adaptative radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01874587","official_title":"Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia","phases":["PHASE3"],"primary_completion":"2019-12-10","sponsor":"Center Eugene Marquis","start":"2013-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma","url":"https://clinicaltrials.gov/study/NCT01874587"},{"conditions":["Cancer of Head and Neck","Cancer","Radiation-induced Xerostomia","Dry Mouth"],"countries":["Thailand"],"enrollment":25,"has_results":false,"interventions":["OTHER: Gel-based artificial saliva"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01885065","official_title":"Efficacy Study of Novel Edible Gel-based Artificial Saliva in Xerostomic Cancer Patients","phases":["NA"],"primary_completion":"2012-09","sponsor":"Dental Innovation Foundation Under Royal Patronage","start":"2012-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients","url":"https://clinicaltrials.gov/study/NCT01885065"},{"conditions":["Chronic Radiation Dermatitis"],"countries":["United States"],"enrollment":12,"has_results":false,"interventions":["DEVICE: Fractional CO2 laser treatment","OTHER: No treatment"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT01910818","official_title":"Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study","phases":["NA"],"primary_completion":"2025-08","sponsor":"Massachusetts General Hospital","start":"2013-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury","url":"https://clinicaltrials.gov/study/NCT01910818"},{"conditions":["All Diagnosed Health Conditions","ADD/ADHD","Alopecia Areata","Ankylosing Spondylitis","Asthma","Atopic Dermatitis Eczema","Beta Thalassemia","Bipolar Disorder","Breast Cancer","Celiac Disease","Cervical Cancer","Chronic Inflammatory Demyelinating Polyneuropathy","Chronic Kidney Diseases","Chronic Obstructive Pulmonary Disease","Colon Cancer","Colorectal Cancer","Crohn's Disease","Cystic Fibrosis","Depression","Diabetes Mellitus","Duchenne Muscular Dystrophy","Endometriosis","Epilepsy","Facioscapulohumeral Muscular Dystrophy","G6PD Deficiency","General Anxiety Disorder","Hepatitis B","Hereditary Hemorrhagic Telangiectasia","HIV/AIDS","Human Papilloma Virus","Huntington's Disease","Idiopathic Thrombocytopenic Purpura","Insomnia","Kidney Cancer","Leukemia","Lung Cancer","Lupus Nephritis","Lymphoma","Melanoma","Multiple Myeloma","Multiple Sclerosis","Myositis","Myotonic Dystrophy","Ovarian Cancer","Pancreatic Cancer","Parkinson's Disease","Polycystic Kidney Diseases","Prostate Cancer","Psoriasis","Psoriatic Arthritis","Rosacea","Scleroderma","Sickle Cell Anemia","Sickle Cell Trait","Sjogren's Syndrome","Skin Cancer","Spinal Muscular Atrophy","Systemic Lupus Erythematosus","Thrombotic Thrombocytopenic Purpura","Trisomy 21","Ulcerative Colitis"],"countries":["United States"],"enrollment":17667,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01931644","official_title":"A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives","phases":[],"primary_completion":"2024-04","sponsor":"Sanguine Biosciences","start":"2013-07","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions","url":"https://clinicaltrials.gov/study/NCT01931644"},{"conditions":["Salivary Gland Cancer"],"countries":["Austria","Belgium","France","Germany","Greece","Hungary","Italy","Netherlands"],"enrollment":149,"has_results":false,"interventions":["DRUG: bicalutamide + triptorelin","DRUG: Cisplatin + Doxorubicin","DRUG: Carboplatin + Paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01969578","official_title":"A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)","phases":["PHASE2"],"primary_completion":"2023-08-23","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","start":"2015-09-24","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Androgen Deprivation Therapy in Advanced Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT01969578"},{"conditions":["Parotid Tumors","Postoperative Complications"],"countries":["Taiwan"],"enrollment":767,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT01983176","official_title":"Retrospective Clinical Outcome of Parotid Tumor Surgery","phases":[],"primary_completion":"2013-11","sponsor":"National Taiwan University Hospital","start":"2013-10","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Retrospective Clinical Outcome of Parotid Tumor Surgery","url":"https://clinicaltrials.gov/study/NCT01983176"},{"conditions":["Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control"],"countries":["United States"],"enrollment":999999,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02012699","official_title":"Integrated Cancer Repository for Cancer Research","phases":[],"primary_completion":"2099-12","sponsor":"University of Nebraska","start":"2013-11-01","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Integrated Cancer Repository for Cancer Research","url":"https://clinicaltrials.gov/study/NCT02012699"},{"conditions":["Prostate Cancer Detection"],"countries":["Turkey (Türkiye)"],"enrollment":480,"has_results":true,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02013180","official_title":"Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection","phases":[],"primary_completion":"2013-01","sponsor":"Bagcilar Training and Research Hospital","start":"2012-07","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection","url":"https://clinicaltrials.gov/study/NCT02013180"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":3,"has_results":false,"interventions":["DRUG: sorafenib tosylate","DRUG: cisplatin","DRUG: docetaxel","OTHER: Correlative Studies"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02035527","official_title":"A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","phases":["PHASE1"],"primary_completion":"2017-04-20","sponsor":"Ohio State University Comprehensive Cancer Center","start":"2014-04-14","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT02035527"},{"conditions":["Prostate Cancer","Salivary Gland Cancer","Endometrial Cancer","Squamous Cell Carcinoma of the Cervix","Breast Cancer","Ovarian Cancer"],"countries":["United Kingdom"],"enrollment":79,"has_results":false,"interventions":["DRUG: OPB-111001"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02042885","official_title":"A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment","phases":["PHASE1","PHASE2"],"primary_completion":"2015-02","sponsor":"Otsuka Novel Products GmbH","start":"2014-01","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer","url":"https://clinicaltrials.gov/study/NCT02042885"},{"conditions":["Metastatic Castration-resistant Prostate Cancer"],"countries":["United States"],"enrollment":28,"has_results":true,"interventions":["DRUG: Carfilzomib","DRUG: Dexamethasone","DRUG: Acyclovir"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02047253","official_title":"A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors","phases":["PHASE2"],"primary_completion":"2017-06-08","sponsor":"University of Alabama at Birmingham","start":"2014-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment","url":"https://clinicaltrials.gov/study/NCT02047253"},{"conditions":["Salivary Gland Cancer"],"countries":["China"],"enrollment":90,"has_results":false,"interventions":["RADIATION: brachytherapy","RADIATION: IMRT"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02048254","official_title":"A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer","phases":["PHASE3"],"primary_completion":"2017-12","sponsor":"Peking University","start":"2014-02","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT02048254"},{"conditions":["Xerostomia","Hyposalivation","Head and Neck Cancer","Sjögren Syndrome"],"countries":["France"],"enrollment":210,"has_results":false,"interventions":["DEVICE: Salivary equivalent","DEVICE: Aequasyal","DEVICE: Biotene"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02049112","official_title":"Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia.","phases":["PHASE4"],"primary_completion":"2013-04","sponsor":"Unither Pharmaceuticals, France","start":"2012-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study","url":"https://clinicaltrials.gov/study/NCT02049112"},{"conditions":["Head and Neck Cancer","Dental Disease","Xerostomia","Osteoradionecrosis"],"countries":["United States"],"enrollment":613,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02057510","official_title":"Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients","phases":[],"primary_completion":"2020-01-28","sponsor":"Wake Forest University Health Sciences","start":"2014-02","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Observational Study of Dental Outcomes in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02057510"},{"conditions":["Ovarian Epithelial Cancer"],"countries":["Austria","Belgium","Czechia","Germany"],"enrollment":50,"has_results":false,"interventions":["PROCEDURE: Lavage of the Cavum uteri and proximal fallopian tubes","PROCEDURE: Liquid-PAP smear"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02062697","official_title":"Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study","phases":["NA"],"primary_completion":"2018-11","sponsor":"Medical University of Vienna","start":"2012-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","url":"https://clinicaltrials.gov/study/NCT02062697"},{"conditions":["Salivary Gland Cancer","Metastatic","Advanced","Recurrent"],"countries":["Canada"],"enrollment":114,"has_results":false,"interventions":["DRUG: Selinexor","DRUG: EGFR or HER2 Inhibitor","DRUG: FGFR Inhibitor","DRUG: C-KIT Inhibitor","DRUG: Anti-androgen","DRUG: NOTCH Inhibitor","DRUG: MEK or PI3K Inhibitor"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02069730","official_title":"Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms","phases":["NA"],"primary_completion":"2023-06","sponsor":"University Health Network, Toronto","start":"2014-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes","url":"https://clinicaltrials.gov/study/NCT02069730"},{"conditions":["Mullerian Mixed Tumor of Ovary"],"countries":["United States"],"enrollment":null,"has_results":false,"interventions":["DRUG: ficlatuzumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02090127","official_title":"Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412","phases":[],"primary_completion":"","sponsor":"AVEO Pharmaceuticals, Inc.","start":"","status":"NO_LONGER_AVAILABLE","study_type":"EXPANDED_ACCESS","title":"Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient","url":"https://clinicaltrials.gov/study/NCT02090127"},{"conditions":["Mucositis","Oral Complications","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Adenoid Cystic Carcinoma of the Oral Cavity","Stage II Basal Cell Carcinoma of the Lip","Stage II Lymphoepithelioma of the Nasopharynx","Stage II Lymphoepithelioma of the Oropharynx","Stage II Mucoepidermoid Carcinoma of the Oral Cavity","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Adenoid Cystic Carcinoma of the Oral Cavity","Stage III Basal Cell Carcinoma of the Lip","Stage III Lymphoepithelioma of the Nasopharynx","Stage III Lymphoepithelioma of the Oropharynx","Stage III Mucoepidermoid Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Lymphoepithelioma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVA Basal Cell Carcinoma of the Lip","Stage IVA Lymphoepithelioma of the Oropharynx","Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVB Basal Cell Carcinoma of the Lip","Stage IVB Lymphoepithelioma of the Oropharynx","Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity","Stage IVC Basal Cell Carcinoma of the Lip","Stage IVC Lymphoepithelioma of the Oropharynx","Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer"],"countries":["United States"],"enrollment":34,"has_results":true,"interventions":["DRUG: acetylcysteine","OTHER: placebo","OTHER: quality-of-life assessment","OTHER: questionnaire administration"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02123511","official_title":"A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies","phases":["PHASE2"],"primary_completion":"2016-03-22","sponsor":"Mayo Clinic","start":"2014-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT02123511"},{"conditions":["Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor"],"countries":["United Kingdom","United States"],"enrollment":32,"has_results":false,"interventions":["DRUG: AZD5312"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02144051","official_title":"A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor","phases":["PHASE1"],"primary_completion":"2016-03","sponsor":"AstraZeneca","start":"2014-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors","url":"https://clinicaltrials.gov/study/NCT02144051"},{"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"countries":["United States"],"enrollment":20,"has_results":false,"interventions":["DRUG: Cisplatin","RADIATION: Stereotactic Body Radiation Therapy (SBRT)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02158234","official_title":"A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck","phases":["PHASE1"],"primary_completion":"2021-08-24","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","start":"2014-07-16","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck","url":"https://clinicaltrials.gov/study/NCT02158234"},{"conditions":["Adenocarcinoma of the Prostate"],"countries":["United States"],"enrollment":3,"has_results":false,"interventions":["DRUG: Cyclophosphamide","BIOLOGICAL: DRibble Vaccine","BIOLOGICAL: HPV Vaccinations","DRUG: Imiquimod"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02234921","official_title":"A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer","phases":["PHASE1"],"primary_completion":"2018-08-15","sponsor":"UbiVac","start":"2014-10-24","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Pilot Study of DRibble Vaccine for Prostate Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02234921"},{"conditions":["Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Salivary Gland Squamous Cell Carcinoma","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary"],"countries":["United States"],"enrollment":130,"has_results":false,"interventions":["OTHER: Cytology specimen","OTHER: Laboratory biomarker analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02245100","official_title":"A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers","phases":[],"primary_completion":"2021-05-14","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","start":"2014-07-22","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02245100"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":427,"has_results":false,"interventions":["BEHAVIORAL: Quality of Life Survey","BEHAVIORAL: Health Management Surveys","OTHER: Monitoring Devices","BEHAVIORAL: Symptoms Surveys","BEHAVIORAL: Device Usability Survey"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02253238","official_title":"Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients","phases":["NA"],"primary_completion":"2027-04-30","sponsor":"M.D. Anderson Cancer Center","start":"2014-01-07","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02253238"},{"conditions":["Hysterectomy"],"countries":["United States"],"enrollment":43,"has_results":false,"interventions":["PROCEDURE: Vaginal cuff closure - vertical","PROCEDURE: Vaginal cuff closure - horizontal"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02276261","official_title":"","phases":["NA"],"primary_completion":"2016-06","sponsor":"Bridgeport Hospital","start":"2014-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy","url":"https://clinicaltrials.gov/study/NCT02276261"},{"conditions":["Head and Neck Cancer"],"countries":["China","United States"],"enrollment":30,"has_results":false,"interventions":["BEHAVIORAL: Questionnaires","PROCEDURE: Acupuncture","PROCEDURE: Electroencephalogram (EEG)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02292368","official_title":"Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia","phases":["NA"],"primary_completion":"2022-08-30","sponsor":"M.D. Anderson Cancer Center","start":"2014-11-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT02292368"},{"conditions":["Parotid Neoplasms"],"countries":["Canada"],"enrollment":10,"has_results":false,"interventions":["DEVICE: MRI","OTHER: Citric acid","OTHER: Gadovist"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02294838","official_title":"Feasibility Study of MRI Imaging on Parotid Gland Stimulation","phases":["NA"],"primary_completion":"2015-08","sponsor":"British Columbia Cancer Agency","start":"2014-12","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Feasibility Study of MRI Imaging on Parotid Gland Stimulation","url":"https://clinicaltrials.gov/study/NCT02294838"},{"conditions":["Skin Neoplasms","Carcinoma, Basal Cell","Carcinoma, Squamous Cell","Dermatofibrosarcoma","Melanoma","Histiocytoma, Malignant Fibrous","Neoplasms, Adnexal and Skin Appendage"],"countries":["Spain"],"enrollment":6000,"has_results":false,"interventions":["PROCEDURE: Mohs surgery"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT02310503","official_title":"Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]","phases":[],"primary_completion":"2020-02-29","sponsor":"Fundación Academia Española de Dermatología","start":"2013-07-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Spanish Registry of Mohs Surgery","url":"https://clinicaltrials.gov/study/NCT02310503"},{"conditions":["Seborrheic Dermatitis"],"countries":["United States"],"enrollment":32,"has_results":false,"interventions":["PROCEDURE: Biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02349854","official_title":"Neurobiology of the Scalp in Seborrheic Dermatitis","phases":[],"primary_completion":"2014-05","sponsor":"Boston University","start":"2013-02","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Neurobiology of the Scalp in Seborrheic Dermatitis","url":"https://clinicaltrials.gov/study/NCT02349854"},{"conditions":["Xerostomia","Hyperthyroidism","Thyroid Cancer"],"countries":["United States"],"enrollment":70,"has_results":false,"interventions":["OTHER: Radioiodine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02375451","official_title":"Effect of Childhood Radioiodine Therapy on Salivary Function","phases":[],"primary_completion":"2016-09","sponsor":"Boston Children's Hospital","start":"2014-09","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Effect of Childhood Radioiodine Therapy on Salivary Function","url":"https://clinicaltrials.gov/study/NCT02375451"},{"conditions":["Salivary Gland Carcinoma"],"countries":["France"],"enrollment":72,"has_results":false,"interventions":["DRUG: pazopanib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02393820","official_title":"Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2015-12-31","sponsor":"UNICANCER","start":"2013-08-26","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT02393820"},{"conditions":["Salivary Gland Cancer","Nasopharyngeal Carcinoma"],"countries":[],"enrollment":200,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02401763","official_title":"Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis","phases":[],"primary_completion":"2016-04","sponsor":"National Taiwan University Hospital","start":"2015-04","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis","url":"https://clinicaltrials.gov/study/NCT02401763"},{"conditions":["Autoimmune Diseases","Lupus Erythematosus, Systemic","Communicable Diseases"],"countries":["United States"],"enrollment":2500,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02422875","official_title":"Comparative Autoantibody and Immunologic Cell Marker Study","phases":[],"primary_completion":"2028-05","sponsor":"Emory University","start":"2012-08","status":"ENROLLING_BY_INVITATION","study_type":"OBSERVATIONAL","title":"Comparative Autoantibody and Immunologic Cell Marker Study","url":"https://clinicaltrials.gov/study/NCT02422875"},{"conditions":["Squamous Cell Head and Neck Cancer","Radiation Induced Xerostomia","Salivary Hypofunction"],"countries":["United States"],"enrollment":17,"has_results":false,"interventions":["BIOLOGICAL: AAV2hAQP1"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02446249","official_title":"Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction","phases":["PHASE1"],"primary_completion":"2026-08-10","sponsor":"MeiraGTx, LLC","start":"2015-05-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction","url":"https://clinicaltrials.gov/study/NCT02446249"},{"conditions":["Rheumatoid Arthritis","Spondyloarthritis","Psoriatic Arthritis","Systemic Lupus Erythematosus","Antiphospholipid Syndrome","Sjogren Syndrome","Scleroderma","Myositis","Vasculitis","Mastocytosis","Various Autoimmune and/or Systemic and/or Rare Diseases"],"countries":["France"],"enrollment":0,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02450396","official_title":"Prospective Observational Study About Pregnancy and Medically Assisted Conception in Rare Diseases","phases":[],"primary_completion":"2025-06","sponsor":"Assistance Publique - Hôpitaux de Paris","start":"2015-06","status":"WITHDRAWN","study_type":"OBSERVATIONAL","title":"Pregnancy and Medically Assisted Conception in Rare Diseases","url":"https://clinicaltrials.gov/study/NCT02450396"},{"conditions":["Head and Neck Carcinoma","Xerostomia"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["OTHER: Quality-of-Life Assessment","PROCEDURE: Transcutaneous Acupoint Electrical Stimulation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02474095","official_title":"Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study","phases":["NA"],"primary_completion":"2018-10-12","sponsor":"Roswell Park Cancer Institute","start":"2014-11-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT02474095"},{"conditions":["Xerostomia"],"countries":[],"enrollment":30,"has_results":true,"interventions":["DRUG: Mesenchymal stem cell","DRUG: Isotonic NaCl"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02513238","official_title":"Mesenchymal Stem Cells for Radiation-induced Xerostomia (MESRIX) in Previous HPV-positive Oropharyngeal Head and Neck Cancer Patients - A Safety and Feasibility Study","phases":["PHASE2"],"primary_completion":"2017-04-06","sponsor":"Copenhagen University Hospital, Rigshospitalet","start":"2015-08-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Mesenchymal Stemcells for Radiation Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT02513238"},{"conditions":["Parotid Neoplasms","Facial Paralysis"],"countries":["United States"],"enrollment":76,"has_results":false,"interventions":["BEHAVIORAL: Facial exercises"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02527226","official_title":"Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors","phases":["NA"],"primary_completion":"2016-07","sponsor":"Mayo Clinic","start":"2015-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors","url":"https://clinicaltrials.gov/study/NCT02527226"},{"conditions":["Head and Neck Squamous Cell Carcinoma","Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Recurrent Nasopharynx Carcinoma","Recurrent Salivary Gland Carcinoma","Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary","Stage III Major Salivary Gland Carcinoma","Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage III Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Stage IVC Major Salivary Gland Carcinoma","Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":50,"has_results":true,"interventions":["OTHER: Laboratory Biomarker Analysis","BIOLOGICAL: Pembrolizumab","DRUG: Vorinostat"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02538510","official_title":"A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies","phases":["PHASE1","PHASE2"],"primary_completion":"2019-09-28","sponsor":"University of Washington","start":"2015-10-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery","url":"https://clinicaltrials.gov/study/NCT02538510"},{"conditions":["Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck"],"countries":["South Korea"],"enrollment":20,"has_results":false,"interventions":["DRUG: BIBF1120"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02558387","official_title":"Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study","phases":["PHASE2"],"primary_completion":"2016-07","sponsor":"Samsung Medical Center","start":"2014-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT02558387"},{"conditions":["Breast Cancer","Cholangiocarcinoma","Colorectal Cancer","Head and Neck Neoplasms","Lymphoma, Large-Cell, Anaplastic","Melanoma","Neuroendocrine Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Papillary Thyroid Cancer","Primary Brain Tumors","Renal Cell Carcinoma","Sarcomas","Salivary Gland Cancers","Adult Solid Tumor"],"countries":["Australia","Belgium","China","France","Germany","Hong Kong","Italy","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom","United States"],"enrollment":534,"has_results":false,"interventions":["DRUG: Entrectinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02568267","official_title":"An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","phases":["PHASE2"],"primary_completion":"2027-06-30","sponsor":"Hoffmann-La Roche","start":"2015-11-19","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","url":"https://clinicaltrials.gov/study/NCT02568267"},{"conditions":["Solid Tumors Harboring NTRK Fusion"],"countries":["Argentina","Australia","Belgium","Brazil","Canada","China","Colombia","Czechia","Denmark","France","Germany","India","Ireland","Italy","Japan","Portugal","Russia","Singapore","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United States"],"enrollment":215,"has_results":false,"interventions":["DRUG: BAY2757556 (Larotrectinib, Vitrakvi)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02576431","official_title":"A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion","phases":["PHASE2"],"primary_completion":"2025-09-29","sponsor":"Bayer","start":"2015-09-30","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02576431"},{"conditions":["Radiation-Induced Xerostomia","Head and Neck Cancer","Radiation Toxicity","Oral Complications of Chemotherapy and Head/Neck Radiation"],"countries":["United States"],"enrollment":258,"has_results":true,"interventions":["OTHER: Standard Oral Hygiene","OTHER: Standard Oral Hygiene + True Acupuncture","OTHER: Standard Oral Hygiene + Sham Acupuncture"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02589938","official_title":"A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer","phases":["NA"],"primary_completion":"2022-07-29","sponsor":"Wake Forest University Health Sciences","start":"2012-11-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT02589938"},{"conditions":["Advanced Cancer","Anal Carcinoma","Anal Cancer","Biliary Cancer","Cholangiocarcinoma","Bile Duct Cancer","Neuroendocrine Tumor","Carcinoid Tumor","Endometrial Carcinoma","Endometrial Cancer","Cervical Carcinoma","Cervical Cancer","Vulvar Carcinoma","Vulvar Cancer","Small Cell Lung Carcinoma","Small Cell Lung Cancer (SCLC)","Mesothelioma","Thyroid Carcinoma","Thyroid Cancer","Salivary Gland Carcinoma","Salivary Gland Cancer","Salivary Cancer","Parotid Gland Cancer","Advanced Solid Tumors","Colorectal Carcinoma"],"countries":[],"enrollment":1609,"has_results":false,"interventions":["BIOLOGICAL: pembrolizumab","BIOLOGICAL: pembrolizumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02628067","official_title":"A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)","phases":["PHASE2"],"primary_completion":"2027-05-04","sponsor":"Merck Sharp & Dohme LLC","start":"2015-12-18","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","url":"https://clinicaltrials.gov/study/NCT02628067"},{"conditions":["Solid Tumors","CNS Tumors"],"countries":["Canada","China","France","Germany","Hong Kong","Italy","Spain","United Kingdom","United States"],"enrollment":69,"has_results":false,"interventions":["DRUG: Entrectinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02650401","official_title":"A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","phases":["PHASE1","PHASE2"],"primary_completion":"2027-06-30","sponsor":"Hoffmann-La Roche","start":"2016-05-03","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","url":"https://clinicaltrials.gov/study/NCT02650401"},{"conditions":["Xerostomia"],"countries":["United Kingdom"],"enrollment":44,"has_results":false,"interventions":["DEVICE: Visco-ease","DEVICE: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02687087","official_title":"Assessing the Safety and Effectiveness of Visco-ease for the Treatment of Radiotherapy Induced Xerostomia in Head and Neck Cancer Patients","phases":["NA"],"primary_completion":"2017-02-02","sponsor":"NHS Greater Glasgow and Clyde","start":"2016-03-24","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy","url":"https://clinicaltrials.gov/study/NCT02687087"},{"conditions":["Adnexal Tumor"],"countries":["Belgium"],"enrollment":126,"has_results":false,"interventions":["OTHER: Correlation of MRI results with clinical characteristics of the adnexal mass"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02742870","official_title":"Diffusion Magnetic Resonance Imaging Using ADC (Apparent Diffusion Coefficient) Histograms in the Evaluation of Adnexal Tumor Aggressiveness","phases":[],"primary_completion":"2019-01-30","sponsor":"Brugmann University Hospital","start":"2016-03-08","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Diffusion MRI (Magnetic Resonance Imaging) Using ADC (Apparent Diffusion Coefficient) Histograms in the Evaluation of Adnexal Tumor Aggressiveness","url":"https://clinicaltrials.gov/study/NCT02742870"},{"conditions":["Androgen Receptor Positive","Locally Advanced Salivary Gland Carcinoma","Metastatic Salivary Gland Carcinoma","Salivary Duct Carcinoma","Salivary Gland Adenocarcinoma, NOS","Salivary Gland Basal Cell Adenocarcinoma","Stage III Major Salivary Gland Cancer AJCC v7"],"countries":["United States"],"enrollment":46,"has_results":true,"interventions":["DRUG: enzalutamide"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02749903","official_title":"A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers","phases":["PHASE2"],"primary_completion":"2019-02-21","sponsor":"Alliance for Clinical Trials in Oncology","start":"2016-09-14","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers","url":"https://clinicaltrials.gov/study/NCT02749903"},{"conditions":["Salivary Gland Tumors","Head and Neck Cancer"],"countries":["China"],"enrollment":107,"has_results":false,"interventions":["DRUG: Nedaplatin","DRUG: Docetaxel","RADIATION: Intensity-modulated radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02776163","official_title":"Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas of Head and Neck, A Non-Randomized, Phase II Trial","phases":["PHASE2"],"primary_completion":"2022-12-31","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2016-06-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas","url":"https://clinicaltrials.gov/study/NCT02776163"},{"conditions":["Acinar Cell Carcinoma","Adenoid Cystic Carcinoma","Adrenal Cortical Carcinoma","Adrenal Gland Pheochromocytoma","Anal Canal Neuroendocrine Carcinoma","Anal Canal Undifferentiated Carcinoma","Angiosarcoma","Apocrine Neoplasm","Appendix Mucinous Adenocarcinoma","Bartholin Gland Transitional Cell Carcinoma","Basal Cell Carcinoma","Bladder Adenocarcinoma","Breast Metaplastic Carcinoma","Cervical Adenocarcinoma","Cholangiocarcinoma","Chordoma","Colorectal Squamous Cell Carcinoma","Desmoid Fibromatosis","Endometrial Transitional Cell Carcinoma","Endometrioid Adenocarcinoma","Esophageal Neuroendocrine Carcinoma","Esophageal Undifferentiated Carcinoma","Extrahepatic Bile Duct Carcinoma","Extramammary Paget Disease","Fallopian Tube Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fibromyxoid Tumor","Gallbladder Carcinoma","Gastric Neuroendocrine Carcinoma","Gastric Squamous Cell Carcinoma","Gastric Undifferentiated Carcinoma","Gastrointestinal Stromal Tumor","Gestational Trophoblastic Tumor","Giant Cell Carcinoma","Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type","Intestinal Neuroendocrine Carcinoma","Intrahepatic Cholangiocarcinoma","Lung Neuroendocrine Tumor","Lung Sarcomatoid Carcinoma","Major Salivary Gland Carcinoma","Malignant Neoplasm of Unknown Primary","Malignant Odontogenic Neoplasm","Malignant Peripheral Nerve Sheath Tumor","Malignant Solid Neoplasm","Malignant Testicular Sex Cord-Stromal Tumor","Metastatic Pituitary Neuroendocrine Tumor","Minimally Invasive Lung Adenocarcinoma","Mixed Mesodermal (Mullerian) Tumor","Mucinous Adenocarcinoma","Mucinous Cystadenocarcinoma","Nasal Cavity Adenocarcinoma","Nasal Cavity Carcinoma","Nasopharyngeal Carcinoma","Nasopharyngeal Low Grade Papillary Adenocarcinoma","Nasopharyngeal Undifferentiated Carcinoma","Oral Cavity Carcinoma","Oropharyngeal Undifferentiated Carcinoma","Ovarian Adenocarcinoma","Ovarian Germ Cell Tumor","Ovarian Mucinous Adenocarcinoma","Ovarian Squamous Cell Carcinoma","Ovarian Transitional Cell Carcinoma","Pancreatic Acinar Cell Carcinoma","Pancreatic Neuroendocrine Carcinoma","Paraganglioma","Paranasal Sinus Adenocarcinoma","Paranasal Sinus Carcinoma","Parathyroid Gland Carcinoma","PEComa","Penile Squamous Cell Carcinoma","Peritoneal Mesothelial Neoplasm","Placental Choriocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Pseudomyxoma Peritonei","Rare Disorder","Scrotal Squamous Cell Carcinoma","Seminal Vesicle Adenocarcinoma","Seminoma","Serous Cystadenocarcinoma","Small Intestinal Adenocarcinoma","Small Intestinal Squamous Cell Carcinoma","Spindle Cell Neoplasm","Teratoma With Somatic-Type Malignancy","Testicular Non-Seminomatous Germ Cell Tumor","Thyroid Gland Carcinoma","Tracheal Carcinoma","Transitional Cell Carcinoma","Ureter Adenocarcinoma","Ureter Squamous Cell Carcinoma","Urethral Adenocarcinoma","Urethral Squamous Cell Carcinoma","Vaginal Adenocarcinoma","Vaginal Squamous Cell Carcinoma, Not Otherwise Specified","Vulvar Carcinoma"],"countries":["Guam","United States"],"enrollment":798,"has_results":false,"interventions":["PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","PROCEDURE: Echocardiography Test","BIOLOGICAL: Ipilimumab","PROCEDURE: Magnetic Resonance Imaging","BIOLOGICAL: Nivolumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02834013","official_title":"DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors","phases":["PHASE2"],"primary_completion":"2026-05-01","sponsor":"National Cancer Institute (NCI)","start":"2017-01-30","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","url":"https://clinicaltrials.gov/study/NCT02834013"},{"conditions":["Mixed Tumor, Malignant","Biopsy","Resection","Carcinoma","Keratosis"],"countries":[],"enrollment":0,"has_results":false,"interventions":["DEVICE: Optical Coherence Tomography (OCT) with Vivosight","DEVICE: Optical Coherence Tomography (OCT) with Skintell"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02851693","official_title":"Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection","phases":["NA"],"primary_completion":"2017-12-01","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","start":"2016-06-01","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection","url":"https://clinicaltrials.gov/study/NCT02851693"},{"conditions":["Xerostomia","Head and Neck Cancers"],"countries":[],"enrollment":60,"has_results":false,"interventions":["DRUG: mixed powder of A. digitata and M. sylvestris","DRUG: Hypozalix spray (artificial saliva)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02854358","official_title":"","phases":["PHASE2"],"primary_completion":"2016-02","sponsor":"Shiraz University of Medical Sciences","start":"2015-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT02854358"},{"conditions":["Nasopharyngeal Carcinoma"],"countries":["China"],"enrollment":30,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Sodium nitrate","DIETARY_SUPPLEMENT: sodium chloride"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02854410","official_title":"Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients Pre and Post Concurrent Chemo-radiation Therapy","phases":["NA"],"primary_completion":"2018-08","sponsor":"Capital Medical University","start":"2016-08","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients","url":"https://clinicaltrials.gov/study/NCT02854410"},{"conditions":["Head and Neck Neoplasms"],"countries":["France"],"enrollment":42,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02857413","official_title":"Assessment of Frequency of Xerostomia and Their Care Management in Upper Aerodigestive Tract Cancer Patients After the End of Radiotherapy","phases":[],"primary_completion":"2016-05","sponsor":"Centre Hospitalier Universitaire de Besancon","start":"2016-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Frequency of Xerostomia and Their Management in Upper Aerodigestive Tract Cancer Patients After the End of Radiotherapy","url":"https://clinicaltrials.gov/study/NCT02857413"},{"conditions":["Adenoid Cystic Carcinomas of the Salivary Glands"],"countries":["Italy"],"enrollment":26,"has_results":false,"interventions":["DRUG: Lenvatinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02860936","official_title":"Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract","phases":["PHASE2"],"primary_completion":"2019-06","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2015-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14","url":"https://clinicaltrials.gov/study/NCT02860936"},{"conditions":["Salivary Glands Tumors"],"countries":["Italy"],"enrollment":24,"has_results":false,"interventions":["DRUG: Abiraterone acetate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02867852","official_title":"Phase II Trial of Abiraterone Acetate in Patients With Relapsed and/or Metastatic, Castration Resistant Salivary Gland Cancers","phases":["PHASE2"],"primary_completion":"2019-11","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2015-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT02867852"},{"conditions":["Mouth Diseases","Quality of Life","Secretion; Salivary Gland, Deficient"],"countries":["Sweden"],"enrollment":33,"has_results":false,"interventions":["OTHER: Cancer treatment"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02870270","official_title":"Prospective Studies on Saliva, Microflora, Diet, Oral Status and Quality of Life in Subjects Undergoing Radiation Therapy in the Head and Neck Region","phases":[],"primary_completion":"2013-12","sponsor":"Göteborg University","start":"2008-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Prospective Studies on Oral Health and Quality of Life in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02870270"},{"conditions":["Non Tumor Salivary Gland Diseases of the Parotid Glands","Non Tumor Salivary Gland Diseases of the Submandibular Glands"],"countries":["France"],"enrollment":50,"has_results":false,"interventions":["OTHER: Three-dimensional sialography CBCT and MRI sialography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02883140","official_title":"Prospective, Pilot, Comparative, Monocentric Study of Diagnosis Capabilities of the Three-dimensional Cone-Beam CT Sialography (3D-CBCT Sialography) and MRI Sialography in Non-tumor Salivary Diseases","phases":[],"primary_completion":"2019-08-18","sponsor":"Nantes University Hospital","start":"2016-06-23","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Imaging Study of 3D-CBCT Sialography and MRI Sialography in Non Tumor Salivary Diseases","url":"https://clinicaltrials.gov/study/NCT02883140"},{"conditions":["Salivary Gland Tumors","Head and Neck Cancer"],"countries":["China"],"enrollment":20,"has_results":false,"interventions":["DRUG: Docetaxel","RADIATION: Intensity-modulated radiotherapy","DRUG: Pemetrexed","DRUG: Cisplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02921984","official_title":"Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors","phases":["PHASE1"],"primary_completion":"2016-12","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2013-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors","url":"https://clinicaltrials.gov/study/NCT02921984"},{"conditions":["Xerostomia","Head and Neck Neoplasms"],"countries":[],"enrollment":84,"has_results":false,"interventions":["DEVICE: Active Electrostimulator device","DEVICE: Sham Electrostimulator device"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02941276","official_title":"Long-term Evaluation of the Effectiveness Of a Novel Intra-oral Electro-stimulator for the Treatment of raDiotherapy-ASsociated Dry Mouth","phases":["NA"],"primary_completion":"2014-11","sponsor":"University College, London","start":"2011-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT02941276"},{"conditions":["Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Apocrine Carcinoma","Carcinoma Arising From Cylindroma","Carcinoma Arising From Spiradenoma","Digital Papillary Adenocarcinoma","Endocrine Mucin-Producing Sweat Gland Carcinoma","Extramammary Paget Disease","Extraocular Sebaceous Carcinoma","Hidradenocarcinoma","Malignant Sweat Gland Neoplasm","Merkel Cell Carcinoma","Microcystic Adnexal Carcinoma","NK-Cell Lymphoma, Unclassifiable","Papillary Adenocarcinoma","Porocarcinoma","Primary Cutaneous Mucinous Carcinoma","Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Anaplastic Large Cell Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Refractory Merkel Cell Carcinoma","Refractory Mycosis Fungoides","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Skin Squamous Cell Carcinoma","Refractory T-Cell Non-Hodgkin Lymphoma","Sezary Syndrome","Signet Ring Cell Adenocarcinoma","Skin Adenoid Cystic Carcinoma","Skin Adnexal Carcinoma","Skin Basal Cell Carcinoma","Skin Basosquamous Cell Carcinoma","Skin Keratoacanthoma","Skin Squamous Cell Carcinoma","Squamoid Eccrine Ductal Carcinoma","Squamous Cell Carcinoma of Unknown Primary","Sweat Gland Carcinoma","Trichilemmal Carcinoma","Vulvar Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":68,"has_results":false,"interventions":["PROCEDURE: Biopsy Procedure","PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","OTHER: Laboratory Biomarker Analysis","BIOLOGICAL: Nivolumab","PROCEDURE: Positron Emission Mammography","BIOLOGICAL: Talimogene Laherparepvec"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT02978625","official_title":"A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors","phases":["PHASE2"],"primary_completion":"2027-09-01","sponsor":"National Cancer Institute (NCI)","start":"2017-09-27","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","url":"https://clinicaltrials.gov/study/NCT02978625"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":29,"has_results":true,"interventions":["DRUG: BMX-001","RADIATION: Radiation Therapy","DRUG: Cisplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02990468","official_title":"A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer","phases":["PHASE1","PHASE2"],"primary_completion":"2020-02-21","sponsor":"BioMimetix JV, LLC","start":"2017-04-19","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT02990468"},{"conditions":["HNSCC"],"countries":["France"],"enrollment":342,"has_results":false,"interventions":["DRUG: Cisplatin","RADIATION: radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT02998385","official_title":"A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)","phases":["PHASE3"],"primary_completion":"2030-02","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","start":"2017-01-20","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)","url":"https://clinicaltrials.gov/study/NCT02998385"},{"conditions":["Caregiver","Malignant Head and Neck Neoplasm","Paranasal Sinus Squamous Cell Carcinoma","Salivary Gland Squamous Cell Carcinoma","Stage I Hypopharyngeal Squamous Cell Carcinoma","Stage I Laryngeal Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Squamous Cell Carcinoma","Stage I Oropharyngeal Squamous Cell Carcinoma","Stage II Hypopharyngeal Squamous Cell Carcinoma","Stage II Laryngeal Squamous Cell Carcinoma","Stage II Lip and Oral Cavity Squamous Cell Carcinoma","Stage II Oropharyngeal Squamous Cell Carcinoma","Stage III Hypopharyngeal Squamous Cell Carcinoma","Stage III Laryngeal Squamous Cell Carcinoma","Stage III Lip and Oral Cavity Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma","Stage IV Laryngeal Squamous Cell Carcinoma","Stage IV Lip and Oral Cavity Squamous Cell Carcinoma","Stage IV Oropharyngeal Squamous Cell Carcinoma","Stage IVA Hypopharyngeal Squamous Cell Carcinoma","Stage IVA Laryngeal Squamous Cell Carcinoma","Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVA Oropharyngeal Squamous Cell Carcinoma","Stage IVB Hypopharyngeal Squamous Cell Carcinoma","Stage IVB Laryngeal Squamous Cell Carcinoma","Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVB Oropharyngeal Squamous Cell Carcinoma","Stage IVC Hypopharyngeal Squamous Cell Carcinoma","Stage IVC Laryngeal Squamous Cell Carcinoma","Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma","Stage IVC Oropharyngeal Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal SCC","Recurrent Paranasal Sinus Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":35,"has_results":true,"interventions":["OTHER: Communication Intervention","OTHER: Watch video","OTHER: Module completion of the Prepare to Care kit","OTHER: Quality-of-Life Assessment","OTHER: Survey Administration","OTHER: Salivary cortisol collection"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03032250","official_title":"Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer Caregivers","phases":["NA"],"primary_completion":"2020-04-10","sponsor":"Wake Forest University Health Sciences","start":"2017-05-15","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT03032250"},{"conditions":["Cancer of Head Neck","Radiation-Induced Xerostomia","Dry Mouth"],"countries":["Thailand"],"enrollment":73,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Oral moisturizing jelly","OTHER: Artificial saliva"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03035825","official_title":"A Randomized Controlled Trial for Efficacy of Oral Moisturizing Jelly on Oral Health and Nutrition in Post-radiotherapy Head and Neck Cancer Patients With Xerostomia","phases":["NA"],"primary_completion":"2019-01-30","sponsor":"Dental Innovation Foundation Under Royal Patronage","start":"2017-03-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Efficacy of Oral Moisturizing Jelly on Oral Health and Nutrition in Post-radiotherapy Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03035825"},{"conditions":["Carcinoma, Non-Small-Cell Lung"],"countries":[],"enrollment":30,"has_results":false,"interventions":["BIOLOGICAL: Dribble vaccine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03057340","official_title":"The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting","phases":["PHASE1"],"primary_completion":"2019-12-01","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","start":"2017-06-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells","url":"https://clinicaltrials.gov/study/NCT03057340"},{"conditions":["Adrenal Insufficiency","Adrenal Cancer"],"countries":["Israel"],"enrollment":50,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Cosyntropin stimulation test"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03083834","official_title":"Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients","phases":["NA"],"primary_completion":"2019-12-31","sponsor":"Bnai Zion Medical Center","start":"2017-03-14","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients","url":"https://clinicaltrials.gov/study/NCT03083834"},{"conditions":["Salivary Gland Carcinoma","Metastatic Cancer","Recurrent Cancer"],"countries":["France"],"enrollment":98,"has_results":false,"interventions":["DRUG: Nivolumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03132038","official_title":"A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2019-01-01","sponsor":"UNICANCER","start":"2017-03-24","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT03132038"},{"conditions":["Major Salivary Gland Carcinoma","Minor Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage IV Major Salivary Gland Carcinoma","Stage IVA Major Salivary Gland Carcinoma","Stage IVB Major Salivary Gland Carcinoma","Stage IVC Major Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":25,"has_results":true,"interventions":["BIOLOGICAL: Ipilimumab","OTHER: Laboratory Biomarker Analysis","BIOLOGICAL: Nivolumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03146650","official_title":"Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland","phases":["PHASE2"],"primary_completion":"2021-02-24","sponsor":"Northwestern University","start":"2017-05-19","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT03146650"},{"conditions":["Hyposalivation","Electric Stimulation Therapy","Head and Neck Neoplasm","Radiotherapy"],"countries":["Brazil"],"enrollment":67,"has_results":false,"interventions":["DEVICE: TENS"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03151889","official_title":"Transcutaneous Electric Nerve Stimulation (TENS) Treatment for Hipossalivation Induced by Radiotherapy","phases":["NA"],"primary_completion":"2017-11-30","sponsor":"Federal University of Health Science of Porto Alegre","start":"2017-08-30","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Eletric Stimulation for Hipossalivation Induced by Radiotherapy","url":"https://clinicaltrials.gov/study/NCT03151889"},{"conditions":["Mass of Soft Tissue"],"countries":[],"enrollment":40,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT03171857","official_title":"Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses","phases":[],"primary_completion":"2019-06-01","sponsor":"Assiut University","start":"2017-06-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses","url":"https://clinicaltrials.gov/study/NCT03171857"},{"conditions":["Salivary Gland Cancer"],"countries":["United States"],"enrollment":64,"has_results":true,"interventions":["DRUG: Nivolumab","DRUG: Ipilimumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03172624","official_title":"A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers","phases":["PHASE2"],"primary_completion":"2024-12-18","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2017-05-26","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT03172624"},{"conditions":["Adnexal Tumor of Skin","Merkel Cell Carcinoma","Advanced Basal Cell Carcinoma Requiring Systemic Treatment"],"countries":["France"],"enrollment":9000,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT03210935","official_title":"French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas","phases":[],"primary_completion":"2026-12-31","sponsor":"University Hospital, Lille","start":"2015-11-24","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"French National Database of Rare Dermatological Cancers","url":"https://clinicaltrials.gov/study/NCT03210935"},{"conditions":["Head and Neck Cancer","Radiation Therapy Complication","Xerostomia","Hyposalivation"],"countries":["Denmark"],"enrollment":109,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Chewing gum"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03302676","official_title":"The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors","phases":["NA"],"primary_completion":"2018-09","sponsor":"Odense University Hospital","start":"2016-09","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors","url":"https://clinicaltrials.gov/study/NCT03302676"},{"conditions":["Salivary Gland Cancer","Adenoid Cystic Carcinoma","Salivary Duct Carcinoma"],"countries":["Netherlands"],"enrollment":25,"has_results":false,"interventions":["DIAGNOSTIC_TEST: PSMA-PET/CT scan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03319641","official_title":"68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma","phases":["NA"],"primary_completion":"2018-05-14","sponsor":"Radboud University Medical Center","start":"2017-10-25","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"PSMA-PET Imaging for Advanced ACC/SDC","url":"https://clinicaltrials.gov/study/NCT03319641"},{"conditions":["Thyroid Cancer","Salivary Gland Cancer"],"countries":["United States"],"enrollment":46,"has_results":false,"interventions":["DRUG: Pembrolizumab","DRUG: Docetaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03360890","official_title":"Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.","phases":["PHASE2"],"primary_completion":"2025-12-05","sponsor":"University of Chicago","start":"2018-03-26","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","url":"https://clinicaltrials.gov/study/NCT03360890"},{"conditions":["HNSCC"],"countries":["Netherlands"],"enrollment":32,"has_results":false,"interventions":["DEVICE: PSMA PET/CT-scan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03367780","official_title":"Determining the Dose-Effect Relation of Salivary Gland Irradiation and Cell Loss With PSMA PET","phases":[],"primary_completion":"2021-07-15","sponsor":"The Netherlands Cancer Institute","start":"2017-11-21","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Dose-Effect Relation of Salivary Gland Irradiation","url":"https://clinicaltrials.gov/study/NCT03367780"},{"conditions":["Scleroderma Disease"],"countries":["Italy"],"enrollment":25,"has_results":false,"interventions":["DRUG: Polydeoxyribonucleotides"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT03388255","official_title":"A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases","phases":["PHASE4"],"primary_completion":"2019-10-30","sponsor":"Mastelli S.r.l","start":"2016-11-08","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases","url":"https://clinicaltrials.gov/study/NCT03388255"},{"conditions":["Head and Neck Cancer","Oropharynx Cancer","Xerostomia Due to Radiotherapy"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["OTHER: Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03418792","official_title":"Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx","phases":["NA"],"primary_completion":"2022-04-22","sponsor":"UNC Lineberger Comprehensive Cancer Center","start":"2018-03-08","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx","url":"https://clinicaltrials.gov/study/NCT03418792"},{"conditions":["Melanoma","Breast Carcinoma","Hepatocellular Carcinoma","Urothelial Carcinoma","Squamous Cell Carcinoma of the Head and Neck","Renal Cell Carcinoma","Colorectal Carcinoma","Non-small Cell Lung Carcinoma","Gastric or Gastroesophageal Junction Adenocarcinoma","Endometrial Carcinoma","Mesothelioma","Neuroendocrine Carcinoma","Cervical Cancer","Small Cell Lung Carcinoma","Squamous Cell Carcinoma of the Anus","Castration-Resistant Prostate Carcinoma","Nasopharyngeal Carcinoma","Cholangiocarcinoma","Basal Cell Carcinoma","Ovarian Carcinoma","Fallopian Tube Carcinoma","Thymoma","Thymic Carcinoma","Squamous Cell Carcinoma of the Penis","Vulvar Carcinoma","Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy","Malignant Adnexal Neoplasms","Non-squamous Cell Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":150,"has_results":false,"interventions":["BIOLOGICAL: XmAb20717"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT03517488","official_title":"A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2022-06-01","sponsor":"Xencor, Inc.","start":"2018-07-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03517488"},{"conditions":["Oral Cavity Squamous Cell Carcinoma","Saliva Altered","Precancerous Lesions"],"countries":[],"enrollment":100,"has_results":false,"interventions":["OTHER: Saliva sampling","DIAGNOSTIC_TEST: ELISA","DIAGNOSTIC_TEST: HPLC"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03529604","official_title":"Isolation, Quantification and Kinetics of Salivary Ap4A, SCCA and TROP2 in Patients With Oral Cancer and Potentially Malignant Oral Disorders","phases":[],"primary_completion":"2020-04-01","sponsor":"University of Zagreb","start":"2016-05-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03529604"},{"conditions":["Squamous Cell Carcinoma of the Head and Neck"],"countries":["United States"],"enrollment":23,"has_results":true,"interventions":["OTHER: Robust Radiotherapy planning","OTHER: Margin-Based Radiotherapy planning"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03552965","official_title":"Prospective Randomized Pilot Clinical Trial of Margin-Based Vs. Robust Photon Radiotherapy Planning in Intensity-Modulated Radiation Therapy of Squamous-Cell Carcinoma of the Head and Neck","phases":["NA"],"primary_completion":"2024-03-09","sponsor":"University of Arkansas","start":"2018-06-19","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC","url":"https://clinicaltrials.gov/study/NCT03552965"},{"conditions":["Head and Neck Carcinoma","Adenoid Cystic Carcinoma","Lung Cancer","Non-Small Cell Lung Cancer","Pancreatic Cancer","Mesothelioma","Esophageal Cancer","Any Solid Tumors Progressed After a Prior Immunotherapy","Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma HNSCC","Salivary Gland Carcinomas","Head and Neck Cancers - Salivary Gland","Head and Neck Cancers - Nasopharyngeal","Head and Neck Cancers - Throat","Small Cell Lung Cancer ( SCLC )","Lung Cancer (Locally Advanced or Metastatic)","Head and Neck Cancers - Tonsils","Head and Neck Cancers Hypopharynx","Head and Neck Cancers Larynx","Head and Neck Cancers Lip","Head and Neck Cancers Nasopharynx","Head and Neck Cancers Oral Cavity","Head and Neck Cancers","Head and Neck Cancers Oropharynx","Head and Neck Cancers Trachea"],"countries":["Puerto Rico","United States"],"enrollment":242,"has_results":false,"interventions":["DRUG: VMD-928 100 mg Tablet","DRUG: VMD-928 Tablet and Pembrolizumab (200 mg)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03556228","official_title":"A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma","phases":["PHASE1","PHASE2"],"primary_completion":"2027-12","sponsor":"VM Oncology, LLC","start":"2018-06-08","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","url":"https://clinicaltrials.gov/study/NCT03556228"},{"conditions":["Salivary Gland Dysfunction","Xerostomia","Head and Neck Cancer"],"countries":["United States"],"enrollment":2,"has_results":false,"interventions":["DRUG: Everolimus","OTHER: Laboratory Biomarker Analysis","OTHER: Survey Administration"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03578432","official_title":"Clinical Evaluation of Everolimus (a Rapamycin Analog) in Restoring Salivary Gland Function to Patients Treated With Radiotherapy for Head and Neck Cancer","phases":["EARLY_PHASE1"],"primary_completion":"2019-11-15","sponsor":"University of Arizona","start":"2018-05-04","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT03578432"},{"conditions":["Xerostomia","Asialia","Hyposalivation","Mouth Dryness"],"countries":["Italy"],"enrollment":100,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Aqualief","OTHER: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03601962","official_title":"Evaluate the Effects of Aqualief® Mucoadhesive Tablets (a Food Supplement Based on Carnosine and Hibiscus) in Patients Who Developed Oral Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer","phases":["NA"],"primary_completion":"2020-01-22","sponsor":"Helsinn Healthcare SA","start":"2017-07-31","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT03601962"},{"conditions":["HER2-positive Breast Cancer","HER2 Gene Mutation","HER-2 Gene Amplification","HER2 Positive Gastric Cancer","Salivary Gland Cancer","Salivary Gland Tumor","Salivary Gland Carcinoma","Salivary Gland Neoplasms","Lung Cancer","Colo-rectal Cancer","Rare Diseases","Solid Tumor","Recurrent Gastric Cancer","Recurrent Colon Cancer","Recurrent Breast Cancer","Head and Neck Cancer","Head and Neck Carcinoma","Bladder Cancer","Cervical Cancer","Liver Cancer","Bile Duct Cancer","Urologic Cancer","Pancreatic Cancer","Prostate Cancer","Recurrent Prostate Cancer","Rectal Cancer","Recurrent Ovarian Carcinoma","Recurrent Renal Cell Cancer","Rectal Cancer Stage II","Rectal Cancer Stage I","Rectal Cancer Stage III","Skin Cancer","Mouth Cancer","Lip Cancer Stage I","Tongue Cancer","Breast Neoplasm Malignant Primary","Larynx Cancer","Tonsil Cancer","Palate Cancer","Mucoepidermoid Carcinoma","Primary Peritoneal Carcinoma","Mucinous Adenocarcinoma Gastric","Mucinous Breast Cancer Recurrent","Cholangiocarcinoma"],"countries":["United States"],"enrollment":49,"has_results":false,"interventions":["DRUG: A166"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03602079","official_title":"A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies","phases":["PHASE1","PHASE2"],"primary_completion":"2022-01-12","sponsor":"Klus Pharma Inc.","start":"2018-07-16","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","url":"https://clinicaltrials.gov/study/NCT03602079"},{"conditions":["Malignant Neoplasm of Salivary Gland","Benign Neoplasm of Salivary Gland"],"countries":["Egypt"],"enrollment":70,"has_results":false,"interventions":["DEVICE: enzyme linked immunosorbent assay (ELISA)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03687294","official_title":"Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas","phases":[],"primary_completion":"2021-09","sponsor":"Cairo University","start":"2019-01-12","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas","url":"https://clinicaltrials.gov/study/NCT03687294"},{"conditions":["Prostate Cancer","Prostate Cancer Metastatic","Prostatic Neoplasm"],"countries":["Canada"],"enrollment":10,"has_results":true,"interventions":["DIAGNOSTIC_TEST: 18F-DCFPyL PET/CT scan","OTHER: Placebo drink","OTHER: MSG drink"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03693742","official_title":"Evaluation of Monosodium Glutamate (MSG) to Reduce Salivary Gland and Renal Accumulation of PSMA-binding Radiopharmaceuticals","phases":["NA"],"primary_completion":"2019-12-12","sponsor":"British Columbia Cancer Agency","start":"2019-11-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"MSG Use With 18F-DCFPyL PET/CT Imaging","url":"https://clinicaltrials.gov/study/NCT03693742"},{"conditions":["Head and Neck Cancer","Caries, Dental","Periodontal Diseases","Radiotherapy Side Effect"],"countries":["United Kingdom"],"enrollment":215,"has_results":false,"interventions":["RADIATION: Radiotherapy (curative) for head and neck cancer"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03703648","official_title":"The Effect of Dental and Salivary Gland Radiation Dose on the Occurrence of Post-radiotherapy Dental Disease in Patients With Head and Neck Cancer","phases":[],"primary_completion":"2023-05-31","sponsor":"Belfast Health and Social Care Trust","start":"2018-12-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Post-radiation Dental Disease Amongst Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03703648"},{"conditions":["Salivary Gland Cancer"],"countries":["Netherlands"],"enrollment":25,"has_results":false,"interventions":["DRUG: Cabozantinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03729297","official_title":"The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial","phases":["PHASE2"],"primary_completion":"2019-11-06","sponsor":"Radboud University Medical Center","start":"2018-09-05","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"Cabozantinib in Advanced Salivary Gland Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03729297"},{"conditions":["Bladder Cancer","Head and Neck Squamous Cell Carcinoma","Cancer of the Salivary Gland","Lung Cancer","Breast Cancer","Gastric Cancer","Esophageal Cancer","Colorectal Cancer","Pancreatic Adenocarcinoma","Solid Tumor"],"countries":["United States"],"enrollment":45,"has_results":false,"interventions":["BIOLOGICAL: CAdVEC"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03740256","official_title":"A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors","phases":["PHASE1"],"primary_completion":"2026-12-30","sponsor":"Baylor College of Medicine","start":"2020-12-14","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03740256"},{"conditions":["Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Lung","Salivary Gland Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IVA Major Salivary Gland Cancer AJCC v8","Stage IVB Major Salivary Gland Cancer AJCC v8","Stage IVC Major Salivary Gland Cancer AJCC v8"],"countries":["United States"],"enrollment":20,"has_results":true,"interventions":["BIOLOGICAL: Nivolumab","BIOLOGICAL: Ipilimumab","RADIATION: Stereotactic Body Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03749460","official_title":"Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers","phases":["PHASE1","PHASE2"],"primary_completion":"2022-11-05","sponsor":"University of Washington","start":"2019-01-15","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT03749460"},{"conditions":["Malignant Salivary Gland Cancer","Salivary Gland Cancer"],"countries":["United States"],"enrollment":41,"has_results":false,"interventions":["DRUG: APG-115","DRUG: Carboplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03781986","official_title":"A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma","phases":["PHASE1","PHASE2"],"primary_completion":"2026-01-19","sponsor":"University of Michigan Rogel Cancer Center","start":"2019-10-28","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"APG-115 in Salivary Gland Cancer Trial","url":"https://clinicaltrials.gov/study/NCT03781986"},{"conditions":["PSA","Prostate Cancer"],"countries":["United States"],"enrollment":950,"has_results":false,"interventions":["DIAGNOSTIC_TEST: MRI prostate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03784924","official_title":"EDRN Prostate MRI Biomarker Study and Reference Set","phases":[],"primary_completion":"2028-06-30","sponsor":"University of Michigan","start":"2019-02-04","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"EDRN Prostate MRI Biomarker Study","url":"https://clinicaltrials.gov/study/NCT03784924"},{"conditions":["Autoimmune Disease","Crohn Disease","Dermatomyositis","Hematopoietic and Lymphoid Cell Neoplasm","Inflammatory Bowel Disease","Malignant Solid Neoplasm","Multiple Sclerosis","Psoriasis","Psoriatic Arthritis","Rheumatoid Arthritis","Sjogren Syndrome","Systemic Lupus Erythematosus","Systemic Scleroderma","Ulcerative Colitis"],"countries":["Canada","United States"],"enrollment":300,"has_results":false,"interventions":["PROCEDURE: Biospecimen Collection","DRUG: Cabozantinib","DRUG: Fluoropyrimidine","BIOLOGICAL: Ipilimumab","BIOLOGICAL: Nivolumab","DRUG: Platinum Compound","DRUG: Platinum Doublet"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03816345","official_title":"A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","phases":["PHASE1"],"primary_completion":"2028-03-30","sponsor":"National Cancer Institute (NCI)","start":"2019-07-16","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","url":"https://clinicaltrials.gov/study/NCT03816345"},{"conditions":["Parotid Tumors","Facial Nerve Paresis"],"countries":["South Korea"],"enrollment":270,"has_results":false,"interventions":["DIAGNOSTIC_TEST: 3D-DESS MRI (3 dimensional double echo steady state MRI)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03822728","official_title":"Postoperative Facial Weakness in Parotidectomy for Deep Seated Parotid Tumor With or Without Intra-parotid Facial Nerve Imaging (3D Double-Echo Steady-State With Water Excitation MRI Imaging)","phases":["NA"],"primary_completion":"2021-07-31","sponsor":"Samsung Medical Center","start":"2017-08-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Intra-parotid Facial Nerve Imaging in Parotidectomy","url":"https://clinicaltrials.gov/study/NCT03822728"},{"conditions":["Premalignant Lesion"],"countries":["Egypt"],"enrollment":120,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03830710","official_title":"Detection of Salivary 8-Hydroxy-2-Deoxyguanosine and Total Antioxidant Capacity in Patients With Oral Premalignant and Malignant Lesions","phases":[],"primary_completion":"2018-10-01","sponsor":"Fayoum University","start":"2018-04-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"8-Hydroxy-2-Deoxyguanosine ,Total Antioxidant Capacity in Oral Premalignant and Malignant Lesions","url":"https://clinicaltrials.gov/study/NCT03830710"},{"conditions":["Xerostomia Due to Radiotherapy","Hyposalivation","Xerostomia","Oropharynx Cancer","Salivary Gland Diseases","Dry Mouth","Mesenchymal Stem Cells","Mesenchymal Stromal Cells","Stem Cells"],"countries":["Denmark"],"enrollment":10,"has_results":false,"interventions":["BIOLOGICAL: Allogeneic adipose derived stem/stromal cells"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03874572","official_title":"A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia in Previous Oropharynx Cancer Patients","phases":["PHASE1"],"primary_completion":"2020-06-22","sponsor":"Copenhagen University Hospital, Rigshospitalet","start":"2019-03-18","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth","url":"https://clinicaltrials.gov/study/NCT03874572"},{"conditions":["Salivary Gland Diseases"],"countries":[],"enrollment":50,"has_results":false,"interventions":["DEVICE: MRI","DEVICE: Ultrasound"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03893812","official_title":"Combined Role of Color Doppler and Diffusion Weighted MRI In Differentiation Between Benign and Malignant Tumors of Major Salivary Glands","phases":[],"primary_completion":"2019-10","sponsor":"Assiut University","start":"2019-10","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Color Doppler and Mri Diffusion in Major Salivary Gland Masses","url":"https://clinicaltrials.gov/study/NCT03893812"},{"conditions":["Metastatic Breast Carcinoma","Locally Advanced Breast Cancer","Cancer of Pancreas","Solid Tumor With Intermediate or High HER2 Expression","Salivary Gland Cancer","Gastric Cancer","Endometrial Cancer","Uterine Cancer","Non Small Cell Lung Cancer","Biliary Tract Cancer","Cholangiocarcinoma","Colorectal Cancer","Urothelial Carcinoma","Prostate Cancer"],"countries":["Belgium"],"enrollment":55,"has_results":false,"interventions":["DRUG: 68GaNOTA-Anti-HER2 VHH1"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03924466","official_title":"Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study","phases":["PHASE2"],"primary_completion":"2024-11","sponsor":"Universitair Ziekenhuis Brussel","start":"2019-04-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients","url":"https://clinicaltrials.gov/study/NCT03924466"},{"conditions":["SCAD","Addison Disease","Ankylosing Spondylitis","Antiphospholipid Antibody Syndrome","Celiac Disease","Crohn Disease","Dermatomyositis","Polymyositis","Guillain-Barre Syndrome","Hepatitis, Autoimmune","Graves Disease","Hashimoto Thyroiditis","Multiple Sclerosis","Myasthenia Gravis","Pernicious Anemia","Polymyalgia Rheumatica","Primary Biliary Cirrhosis","Psoriasis","Rheumatoid Arthritis","Systemic Sclerosis","Sjögren Syndrome","Systemic Lupus Erythematosus","Takayasu Arteritis","Type 1 Diabetes Mellitus","Ulcerative Colitis","Uveitis","Vasculitis","Vitiligo","Raynaud"],"countries":["United States"],"enrollment":114,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03941184","official_title":"Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","phases":[],"primary_completion":"2020-11-10","sponsor":"Mayo Clinic","start":"1995-01-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity","url":"https://clinicaltrials.gov/study/NCT03941184"},{"conditions":["Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Squamous Cell Carcinoma","Oropharynx Cancer","Oropharynx Neoplasm","Oropharynx Carcinoma","Oral Cavity Cancer","Oral Cancer","Oral Neoplasm","Larynx Cancer","Larynx Carcinoma","Larynx Neoplasm","Nasopharyngeal Carcinoma","Nasopharyngeal Cancer","Nasopharynx Neoplasm","Hypopharynx Cancer","Hypopharynx Neoplasm","Hypopharynx Carcinoma","Sinonasal Carcinoma","Thyroid Carcinoma","Thyroid Cancer","Thyroid Neoplasms","Salivary Gland Cancer","Salivary Gland Neoplasms","Salivary Gland Carcinoma","Sinonasal Cancer","Sinonasal Neoplasm"],"countries":["Denmark"],"enrollment":500,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Liquid biopsy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03942380","official_title":"Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer","phases":["NA"],"primary_completion":"2025-02-01","sponsor":"Christian von Buchwald","start":"2017-02-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03942380"},{"conditions":["Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":20,"has_results":false,"interventions":["DRUG: Goserelin Acetate","DRUG: Pembrolizumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03942653","official_title":"Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111","phases":["PHASE2"],"primary_completion":"2026-07","sponsor":"Manish Patel","start":"2019-05-30","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT03942653"},{"conditions":["Parotid Tumor"],"countries":["France"],"enrollment":40,"has_results":false,"interventions":["RADIATION: MRI with Facial nerve tractography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03950323","official_title":"Intra-parotid Facial Nerve by MRI Tractography: Clinical vs Radiologic Description in Parotid Tumors","phases":["NA"],"primary_completion":"2020-12-24","sponsor":"CHU de Reims","start":"2019-06-24","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Intra-parotid Facial Nerve Tractography","url":"https://clinicaltrials.gov/study/NCT03950323"},{"conditions":["Adenocarcinoma; Mucoepidermoid Carcinoma"],"countries":["Egypt"],"enrollment":7,"has_results":false,"interventions":["PROCEDURE: resection of mucoeidermoid carcinoma"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03988959","official_title":"Surgical Management of Multiple Mucoepidermoid Carcinoma and Adenocarcinoma","phases":["NA"],"primary_completion":"2019-06-01","sponsor":"Ain Shams University","start":"2019-01-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Surgical Management of Multiple Mucoepidermoid Carcinoma and Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT03988959"},{"conditions":["Head and Neck Cancer","Multiparametric MRI","Cervical Lymph Node"],"countries":[],"enrollment":30,"has_results":false,"interventions":["OTHER: multiparametric MRI"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03991533","official_title":"Use of Multiparametric Magnetic Resonance Imaging in the Management of Head and Neck Cancer","phases":[],"primary_completion":"2018-09","sponsor":"AZ Sint-Jan AV","start":"2016-11-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Use of Multiparametric MRI in the Management of Head and Neck Cancer: a Retrospective Analysis","url":"https://clinicaltrials.gov/study/NCT03991533"},{"conditions":["Head and Neck Cancer","Multiparametric MRI","Cervical Lymph Node","Bone Invasion","Tumour Relapse","Treatment Response"],"countries":["Belgium"],"enrollment":70,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT03993665","official_title":"Use of Multiparametric Magnetic Resonance Imaging in the Management of Head and Neck Cancer: a Prospective Analysis","phases":[],"primary_completion":"2023-12","sponsor":"AZ Sint-Jan AV","start":"2018-11-20","status":"ACTIVE_NOT_RECRUITING","study_type":"OBSERVATIONAL","title":"Use of Multiparametric MRI in the Management of Head and Neck Cancer: a Prospective Analysis","url":"https://clinicaltrials.gov/study/NCT03993665"},{"conditions":["Xerostomia","Head and Neck Cancer"],"countries":["United States"],"enrollment":12,"has_results":false,"interventions":["PROCEDURE: Bone Marrow Aspiration","DIAGNOSTIC_TEST: Ultrasound Imaging of Salivary Glands","OTHER: Salivary Assay","OTHER: Quality of Life Instruments"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04007081","official_title":"Salivary Gland Autotransplantation of Marrow Mesenchymal Stromal Cells for Treatment of Radiation-induced Xerostomia - FDA IND (Investigational New Drug) Enabling Studies","phases":["NA"],"primary_completion":"2021-03-10","sponsor":"University of Wisconsin, Madison","start":"2019-10-18","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT04007081"},{"conditions":["Adenocarcinoma","Adenocystic Carcinoma","Anal Cancer","Appendix Cancer","Brain Tumor","Glioblastoma","Astrocytoma","Bile Duct Cancer","Cholangiocarcinoma","Bladder Cancer","Bone Cancer","Synovial Sarcoma","Chondrosarcoma","Liposarcoma","Sarcoma, Kaposi","Sarcoma,Soft Tissue","Sarcoma","Osteosarcoma","CNS Cancer","Brain Stem Neoplasms","Breast Cancer","Cervical Cancer","Colorectal Cancer","Rectal Cancer","Colon Cancer","Esophageal Cancer","Esophagus Cancer","Cancer of Colon","Pancreatic Cancer","Cancer of Pancreas","Testis Cancer","Testicular Cancer","Ureter Cancer","Renal Cell Carcinoma","Kidney Cancer","Gestational Trophoblastic Tumor","Head and Neck Neoplasms","Parotid Tumor","Larynx Cancer","Tongue Cancer","Pharynx Cancer","Salivary Gland Cancer","Acute Myeloid Leukemia","Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia","Multiple Myeloma","Non Hodgkin Lymphoma","Carcinoid Tumor","Lung Cancer","Neuroendocrine Tumors","Mesothelioma","Thyroid Cancer","Parathyroid Neoplasms","Adrenal Cancer","Small Bowel Cancer","Stomach Cancer","Liver Cancer","Hepatic Cancer","Melanoma","Skin Cancer","Unknown Primary Tumors","Uterine Cancer","Fallopian Tube Cancer","Ovarian Cancer","Prostate Cancer","Vaginal Cancer","Penile Cancer","Vulvar Cancer","Waldenstrom Macroglobulinemia","Cancer, Advanced","Thymus Cancer","Nasopharyngeal Carcinoma","Multiple Endocrine Neoplasia","Pheochromocytoma","Small Cell Carcinoma","Pulmonary Carcinoma"],"countries":["United States"],"enrollment":167,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Biomarker Testing (L)","DRUG: Systemic Treatment (T)","OTHER: Patient Reported Outcomes (P)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04028479","official_title":"The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)","phases":[],"primary_completion":"2024-10-31","sponsor":"Taproot Health","start":"2021-05-05","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","url":"https://clinicaltrials.gov/study/NCT04028479"},{"conditions":["Parotid Tumor"],"countries":["France"],"enrollment":0,"has_results":false,"interventions":["DEVICE: MRI"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04104802","official_title":"Study of the Facial Nerve in MRI 3T in the Preoperative Assessment of Parotid Tumors","phases":[],"primary_completion":"2019-10","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","start":"2019-10","status":"WITHDRAWN","study_type":"OBSERVATIONAL","title":"Study of the Facial Nerve in MRI 3T in the Preoperative Assessment of Parotid Tumors","url":"https://clinicaltrials.gov/study/NCT04104802"},{"conditions":["Non Small Cell Lung Cancer","Advanced Solid Tumor","Metastatic Melanoma","Metastatic Head and Neck Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Colorectal Cancer","Sarcomas","Metastatic Prostate Cancer","Ovarian Cancer","Small Cell Lung Cancer","Metastatic Breast Cancer","Pancreas Cancer","Gastric Cancer","Esophageal Cancer","Gastroesophageal Junction Adenocarcinoma","Cervical Cancer","Adenoid Cystic Carcinoma","Salivary Gland Cancer","Urothelial Carcinoma"],"countries":["Australia","United States"],"enrollment":733,"has_results":false,"interventions":["DRUG: ONC-392","DRUG: Pembrolizumab","DRUG: Docetaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04140526","official_title":"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)","phases":["PHASE1","PHASE2"],"primary_completion":"2026-12-31","sponsor":"OncoC4, Inc.","start":"2020-09-16","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","url":"https://clinicaltrials.gov/study/NCT04140526"},{"conditions":["Psoriatic Arthritis"],"countries":["Canada","United States"],"enrollment":92,"has_results":true,"interventions":["OTHER: Diet 1","OTHER: Diet 2"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04180904","official_title":"Diet Interventions in Psoriatic Arthritis","phases":["NA"],"primary_completion":"2024-11-25","sponsor":"University of Pennsylvania","start":"2021-03-11","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Diet Interventions in Psoriatic Arthritis","url":"https://clinicaltrials.gov/study/NCT04180904"},{"conditions":["Adenoid Cystic Carcinoma","Salivary Gland Cancer"],"countries":["United States"],"enrollment":64,"has_results":false,"interventions":["DRUG: Lenvatinib","DRUG: Pembrolizumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04209660","official_title":"A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers","phases":["PHASE2"],"primary_completion":"2026-12","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2020-06-02","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT04209660"},{"conditions":["Salivary Gland Cancer","Salivary Duct Carcinoma"],"countries":["Netherlands"],"enrollment":14,"has_results":false,"interventions":["DIAGNOSTIC_TEST: 68Ga-PSMA-PET/CT","DIAGNOSTIC_TEST: 18FDG-PET/CT"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04214353","official_title":"Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma: an Explorative Study.","phases":["NA"],"primary_completion":"2023-05","sponsor":"Radboud University Medical Center","start":"2020-01-14","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"PSMA-PET Imaging Before and After ADT in Advanced SDC Patients","url":"https://clinicaltrials.gov/study/NCT04214353"},{"conditions":["Adenoid Cystic Carcinoma"],"countries":["Germany"],"enrollment":314,"has_results":false,"interventions":["RADIATION: Carbon ion irradiation","RADIATION: Bimodal irradiation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04214366","official_title":"Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation","phases":["PHASE2"],"primary_completion":"2027-12-01","sponsor":"Heidelberg University","start":"2019-12-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation","url":"https://clinicaltrials.gov/study/NCT04214366"},{"conditions":["Xerostomia"],"countries":["France"],"enrollment":65,"has_results":false,"interventions":["OTHER: Specific auriculotherapy","OTHER: Non-specific auriculotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04222478","official_title":"Interest of Auriculotherapy in the Treatment of Xerostomia.","phases":["NA"],"primary_completion":"2025-09-15","sponsor":"Hopital Foch","start":"2019-12-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Interest of Auriculotherapy in the Treatment of Xerostomia","url":"https://clinicaltrials.gov/study/NCT04222478"},{"conditions":["Prostatic Neoplasms, Castration-Resistant","Neoplasms by Histologic Type","Neoplasms, Prostate","Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Neoplasms","Prostatic Neoplasms","Genital Neoplasms, Male","Urogenital Neoplasms","Neoplasms by Site","Prostatic Disease","Salivary Gland Cancer","Salivary Gland Tumor","Adenoid Cystic Carcinoma","Salivary Duct Carcinoma","Mucoepidermoid Carcinoma","Acinic Cell Tumor"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["BIOLOGICAL: P-PSMA-101 CAR-T cells","DRUG: Rimiducid"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04249947","official_title":"A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","phases":["PHASE1"],"primary_completion":"2024-09-30","sponsor":"Poseida Therapeutics, Inc.","start":"2020-02-28","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)","url":"https://clinicaltrials.gov/study/NCT04249947"},{"conditions":["Prostate Carcinoma"],"countries":["United States"],"enrollment":14,"has_results":false,"interventions":["PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","DRUG: Gallium Ga 68-labeled PSMA-11","DIETARY_SUPPLEMENT: Monosodium Glutamate","PROCEDURE: Positron Emission Tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04282824","official_title":"Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study","phases":["EARLY_PHASE1"],"primary_completion":"2020-05-06","sponsor":"Jonsson Comprehensive Cancer Center","start":"2019-06-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04282824"},{"conditions":["Salivary Gland Cancer","Salivary Duct Carcinoma","Adenoid Cystic Carcinoma"],"countries":["Netherlands"],"enrollment":12,"has_results":false,"interventions":["DRUG: Lutetium-177-PSMA-I&T"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04291300","official_title":"Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.","phases":["PHASE2"],"primary_completion":"2023-02-13","sponsor":"Radboud University Medical Center","start":"2020-05-26","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients","url":"https://clinicaltrials.gov/study/NCT04291300"},{"conditions":["Submandibular Gland Tumor","Parotid Gland Tumor"],"countries":["United States"],"enrollment":10,"has_results":false,"interventions":["DRUG: Alda-341"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04296266","official_title":"Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery","phases":["EARLY_PHASE1"],"primary_completion":"2017-12-18","sponsor":"Stanford University","start":"2016-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery","url":"https://clinicaltrials.gov/study/NCT04296266"},{"conditions":["Salivary Gland Neoplasms"],"countries":["Japan"],"enrollment":31,"has_results":true,"interventions":["DRUG: Apalutamide","DRUG: GnRH Agonist"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04325828","official_title":"An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2021-06-09","sponsor":"Janssen Pharmaceutical K.K.","start":"2020-04-07","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT04325828"},{"conditions":["Xerostomia"],"countries":["United States"],"enrollment":40,"has_results":false,"interventions":["DRUG: D-Limonene Gelcaps","RADIATION: Intensity modulated radiotherapy (IMRT)","DRUG: Cisplatin","OTHER: Xerostomia questionnaire"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04392622","official_title":"A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","phases":["PHASE1"],"primary_completion":"2027-08-15","sponsor":"Stanford University","start":"2021-02-15","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC","url":"https://clinicaltrials.gov/study/NCT04392622"},{"conditions":["Parotid Neoplasm","Thyroid Neoplasms","Head and Neck Neoplasms","Surgery","Nerve Injury","Imaging"],"countries":["United States"],"enrollment":27,"has_results":true,"interventions":["DRUG: Bevonescein"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04420689","official_title":"Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery","phases":["PHASE1","PHASE2"],"primary_completion":"2021-06-25","sponsor":"Alume Biosciences, Inc.","start":"2020-06-18","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery","url":"https://clinicaltrials.gov/study/NCT04420689"},{"conditions":["HER2-positive Breast Cancer","HER2-positive Biliary Tract Cancer","HER2-Positive Salivary Gland Carcinomas","HER2-Positive Advanced Solid Tumor"],"countries":["Australia","China","United States"],"enrollment":96,"has_results":false,"interventions":["DRUG: GQ1001"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04450732","official_title":"A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors","phases":["PHASE1"],"primary_completion":"2024-03-01","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","start":"2020-07-07","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04450732"},{"conditions":["Salivary Gland Tumor"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["DIAGNOSTIC_TEST: MRI"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04452162","official_title":"Physiologic MR Imaging in Distinguishing Benign From Malignant Salivary Gland Tumors","phases":["NA"],"primary_completion":"2026-06","sponsor":"Abramson Cancer Center at Penn Medicine","start":"2020-08-25","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Physiologic MR Imaging of Salivary Gland Tumors","url":"https://clinicaltrials.gov/study/NCT04452162"},{"conditions":["Xerostomia, Hyposalivation, Saliva Substitute, Radiation-induced Toxicity, Nasopharyngeal Cancer"],"countries":["Malaysia"],"enrollment":94,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Summated Xerostomia Inventory","DIAGNOSTIC_TEST: Sialometry"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04491435","official_title":"Saliva Substitute Mouthwash in NPC Survivors With Xerostomia: A Randomized Controlled Trial","phases":["NA"],"primary_completion":"2020-01-05","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","start":"2018-06-05","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Saliva Substitute Mouthwash in NPC Survivors With Xerostomia: A Randomized Controlled Trial","url":"https://clinicaltrials.gov/study/NCT04491435"},{"conditions":["Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Recurrent Paranasal Sinus Squamous Cell Carcinoma","Recurrent Salivary Gland Carcinoma","Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Major Salivary Gland Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage III Sinonasal Cancer AJCC v8","Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Sinonasal Cancer AJCC v8","Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma","Unresectable Head and Neck Squamous Cell Carcinoma","Unresectable Hypopharyngeal Squamous Cell Carcinoma","Unresectable Laryngeal Squamous Cell Carcinoma","Unresectable Oral Cavity Squamous Cell Carcinoma","Unresectable Oropharyngeal Squamous Cell Carcinoma","Unresectable Paranasal Sinus Squamous Cell Carcinoma","Unresectable Salivary Gland Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":7,"has_results":true,"interventions":["PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","DRUG: Elimusertib","BIOLOGICAL: Pembrolizumab","PROCEDURE: Positron Emission Tomography","OTHER: Quality-of-Life Assessment","RADIATION: Stereotactic Body Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04576091","official_title":"Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma","phases":["PHASE1"],"primary_completion":"2025-07-22","sponsor":"National Cancer Institute (NCI)","start":"2022-07-06","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT04576091"},{"conditions":["Head and Neck Cancer"],"countries":["Netherlands"],"enrollment":18,"has_results":false,"interventions":["OTHER: Submandibular Gland Stem Cell Transplantation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04593589","official_title":"Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function After Radiotherapy","phases":["PHASE1"],"primary_completion":"2026-01-01","sponsor":"University Medical Center Groningen","start":"2022-05-10","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Submandibular Gland Stem Cell Transplantation","url":"https://clinicaltrials.gov/study/NCT04593589"},{"conditions":["Xerostomia","Head and Neck Cancer","Xerostomia Following Radiotherapy"],"countries":["United States"],"enrollment":129,"has_results":true,"interventions":["OTHER: Remineralizing Extreme Dry Mouth Spray with Xylitol","DEVICE: Alcohol-Free Moisturizing Dry Mouth Spray"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04608773","official_title":"Evaluation of Two Mouth Sprays for Post-irradiation Xerostomia in Head and Neck Cancer Survivors: a Randomized, Double-blind Clinical Trial","phases":["NA"],"primary_completion":"2022-11-15","sponsor":"Jonas Johnson","start":"2021-01-14","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Blinded Dry Mouth Spray Crossover Study","url":"https://clinicaltrials.gov/study/NCT04608773"},{"conditions":["Parotid Tumor"],"countries":["France"],"enrollment":88,"has_results":false,"interventions":["OTHER: MRI"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04613349","official_title":"FArial NErf MRI in the Preoperative Assessment of PArotide Tumors","phases":[],"primary_completion":"2027-01-13","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","start":"2021-01-13","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"FArial NErf MRI in the Preoperative Assessment of PArotide Tumors","url":"https://clinicaltrials.gov/study/NCT04613349"},{"conditions":["Salivary Gland Cancer","HER2 Gene Mutation"],"countries":["United States"],"enrollment":37,"has_results":false,"interventions":["DRUG: Ado-trastuzumab (T) emtansine (T-DM1)","RADIATION: Standard of Care Radiotherapy","DRUG: Standard of Care Chemotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04620187","official_title":"A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas","phases":["PHASE2"],"primary_completion":"2028-02-01","sponsor":"Dana-Farber Cancer Institute","start":"2020-12-24","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","url":"https://clinicaltrials.gov/study/NCT04620187"},{"conditions":["Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast"],"countries":["Belgium","Canada","Denmark","France","Italy","Japan","South Korea","Spain","United States"],"enrollment":102,"has_results":true,"interventions":["DRUG: Trastuzumab deruxtecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04639219","official_title":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology","phases":["PHASE2"],"primary_completion":"2023-01-25","sponsor":"AstraZeneca","start":"2020-12-30","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","url":"https://clinicaltrials.gov/study/NCT04639219"},{"conditions":["Neoplasms","Colorectal Neoplasms","Melanoma","Pancreatic Neoplasms","Sarcoma","Ovarian Neoplasms","Brain Neoplasms","Thyroid Neoplasms","Neuroendocrine Tumors","Cholangiocarcinoma","Salivary Gland Neoplasms","Head and Neck Neoplasms","Thyroid Cancer, Papillary","Lymphoma, Large-Cell, Anaplastic","Neoplasms by Site","Respiratory Tract Neoplasms","Thoracic Neoplasms","Respiratory Tract Diseases","Carcinoma, Bronchogenic","Bronchial Neoplasms","Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Digestive System Diseases","Gastrointestinal Diseases","Colonic Diseases","Intestinal Diseases","Central Nervous System"],"countries":["United States"],"enrollment":1,"has_results":true,"interventions":["DRUG: Alectinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04644315","official_title":"A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","phases":["PHASE2"],"primary_completion":"2022-05-16","sponsor":"Hoffmann-La Roche","start":"2021-05-24","status":"TERMINATED","study_type":"INTERVENTIONAL","title":"A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04644315"},{"conditions":["Isotretinoin","Nail Abnormality"],"countries":["Turkey (Türkiye)"],"enrollment":70,"has_results":false,"interventions":["DRUG: Isotretinoin"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT04660916","official_title":"Effects of Isotretinoin on the Morphology, Growth Rate, and Thickness of the Nail Plate","phases":[],"primary_completion":"2020-09-01","sponsor":"Sinan Özçelik","start":"2019-10-22","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Effects of Isotretinoin on the Growth Rate and Thickness of the Nail Plate","url":"https://clinicaltrials.gov/study/NCT04660916"},{"conditions":["Head and Neck Cancer"],"countries":["Egypt"],"enrollment":60,"has_results":false,"interventions":["DEVICE: low level laser","DRUG: citric acid solution"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04700475","official_title":"Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.","phases":["NA"],"primary_completion":"2020-11-01","sponsor":"Nada Yousef","start":"2020-09-04","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.","url":"https://clinicaltrials.gov/study/NCT04700475"},{"conditions":["Advanced Breast Carcinoma","Advanced Colon Carcinoma","Advanced Colorectal Carcinoma","Advanced Endometrial Carcinoma","Advanced Gastric Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Malignant Solid Neoplasm","Advanced Salivary Gland Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","HER2-Positive Breast Carcinoma","Malignant Hepatobiliary Neoplasm","Metastatic Breast Carcinoma","Metastatic Colon Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Gastric Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Salivary Gland Carcinoma","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Major Salivary Gland Cancer AJCC v8","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Major Salivary Gland Cancer AJCC v8","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Unresectable Breast Carcinoma","Unresectable Colon Carcinoma","Unresectable Colorectal Carcinoma","Unresectable Endometrial Carcinoma","Unresectable Gastric Carcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":51,"has_results":false,"interventions":["PROCEDURE: Biopsy Procedure","PROCEDURE: Biospecimen Collection","DRUG: Ceralasertib","PROCEDURE: Computed Tomography","PROCEDURE: Echocardiography Test","PROCEDURE: Multigated Acquisition Scan","PROCEDURE: Positron Emission Tomography","BIOLOGICAL: Trastuzumab Deruxtecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04704661","official_title":"Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)","phases":["PHASE1"],"primary_completion":"2027-03-31","sponsor":"National Cancer Institute (NCI)","start":"2021-08-09","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","url":"https://clinicaltrials.gov/study/NCT04704661"},{"conditions":["Facial Nerve Injuries","Adenoma, Pleomorphic"],"countries":["Pakistan"],"enrollment":101,"has_results":false,"interventions":["OTHER: Superficial Parotidectomy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04706052","official_title":"Facial Nerve Morbidity After Superficial Parotidectomy in the Absence of Nerve Conductor: an Experience From a Low Resource Country","phases":[],"primary_completion":"2020-08","sponsor":"Liaquat University of Medical & Health Sciences","start":"2012-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Facial Nerve Morbidity After Superficial Parotidectomy in the Absence of Nerve Conductor","url":"https://clinicaltrials.gov/study/NCT04706052"},{"conditions":["Oral Mucositis","Osteoradionecrosis","Osteonecroses, Bisphosphonate","Osteonecrosis Due to Drugs, Jaw","Hyposalivation","Head and Neck Cancer","Oral Cancer"],"countries":["Spain"],"enrollment":60,"has_results":false,"interventions":["DEVICE: Preventive, LLL Phototherapy and topical Vit E","DEVICE: Curative, LLL Phototherapy and topical Vit E","DEVICE: Preventive, LLL Phototherapy and LPRF","DEVICE: Curative, LLL Phototherapy and LPRF"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04717765","official_title":"Photobiomodulation With Low Level Laser in the Prevention and Treatment of Oral Lesions (Mucositis, Hyposalivation and Osteonecrosis) Resulting From Anti-neoplastic Treatment With Chemotherapy or Radiotherapy.","phases":["NA"],"primary_completion":"2023-02-28","sponsor":"University of Santiago de Compostela","start":"2021-02-10","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention","url":"https://clinicaltrials.gov/study/NCT04717765"},{"conditions":["Xerostomia"],"countries":["Pakistan"],"enrollment":34,"has_results":false,"interventions":["RADIATION: Low-Level Laser Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04738227","official_title":"Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients.","phases":["NA"],"primary_completion":"2021-02-03","sponsor":"Ziauddin University","start":"2020-11-06","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients","url":"https://clinicaltrials.gov/study/NCT04738227"},{"conditions":["Parotid Tumor","Parotid Neoplasms","Surgery","Head and Neck Disorder"],"countries":["Egypt"],"enrollment":60,"has_results":false,"interventions":["PROCEDURE: Superficial parotidectomy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04803032","official_title":"Trident Landmark as a Safe and Easy Method for Facial Nerve Trunk Identification During Superficial Parotidectomy","phases":["NA"],"primary_completion":"2019-12-28","sponsor":"Kafrelsheikh University","start":"2018-01-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Trident Landmark as a Safe and Easy Method for Facial Nerve Trunk Identification During Superficial Parotidectomy","url":"https://clinicaltrials.gov/study/NCT04803032"},{"conditions":["Head and Neck Cancer"],"countries":["United States"],"enrollment":75,"has_results":false,"interventions":["RADIATION: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04805528","official_title":"Prospective Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck","phases":["NA"],"primary_completion":"2028-05-31","sponsor":"University of Rochester","start":"2022-03-10","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT04805528"},{"conditions":["Salivary Gland Malignant Neoplasms","Salivary Gland Tumors"],"countries":["China"],"enrollment":15,"has_results":false,"interventions":["DRUG: Toripalimab , Carboplatin, Nab-paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04825938","official_title":"Phase II Trial of Toripalimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Combination Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Salivary Gland Malignant Neoplasms","phases":["PHASE2"],"primary_completion":"2022-06-01","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","start":"2021-04-30","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms","url":"https://clinicaltrials.gov/study/NCT04825938"},{"conditions":["Salivary Gland Carcinoma","Adenoid Cystic Carcinoma","Salivary Gland Cancer","Salivary Gland Neoplasms"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["DRUG: 9-ING-41","DRUG: Carboplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04832438","official_title":"Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2033-06-18","sponsor":"Actuate Therapeutics Inc.","start":"2030-12-18","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT04832438"},{"conditions":["Head and Neck Carcinoma","Malignant Parotid Gland Neoplasm","Maxillary Sinus Carcinoma","Nasal Cavity Carcinoma","Oral Cavity Carcinoma","Tongue Carcinoma","Tonsillar Carcinoma"],"countries":["United States"],"enrollment":88,"has_results":false,"interventions":["OTHER: Best Practice","OTHER: Medical Device Usage and Evaluation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04870762","official_title":"A Randomized Study of Head and Neck Radiotherapy With or Without Customized 3D Printed Oral Stents","phases":["PHASE2"],"primary_completion":"2026-12-31","sponsor":"M.D. Anderson Cancer Center","start":"2021-05-26","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Customized 3D Printed Oral Stents During Head and Neck Radiotherapy","url":"https://clinicaltrials.gov/study/NCT04870762"},{"conditions":["Thyroid Cancer"],"countries":["France"],"enrollment":138,"has_results":false,"interventions":["DRUG: Radioiodine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04876287","official_title":"Salivary dysfuncTion After Radioiodine Treatment","phases":[],"primary_completion":"2021-04-26","sponsor":"French Nuclear Safety and Radiation Protection Authority (ASNR)","start":"2020-09-02","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Salivary dysfuncTion After Radioiodine Treatment","url":"https://clinicaltrials.gov/study/NCT04876287"},{"conditions":["Cancer of the Head and Neck","Xerostomia","Oral Mucositis","Radiation Toxicity"],"countries":["Cyprus"],"enrollment":200,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: Thyme and Honey-based oral spray","DIETARY_SUPPLEMENT: Placebo oral spray"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04880148","official_title":"The Effectiveness of a Thyme and Honey Spray for the Management of Oral Mucositis and Xerostomia in Head and Neck Cancer Patients Undergoing Radiotherapy","phases":["NA"],"primary_completion":"2024-06-01","sponsor":"Cyprus University of Technology","start":"2021-11-03","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"The Effectiveness of a Thyme and Honey Spray for Oral Toxicities","url":"https://clinicaltrials.gov/study/NCT04880148"},{"conditions":["Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage IV Major Salivary Gland Cancer AJCC v8","Adenoid Cystic Carcinoma"],"countries":["United States"],"enrollment":45,"has_results":true,"interventions":["BIOLOGICAL: Pembrolizumab","DRUG: Pemetrexed Disodium","PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","PROCEDURE: Positron Emission Tomography","PROCEDURE: Magnetic Resonance Imaging","PROCEDURE: PSMA PET Scan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04895735","official_title":"Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies","phases":["PHASE2"],"primary_completion":"2025-08-13","sponsor":"Mayo Clinic","start":"2021-07-23","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT04895735"},{"conditions":["Carcinoma Ex Pleomorphic Adenoma of Salivary Glands","Pleomorphic Adenoma of Salivary Glands"],"countries":["Egypt"],"enrollment":60,"has_results":false,"interventions":["DIAGNOSTIC_TEST: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction","DIAGNOSTIC_TEST: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04907422","official_title":"Gold Nanoparticles as Novel Biomarkers for Cancer Stem Cells in Salivary Gland Tumors: A Diagnostic and Prognostic Accuracy Study","phases":[],"primary_completion":"2019-02-03","sponsor":"Amina Fouad Farag","start":"2018-08-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours","url":"https://clinicaltrials.gov/study/NCT04907422"},{"conditions":["Head and Neck Cancers - Salivary Gland"],"countries":["China"],"enrollment":27,"has_results":false,"interventions":["DRUG: Surufatinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04910854","official_title":"A Study of Surufatinib in the Treatment of Recurrent/Metastatic Adenocarcinomas of the Head and Neck","phases":["PHASE2"],"primary_completion":"2022-03-31","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2021-05-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas","url":"https://clinicaltrials.gov/study/NCT04910854"},{"conditions":["Dermatologic Disease"],"countries":[],"enrollment":90,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Markers data from PBMCs"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04915105","official_title":"Personal Precise Treatment on Psoriasis and Psoriatic Arthritis and Investigate the Mechanisms of Biological Agents Induced Systemic Lupus Erythematosus","phases":["NA"],"primary_completion":"2025-05-31","sponsor":"Taichung Veterans General Hospital","start":"2021-05-31","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Personal Precise Treatment on Psoriasis and Psoriatic Arthritis","url":"https://clinicaltrials.gov/study/NCT04915105"},{"conditions":["One Lung Ventilation OLV","Esophageal Atresia","Hydrocystoma","Pneumonectomy","Pleura; Abscess"],"countries":["Syria"],"enrollment":110,"has_results":false,"interventions":["DRUG: Dexmedetomidine","DRUG: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT04932746","official_title":"The Effect of Dexmedetomidine on Oxygen and Intrapulmonary Shunt During One Lung Ventilation in Pediatric Surgery: Randomized Controlled Trial","phases":["NA"],"primary_completion":"2023-02-01","sponsor":"Damascus University","start":"2021-03-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.","url":"https://clinicaltrials.gov/study/NCT04932746"},{"conditions":["Salivary Gland Tumor","Urothelial Carcinoma","Ovarian Carcinoma","Breast Cancer","Soft Tissue Sarcoma"],"countries":["United Kingdom","United States"],"enrollment":158,"has_results":false,"interventions":["DRUG: AVA6000"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04969835","official_title":"A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours","phases":["PHASE1"],"primary_completion":"2026-08-07","sponsor":"Avacta Life Sciences Ltd","start":"2021-07-16","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours","url":"https://clinicaltrials.gov/study/NCT04969835"},{"conditions":["Salivary Gland Tumor"],"countries":["Israel"],"enrollment":50,"has_results":false,"interventions":["OTHER: Questionnaire"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT04970875","official_title":"Effect of Parotid Mass Location on Benign Tumor Parotidectomy Scar's Characteristics","phases":[],"primary_completion":"2021-06-15","sponsor":"Western Galilee Hospital-Nahariya","start":"2021-06-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Partial Modified Blair Incision on Benign Tumor Parotidectomy Scar's Characteristics","url":"https://clinicaltrials.gov/study/NCT04970875"},{"conditions":["Salivary Gland Malignant Neoplasms","Salivary Gland Tumors"],"countries":["China"],"enrollment":15,"has_results":false,"interventions":["DRUG: Sintilimab , Carboplatin, Nab-paclitaxel"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05000892","official_title":"Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Combination Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Salivary Gland Malignant Neoplasms","phases":["PHASE2"],"primary_completion":"2023-06-01","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","start":"2021-12-10","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms","url":"https://clinicaltrials.gov/study/NCT05000892"},{"conditions":["Salivary Gland Cancer"],"countries":["South Korea"],"enrollment":42,"has_results":false,"interventions":["DRUG: docetaxel plus Cisplatin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05008237","official_title":"Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study","phases":["PHASE2"],"primary_completion":"2022-05","sponsor":"Samsung Medical Center","start":"2014-05-02","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study","url":"https://clinicaltrials.gov/study/NCT05008237"},{"conditions":["Salivary Gland Cancer","Recurrent Salivary Gland Cancer","Metastatic Cancer","Adenoid Cystic Carcinoma"],"countries":["United States"],"enrollment":32,"has_results":true,"interventions":["DRUG: 9-ING-41","DRUG: Carboplatin","DRUG: Pembrolizumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05010629","official_title":"Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2025-02-14","sponsor":"Robert Haddad, MD","start":"2021-09-17","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT05010629"},{"conditions":["Salivary Gland Carcinomas"],"countries":["China"],"enrollment":20,"has_results":false,"interventions":["DRUG: Surufatinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05013515","official_title":"A Study of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma：a Single-arm, Prospective,Open Label Study","phases":["NA"],"primary_completion":"2022-09","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2021-08-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas","url":"https://clinicaltrials.gov/study/NCT05013515"},{"conditions":["Oropharynx Cancer"],"countries":["France"],"enrollment":132,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05025618","official_title":"Medico-economic Assessment of Adaptative Radiotherapy to Decrease Xerostomia in Locally Advanced Oropharynx Xerostomia","phases":[],"primary_completion":"2019-12-10","sponsor":"Center Eugene Marquis","start":"2013-07-05","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)","url":"https://clinicaltrials.gov/study/NCT05025618"},{"conditions":["Eyelid Tumor"],"countries":["China"],"enrollment":120,"has_results":false,"interventions":["PROCEDURE: Mohs surgery","PROCEDURE: cryotherapy"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05072327","official_title":"Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors: a Prospective Randomized Controlled Study.","phases":["NA"],"primary_completion":"2025-12","sponsor":"Sun Yat-sen University","start":"2020-10-15","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors.","url":"https://clinicaltrials.gov/study/NCT05072327"},{"conditions":["Salivary Gland Cancer"],"countries":["United States"],"enrollment":21,"has_results":true,"interventions":["DRUG: Amivantamab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05074940","official_title":"Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma","phases":["PHASE2"],"primary_completion":"2026-03-02","sponsor":"Trisha Wise-Draper","start":"2022-08-05","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Amivantamab in Adenoid Cystic Carcinoma","url":"https://clinicaltrials.gov/study/NCT05074940"},{"conditions":["Head and Neck Carcinoma","Head and Neck Carcinoma of Unknown Primary","Hypopharyngeal Carcinoma","Laryngeal Carcinoma","Metastatic Malignant Neoplasm in the Lymph Nodes","Nasal Cavity Carcinoma","Oral Cavity Carcinoma","Oropharyngeal Carcinoma","Paranasal Sinus Carcinoma","Salivary Gland Carcinoma","Cutaneous Squamous Cell Carcinoma of the Head and Neck","Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck"],"countries":["United States"],"enrollment":174,"has_results":false,"interventions":["DRUG: Cisplatin","PROCEDURE: Intensity-Modulated Proton Therapy","OTHER: Quality-of-Life Assessment","OTHER: Questionnaire Administration","PROCEDURE: Computed Tomography","PROCEDURE: Magnetic Resonance Imaging","PROCEDURE: Positron Emission Tomography","PROCEDURE: Biospecimen Collection","RADIATION: Intensity-Modulated Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05075980","official_title":"HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers","phases":["PHASE2"],"primary_completion":"2028-02-05","sponsor":"Mayo Clinic","start":"2022-02-16","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","url":"https://clinicaltrials.gov/study/NCT05075980"},{"conditions":["Salivary Gland Neoplasms"],"countries":["China"],"enrollment":182,"has_results":false,"interventions":["DRUG: Pyrotinib","DRUG: Bicalutamide","DRUG: Leuprorelin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05087706","official_title":"Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer","phases":[],"primary_completion":"2023-03-19","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2021-07-30","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）","url":"https://clinicaltrials.gov/study/NCT05087706"},{"conditions":["Head and Neck Cancer","Head and Neck Neoplasms","Xerostomia"],"countries":["Spain"],"enrollment":60,"has_results":false,"interventions":["DEVICE: Energy density photobiomodulation (7.5)","DEVICE: Energy density photobiomodulation (3)","DEVICE: Sham placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05106608","official_title":"Photobiomodulation Therapy With M-health Tool for the Management of Oral Health and Quality of Life in Head and Neck Cancer Patients: LAXER Study","phases":["NA"],"primary_completion":"2027-12","sponsor":"Universidad de Granada","start":"2022-07-13","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study","url":"https://clinicaltrials.gov/study/NCT05106608"},{"conditions":["Oral Squamous Cell Carcinoma"],"countries":["Bangladesh"],"enrollment":110,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Oral Squamous Cell Carcinoma"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05150509","official_title":"Association of Salivary Amino Acid With Oral Squamous Cell Carcinoma Identified by Liquid Chromatography Mass Spectroscopy","phases":[],"primary_completion":"2022-03-20","sponsor":"DR. MALA KHAN","start":"2020-12-15","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy","url":"https://clinicaltrials.gov/study/NCT05150509"},{"conditions":["Parotid Tumor"],"countries":["France"],"enrollment":133,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05152056","official_title":"Role of MRI and Fine Needle Aspiration in the Diagnosis of Parotid Tumors","phases":[],"primary_completion":"2021-12-09","sponsor":"University Hospital, Strasbourg, France","start":"2021-11-15","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"MRI and Fine Needle Aspiration in the Diagnosis of Parotid Tumors","url":"https://clinicaltrials.gov/study/NCT05152056"},{"conditions":["Solid Tumors With PTCH1 Loss-of-function Mutations"],"countries":["United States"],"enrollment":20,"has_results":false,"interventions":["DRUG: ENV-101 (taladegib)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05199584","official_title":"A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","phases":["PHASE2"],"primary_completion":"2024-02-20","sponsor":"Endeavor Biomedicines, Inc.","start":"2022-05-24","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","url":"https://clinicaltrials.gov/study/NCT05199584"},{"conditions":["Mucositis","Xerostomia","Hyposalivation"],"countries":["Brazil"],"enrollment":132,"has_results":false,"interventions":["DEVICE: Photobiomodulation therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05242991","official_title":"Comparison of Two Photobiomodulation Protocols for the Oral Mucositis and Xerostomia Prevention in Irradiated Head and Neck Cancer Patients: a Randomized, Multicenter, Single-blind Controlled Clinical Trial","phases":["NA"],"primary_completion":"2023-03-01","sponsor":"Federal University of Rio Grande do Sul","start":"2021-03-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients","url":"https://clinicaltrials.gov/study/NCT05242991"},{"conditions":["Parotid Neoplasms"],"countries":["Hong Kong"],"enrollment":50,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05296109","official_title":"Application of 3D Magnetic Resonance Neurogram Sequences for Evaluation of Intraparotid Facial Nerves in Patients With Parotid Neoplasm","phases":["NA"],"primary_completion":"2027-06-30","sponsor":"Chinese University of Hong Kong","start":"2022-02-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Application of 3D MR Neurogram for Intraparotid Facial Nerves Evaluation","url":"https://clinicaltrials.gov/study/NCT05296109"},{"conditions":["Wound of Skin","Burns"],"countries":[],"enrollment":40,"has_results":false,"interventions":["PROCEDURE: Split-thickness skin grafting","DEVICE: High density microscopic skin tissue column grafting","DEVICE: Low density microscopic skin tissue column grafting"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05324514","official_title":"Full-Thickness Microscopic Skin Tissue Column Grafting Technique Using the ART (Autologous Regeneration Tissue) System: An Interventional Clinical Trial","phases":["NA"],"primary_completion":"2024-10","sponsor":"The Metis Foundation","start":"2022-10-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Microscopic Skin Tissue Column Grafting Technique Using the Autologous Regeneration of Tissue System","url":"https://clinicaltrials.gov/study/NCT05324514"},{"conditions":["BCC - Basal Cell Carcinoma","SCC - Squamous Cell Carcinoma","Merkel Cell Carcinoma","Keratoacanthoma of Skin","Malignant Adnexal Tumors of the Skin (MATS)","Tumors From Cutaneous T-cell Lymphoma (CTCL)","Kaposi Sarcoma"],"countries":["France","Italy","Spain"],"enrollment":70,"has_results":false,"interventions":["DRUG: L19IL2/L19TNF"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05329792","official_title":"A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment","phases":["PHASE2"],"primary_completion":"2024-06","sponsor":"Philogen S.p.A.","start":"2023-03-09","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"L19IL2/L19TNF in Skin Cancer Patients","url":"https://clinicaltrials.gov/study/NCT05329792"},{"conditions":["Salivary Gland Cancer","Salivary Gland Neoplasms"],"countries":["Serbia"],"enrollment":250,"has_results":false,"interventions":["PROCEDURE: Surgical intervention with or without postoperative adjuvant therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05390294","official_title":"Prognostic Factors for Survival of Patients With Salivary Gland Malignancies","phases":[],"primary_completion":"2022-03-30","sponsor":"Clinical Center of Vojvodina","start":"2022-01-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Survival With Patients Treated With Salivary Gland Cancer","url":"https://clinicaltrials.gov/study/NCT05390294"},{"conditions":["Parotid Tumor"],"countries":["Egypt"],"enrollment":20,"has_results":false,"interventions":["PROCEDURE: Methylene blue dye"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05401370","official_title":"Role of Methylene Blue Dye in Identification of Facial Nerve in Parotid Surgery","phases":["NA"],"primary_completion":"2023-10","sponsor":"Assiut University","start":"2022-06","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Role of Methylene Blue in Parotid Surgery","url":"https://clinicaltrials.gov/study/NCT05401370"},{"conditions":["Dental Caries"],"countries":["United States"],"enrollment":56,"has_results":false,"interventions":["DEVICE: silver diamine fluoride, 38%","DEVICE: Sodium fluoride gel, 5000 PPM"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05403125","official_title":"Silver Diamine Fluoride: Novel Addition to the Prophylactic Bundle for Dental Management of Radiation-Induced Dental Caries in Oral and Pharyngeal Cancer Patients","phases":["EARLY_PHASE1"],"primary_completion":"2023-08-11","sponsor":"Texas A & M University Baylor College Of Dentistry","start":"2022-05-20","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"SDF Application in Oral Cancer Patients to Prevent Dental Caries","url":"https://clinicaltrials.gov/study/NCT05403125"},{"conditions":["Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Stage III Major Salivary Gland Cancer AJCC v8","Stage IV Major Salivary Gland Cancer AJCC v8","Unresectable Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":146,"has_results":false,"interventions":["PROCEDURE: Biopsy Procedure","PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","DRUG: Docetaxel","PROCEDURE: Echocardiography Test","PROCEDURE: Magnetic Resonance Imaging","PROCEDURE: Multigated Acquisition Scan","OTHER: Questionnaire Administration","BIOLOGICAL: Trastuzumab","BIOLOGICAL: Trastuzumab Deruxtecan","BIOLOGICAL: Trastuzumab Emtansine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05408845","official_title":"A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","phases":["PHASE2"],"primary_completion":"2028-07-31","sponsor":"NRG Oncology","start":"2023-03-03","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT05408845"},{"conditions":["Wounds and Injuries","Skin Graft Scar","Skin Graft Complications"],"countries":["Italy"],"enrollment":60,"has_results":false,"interventions":["DEVICE: Fitostimoline plus","DEVICE: Connettivina bio plus"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05447793","official_title":"Clinical Evalutation of the Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze in the Treatment of Skin Graft Controlled Randomized Pilot Study","phases":[],"primary_completion":"2021-12-18","sponsor":"Federico II University","start":"2021-01-18","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Effectiveness and Tolerability of Fitostimoline Plus vs Connettivina Bio Plus in Skin Graft","url":"https://clinicaltrials.gov/study/NCT05447793"},{"conditions":["Head and Neck Cancer","Nasopharynx Cancer","Nasal Cavity and Paranasal Sinus Cancer","Salivary Gland Cancer","Middle Ear Carcinoma"],"countries":["Czechia","Germany","Italy"],"enrollment":13600,"has_results":false,"interventions":["OTHER: observation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05483374","official_title":"The Observational Clinical Registry of the European Reference Network on Rare Adult Solid Cancers: the Protocol for the Rare Head and Neck Cancers","phases":[],"primary_completion":"2030-12-31","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2022-05-31","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers","url":"https://clinicaltrials.gov/study/NCT05483374"},{"conditions":["Prostate Cancer"],"countries":["Japan"],"enrollment":51,"has_results":false,"interventions":["DEVICE: The Visual Ice Cryoablation System"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05500846","official_title":"Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial","phases":["NA"],"primary_completion":"2023-11-14","sponsor":"Osamu Ukimura","start":"2021-10-19","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial","url":"https://clinicaltrials.gov/study/NCT05500846"},{"conditions":["Parotid Gland Neoplasm"],"countries":["Egypt"],"enrollment":60,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05505318","official_title":"Pattern and Outcome of Surgical Treatment of Parotid Gland Neoplasms in Upper Egypt(Retrospective Study)","phases":[],"primary_completion":"2021-05-20","sponsor":"Sohag University","start":"2015-05-20","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Pattern and Surgical Treatment of Parotid Gland Neoplasms","url":"https://clinicaltrials.gov/study/NCT05505318"},{"conditions":["Ovarian Cancer","Ovarian Cyst Benign","Borderline Ovarian Cancer"],"countries":["France","Switzerland","Tunisia"],"enrollment":746,"has_results":false,"interventions":["OTHER: Salivary samples"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05514028","official_title":"Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin - OVAmiARN Study","phases":[],"primary_completion":"2025-04-10","sponsor":"ZIWIG","start":"2022-05-04","status":"ACTIVE_NOT_RECRUITING","study_type":"OBSERVATIONAL","title":"Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin","url":"https://clinicaltrials.gov/study/NCT05514028"},{"conditions":["Optical Coherence Tomography","Artificial Intelligence","Radiomics"],"countries":["Netherlands"],"enrollment":20,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Optical coherence tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05517889","official_title":"Assessing the Stability and Repeatability of OCT Features in Healthy Skin: a Test-retest Study","phases":[],"primary_completion":"2023-12-31","sponsor":"Maastricht University Medical Center","start":"2022-09-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Repeatability and Stability of Healthy Skin Features on OCT","url":"https://clinicaltrials.gov/study/NCT05517889"},{"conditions":["Salivary Gland Cancer","Adenoid Cystic Carcinoma of the Salivary Gland","Squamous Cell Carcinoma of Head and Neck","Head and Neck Cancer"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["COMBINATION_PRODUCT: Implantable Microdevice (IMD)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05553782","official_title":"Therapeutic Drug Screening Using a Novel Implantable Microdevice (IMD) in Head and Neck Cancers: a Window of Opportunity Study","phases":["EARLY_PHASE1"],"primary_completion":"2029-04-01","sponsor":"Brigham and Women's Hospital","start":"2023-11-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","url":"https://clinicaltrials.gov/study/NCT05553782"},{"conditions":["Salivary Gland Tumor","Rare Malignant Neoplasm"],"countries":["Singapore"],"enrollment":4,"has_results":false,"interventions":["DIAGNOSTIC_TEST: 68-Ga PSMA PET scan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05581979","official_title":"PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers","phases":[],"primary_completion":"2023-05-31","sponsor":"National Cancer Centre, Singapore","start":"2022-01-26","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers","url":"https://clinicaltrials.gov/study/NCT05581979"},{"conditions":["Salivary Gland Tumors"],"countries":["China"],"enrollment":10,"has_results":false,"interventions":["DRUG: RC48-ADC"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05601401","official_title":"Phase II Clinical Study to Assess the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody MMAE Coupling Agent in Treating Patients With Locally Advanced or Metastatic Salivary Gland Tumors Expressing HER2","phases":["PHASE2"],"primary_completion":"2023-03-31","sponsor":"Peking Union Medical College Hospital","start":"2022-03-31","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2","url":"https://clinicaltrials.gov/study/NCT05601401"},{"conditions":["Head and Neck Cancer"],"countries":["Australia","United Kingdom"],"enrollment":15,"has_results":false,"interventions":["DRUG: Tigilanol Tiglate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05608876","official_title":"A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies","phases":["PHASE2"],"primary_completion":"2025-07-31","sponsor":"QBiotics Group Limited","start":"2022-11-03","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT05608876"},{"conditions":["Basal Cell Carcinoma","Tomography, Optical Coherence"],"countries":["France"],"enrollment":22,"has_results":false,"interventions":["OTHER: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05608902","official_title":"Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study","phases":[],"primary_completion":"2023-01-26","sponsor":"Centre Hospitalier William Morey - Chalon sur Saône","start":"2022-09-06","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)","url":"https://clinicaltrials.gov/study/NCT05608902"},{"conditions":["Head and Neck Cancer","Head and Neck Neoplasms","Xerostomia"],"countries":["Spain"],"enrollment":32,"has_results":false,"interventions":["DEVICE: Energy density photobiomodulation (7.5)","DEVICE: Sham placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05614843","official_title":"Pilot Study Evaluating the Impact of a Photobiomodulation Therapy on Xerostomia and Hyposalivation in Patients With Head and Neck Cancer Post-Radiotherapy","phases":["NA"],"primary_completion":"2023-02-28","sponsor":"Universidad de Granada","start":"2022-10-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Photobiomodulation Therapy in Patients With Head and Neck Cancer Post-Radiotherapy","url":"https://clinicaltrials.gov/study/NCT05614843"},{"conditions":["Locally Advanced Salivary Gland Carcinoma","Metastatic Salivary Gland Carcinoma","Recurrent Salivary Gland Carcinoma","Unresectable Salivary Gland Carcinoma"],"countries":["United States"],"enrollment":21,"has_results":false,"interventions":["PROCEDURE: Biopsy Procedure","PROCEDURE: Biospecimen Collection","PROCEDURE: Computed Tomography","DRUG: Darolutamide","DRUG: Leuprolide Acetate","PROCEDURE: Magnetic Resonance Imaging"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05669664","official_title":"A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer","phases":["PHASE2"],"primary_completion":"2026-11-30","sponsor":"National Cancer Institute (NCI)","start":"2023-07-20","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT05669664"},{"conditions":["Salivary Gland Cancer"],"countries":["Japan"],"enrollment":57,"has_results":false,"interventions":["DRUG: Darolutamide","DRUG: Goserelin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05694819","official_title":"Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)","phases":["PHASE2"],"primary_completion":"2024-08-09","sponsor":"National Cancer Center Hospital East","start":"2020-04-17","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","url":"https://clinicaltrials.gov/study/NCT05694819"},{"conditions":["Oral Squamous Cell Carcinoma"],"countries":["Egypt"],"enrollment":40,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05708209","official_title":"The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124","phases":[],"primary_completion":"2022-12-01","sponsor":"Fayoum University","start":"2022-11-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124","url":"https://clinicaltrials.gov/study/NCT05708209"},{"conditions":["High-grade Salivary Gland Carcinoma"],"countries":["South Korea"],"enrollment":50,"has_results":false,"interventions":["DRUG: nivolumab, docetaxel, cisplatin Group"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05727410","official_title":"A Phase II Trial of Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2026-08-31","sponsor":"Myung-Ju Ahn","start":"2022-11-15","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT05727410"},{"conditions":["Parotid Neoplasms"],"countries":["Italy"],"enrollment":20,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Questions"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05738395","official_title":"Typical and Atypical Symptoms of Frey's Syndrome: a Pilot Study","phases":[],"primary_completion":"2025-11-01","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","start":"2020-11-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Symptoms of Frey's Syndrome","url":"https://clinicaltrials.gov/study/NCT05738395"},{"conditions":["Oral Mucositis","Hematopoietic Neoplasm","Xerostomia","Hyposalivation"],"countries":["Brazil"],"enrollment":42,"has_results":false,"interventions":["DEVICE: Photobiomodulation therapy (intraoral)","DEVICE: Photobiomodulation therapy (extraoral)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05759975","official_title":"Effectiveness of Extraoral Photobiomodulation Protocols in Management of Oral Adverse Effects in Patients Undergoing Hematopoietic Stem Cell Transplantation","phases":["NA"],"primary_completion":"2023-12-30","sponsor":"Federal University of Rio Grande do Sul","start":"2023-01-13","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Effectiveness of Extraoral Photobiomodulation in Management of Oral Adverse Effects in Patients Undergoing HSCT","url":"https://clinicaltrials.gov/study/NCT05759975"},{"conditions":["Haematological Malignancy","Colorectal Neoplasms","Urinary Bladder Neoplasm","Gallbladder Neoplasms","Salivary Gland Neoplasm","Lung Neoplasm","Pancreatic Neoplasm","Ovarian Neoplasms","Prostatic Neoplasm","Skin Neoplasm","Solid Tumour"],"countries":["United Kingdom"],"enrollment":30,"has_results":false,"interventions":["DRUG: Trastuzumab","DRUG: Pertuzumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05786716","official_title":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations.","phases":["PHASE2","PHASE3"],"primary_completion":"2029-10","sponsor":"Cancer Research UK","start":"2023-03-07","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations","url":"https://clinicaltrials.gov/study/NCT05786716"},{"conditions":["Basal Cell Carcinoma","Optical Coherence Tomography"],"countries":["Netherlands"],"enrollment":124,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Optical coherence tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05817279","official_title":"AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma","phases":[],"primary_completion":"2024-12-31","sponsor":"Maastricht University Medical Center","start":"2023-04-10","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05817279"},{"conditions":["Head and Neck Cancer","Xerostomia"],"countries":["United States"],"enrollment":23,"has_results":false,"interventions":["DRUG: MSC"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05820711","official_title":"A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer","phases":["PHASE1"],"primary_completion":"2025-12-09","sponsor":"University of Wisconsin, Madison","start":"2023-07-17","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT05820711"},{"conditions":["Oral Squamous Cell Carcinoma"],"countries":["Egypt"],"enrollment":36,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05821179","official_title":"Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma","phases":[],"primary_completion":"2023-01-01","sponsor":"Fayoum University","start":"2022-01-01","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05821179"},{"conditions":["Ovarian Neoplasms","Ovarian Cancer","Ovarian Cysts","Adnexal Mass","Adnexal Lesion","Adnexal Carcinoma","Adnexal Neoplasm"],"countries":["Denmark"],"enrollment":1700,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05842629","official_title":"Improved Diagnosis of Ovarian Cancer","phases":[],"primary_completion":"2024-06","sponsor":"University of Aarhus","start":"2021-05-15","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Improved Diagnosis of Ovarian Cancer","url":"https://clinicaltrials.gov/study/NCT05842629"},{"conditions":["Cutaneous Squamous Cell Carcinoma","SCC - Squamous Cell Carcinoma","Basal Cell Carcinoma","BCC","BCC - Basal Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Sebaceous Carcinoma","Extramammary Paget Disease","Kaposi Sarcoma","Head and Neck Squamous Cell Carcinoma","HNSCC","Adnexal Carcinoma","Angiosarcoma","Cutaneous Neoplasm","Advanced Cancer","Metastatic Cancer","Refractory Cancer","Solid Tumor"],"countries":["United States"],"enrollment":56,"has_results":false,"interventions":["BIOLOGICAL: MQ719","DRUG: Pembrolizumab"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT05859074","official_title":"A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors","phases":["PHASE1"],"primary_completion":"2028-05-04","sponsor":"Memorial Sloan Kettering Cancer Center","start":"2023-05-04","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","url":"https://clinicaltrials.gov/study/NCT05859074"},{"conditions":["Head and Neck Cancer Patients"],"countries":["Egypt"],"enrollment":90,"has_results":false,"interventions":["DRUG: thyme honey mouth rinse","DRUG: saline mouth rinse"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05859711","official_title":"Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients A Randomized Controlled Clinical Trial With a Biochemical Assessment","phases":["PHASE4"],"primary_completion":"2021-06-20","sponsor":"Ain Shams University","start":"2021-02-20","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients","url":"https://clinicaltrials.gov/study/NCT05859711"},{"conditions":["Xerostomia"],"countries":[],"enrollment":52,"has_results":false,"interventions":["OTHER: Artificial saliva containing cumin and ginger extract","OTHER: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05872464","official_title":"Efficacy and Safety of Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia","phases":["NA"],"primary_completion":"2025-05-30","sponsor":"Chulalongkorn University","start":"2024-07-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia","url":"https://clinicaltrials.gov/study/NCT05872464"},{"conditions":["Xerostomia Following Radiotherapy","Xerostomia Following in Neck or Head After Cancer Surgery","Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head"],"countries":["Denmark"],"enrollment":11,"has_results":true,"interventions":["OTHER: Craniosacral Therapy","OTHER: Exercices Targeting Upper Posture and Respiration"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05882890","official_title":"Does Manuel Treatment With Craniosacral Therapy Change the Experience of Dry Mouth in People Who Suffers With Dry Mouth After Cancer in Throat Ore Mouth - a Pilot Study","phases":["NA"],"primary_completion":"2023-01-20","sponsor":"Cathrine Rahbek","start":"2022-03-18","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?","url":"https://clinicaltrials.gov/study/NCT05882890"},{"conditions":["Gland","Salivary Gland Cancers"],"countries":["United States"],"enrollment":63,"has_results":false,"interventions":["DRUG: Sacituzumab Govitecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05884320","official_title":"Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers","phases":["PHASE2"],"primary_completion":"2028-07-31","sponsor":"M.D. Anderson Cancer Center","start":"2023-07-27","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers","url":"https://clinicaltrials.gov/study/NCT05884320"},{"conditions":["Salivary Gland Cancer"],"countries":[],"enrollment":120,"has_results":false,"interventions":["DRUG: vedicitumomab (Edisil, RC48）","DRUG: vedicitumomab in combination with pyrrolizidine","DRUG: RC48 in combination with a platinum-based chemotherapeutic agent","DRUG: RC48 in combination with teraplizumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05898373","official_title":"Phase II, Multi-arm, Open Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Coupling Agent Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic Salivary Gland Ductal Carcinoma","phases":["PHASE1","PHASE2"],"primary_completion":"2025-06-06","sponsor":"Peking Union Medical College","start":"2023-06-07","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC","url":"https://clinicaltrials.gov/study/NCT05898373"},{"conditions":["Advanced Salivary Gland Carcinoma"],"countries":["China"],"enrollment":88,"has_results":false,"interventions":["DRUG: SHR-A1811","DRUG: SHR 3680 + leuprolide","DRUG: SHR-A1921","DRUG: SHR-A1811"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05924256","official_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","phases":["PHASE2"],"primary_completion":"2026-12-30","sponsor":"Fudan University","start":"2023-07-26","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","url":"https://clinicaltrials.gov/study/NCT05924256"},{"conditions":["Advanced Solid Tumors"],"countries":["Canada","United States"],"enrollment":300,"has_results":false,"interventions":["DRUG: LCB84","DRUG: Anti-PD-1 monoclonal antibody"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05941507","official_title":"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors","phases":["PHASE1","PHASE2"],"primary_completion":"2027-01","sponsor":"LigaChem Biosciences, Inc.","start":"2023-10-05","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05941507"},{"conditions":["Head Cancer","Neck Cancer"],"countries":["France"],"enrollment":140,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05946577","official_title":"Association Between Tinnitus and Hearing Loss in Patients With Locally Advanced Head and Neck Cancer Treated by Concomitant Chemoradiotherapy or Exclusive Radiotherapy: a Prospective and Multicenter Study","phases":[],"primary_completion":"2027-07-09","sponsor":"Assistance Publique - Hôpitaux de Paris","start":"2023-03-09","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study","url":"https://clinicaltrials.gov/study/NCT05946577"},{"conditions":["Adnexal Mass","Adnexal Tumor","Adnexal Cyst","Pregnancy Related"],"countries":["Belgium"],"enrollment":1000,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Ultrasound"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT05974618","official_title":"Prospective Validation of the ADNEX Model for Discrimination Between Benign and Malignant Adnexal Masses in Pregnancy: the International Ovarian Tumour Analysis in Pregnancy Study (p-IOTA).","phases":[],"primary_completion":"2026-07","sponsor":"Universitaire Ziekenhuizen KU Leuven","start":"2023-06-05","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Prospective Validation of the ADNEX Model for Discrimination Between Benign and Malignant Adnexal Masses in Pregnancy: International Ovarian Tumour Analysis in Pregnancy Study (p-IOTA)","url":"https://clinicaltrials.gov/study/NCT05974618"},{"conditions":["Oral Cancer","Oral Squamous Cell Carcinoma"],"countries":["Egypt"],"enrollment":46,"has_results":false,"interventions":["DIAGNOSTIC_TEST: ELISA"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06031337","official_title":"Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study","phases":[],"primary_completion":"2023-11-22","sponsor":"Fayoum University","start":"2023-09-03","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study","url":"https://clinicaltrials.gov/study/NCT06031337"},{"conditions":["Salivary Gland Tumor","Diagnosis"],"countries":["Greece"],"enrollment":128,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Fine Needle Aspiration","PROCEDURE: Histologic Examination"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06034782","official_title":"Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors,a Retrospective Study","phases":[],"primary_completion":"2022-05-15","sponsor":"Aristotle University Of Thessaloniki","start":"2021-02-22","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.","url":"https://clinicaltrials.gov/study/NCT06034782"},{"conditions":["Salivary Gland Tumor","Benign Salivary Gland Tumor"],"countries":["Germany"],"enrollment":300,"has_results":false,"interventions":["OTHER: Sampling"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06047236","official_title":"Immune Biomarker Study for Salivary Gland Carcinoma","phases":[],"primary_completion":"2029-09-30","sponsor":"University of Erlangen-Nürnberg Medical School","start":"2024-01-08","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Immune Biomarker Study for Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT06047236"},{"conditions":["Pleomorphic Adenoma of the Parotid","Warthin Tumor","Head and Neck Disorder","Head and Neck","Thyroid Disease","Thyroidectomy"],"countries":["United States"],"enrollment":8,"has_results":true,"interventions":["DRUG: Fluorescein Sodium"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06054178","official_title":"Intraoperative Nerve Identification With Fluorescein Sodium","phases":["PHASE2"],"primary_completion":"2025-05-22","sponsor":"Stanford University","start":"2024-11-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Identification of Nerves Using Fluorescein Sodium","url":"https://clinicaltrials.gov/study/NCT06054178"},{"conditions":["Sebaceous Cell Tumor of Eyelid"],"countries":["Italy"],"enrollment":20,"has_results":false,"interventions":["GENETIC: exome sequencing (retrospective) and exome and methylome sequencing (prospective)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06080009","official_title":"Analysis of Molecular Biomarkers in Periocular Adnexal Tumours","phases":["NA"],"primary_completion":"2024-10-06","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","start":"2023-10-31","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Analysis of Molecular Biomarkers in Periocular Adnexal Tumours","url":"https://clinicaltrials.gov/study/NCT06080009"},{"conditions":["Salivary Gland Cancer"],"countries":[],"enrollment":250,"has_results":false,"interventions":["OTHER: Observation"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06091878","official_title":"Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers: The INDAGA-UK Trial","phases":[],"primary_completion":"2025-01-31","sponsor":"Royal Marsden NHS Foundation Trust","start":"2024-09-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT06091878"},{"conditions":["Quality of Life","Oral Mucositis","Dental Plaque","Periodontal Diseases","Xerostomia","Dysbiosis"],"countries":["Spain"],"enrollment":62,"has_results":false,"interventions":["DIETARY_SUPPLEMENT: The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory","OTHER: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06122636","official_title":"Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With Head and Neck Cancer: Randomized Clinical Study","phases":["NA"],"primary_completion":"2024-12-20","sponsor":"University of Barcelona","start":"2022-10-03","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Efficacy of a Probiotic and Microbiological Analysis on Oral Complications in Patients With HNC","url":"https://clinicaltrials.gov/study/NCT06122636"},{"conditions":["Salivary Gland Carcinoma","Precision Therapy"],"countries":["China"],"enrollment":39,"has_results":false,"interventions":["DRUG: Cohort 1 (HER2-positive, RC48-ADC)","DRUG: Cohort 2 (NTRK-fusion or NTRK-mutant)","DRUG: Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)","DRUG: TROP2 ADC","DRUG: TKI","DRUG: Albumin-paclitaxel + platinum","DRUG: Albumin-paclitaxel + carboplatin + apatinib + camrelizumab","DRUG: albumin-bound paclitaxel+trastuzumab+pyrotinib","DRUG: HER2,trastuzumab deruxtecan± pertuzumab","DRUG: AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab","DRUG: AR,AR antagonist +goserelin +docetaxel","DRUG: ivonescimab + investigator-choice platinum doublet+","DRUG: iparomlimab + tuvonralimab","DRUG: cadonilimab","DRUG: CDK4/6 inhibitor+AI or fulvestrant","DRUG: alpelisib+fulvestrant","DRUG: PARP inhibitor","DRUG: enfortumab vedotin","DRUG: HER2, pyrotinib + pertuzumab/trastuzumab","DRUG: vebecotutamab ±lenvatinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06145308","official_title":"Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China","phases":["PHASE2"],"primary_completion":"2028-07-10","sponsor":"Peking Union Medical College","start":"2023-08-15","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","url":"https://clinicaltrials.gov/study/NCT06145308"},{"conditions":["Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects"],"countries":["Egypt"],"enrollment":45,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Paxillin biomarker"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06154551","official_title":"Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions","phases":[],"primary_completion":"2023-06-20","sponsor":"Cairo University","start":"2022-11-29","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions","url":"https://clinicaltrials.gov/study/NCT06154551"},{"conditions":["Adenoid Cystic Carcinoma"],"countries":["Poland"],"enrollment":0,"has_results":false,"interventions":["DRUG: Lutetium (177Lu) vipivotide tetraxetan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06199453","official_title":"The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a Specialized Prostate-specific Membrane Antigen (PSMA) Labeled with Lutetium177, in Patients with Recurrent And/or Metastatic Adenoid Cystic Carcinoma Originating from the Salivary Glands - an Open, Non-commercial Clinical Trial","phases":["PHASE2"],"primary_completion":"2027-11","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","start":"2024-01","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial","url":"https://clinicaltrials.gov/study/NCT06199453"},{"conditions":["Prostatic Neoplasms"],"countries":["Egypt"],"enrollment":59,"has_results":false,"interventions":["DEVICE: PSMA PET/CT"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06209853","official_title":"Correlation Between Prostate-Specific Antigen (PSA) Levels and Fluorine-18 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (F-18 PSMA PET/CT) Scan Findings in Patients With Prostate Cancer","phases":[],"primary_completion":"2025-03-01","sponsor":"Assiut University","start":"2024-01-20","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient","url":"https://clinicaltrials.gov/study/NCT06209853"},{"conditions":["Oropharynx Cancer","Head and Neck Cancer","Xerostomia"],"countries":["United States"],"enrollment":0,"has_results":false,"interventions":["RADIATION: standard radiotherapy","RADIATION: experimental radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06276946","official_title":"Randomized Assessment of Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia Following Radiotherapy for Oropharynx Cancer","phases":["NA"],"primary_completion":"2028-07","sponsor":"UNC Lineberger Comprehensive Cancer Center","start":"2025-08-08","status":"WITHDRAWN","study_type":"INTERVENTIONAL","title":"Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia","url":"https://clinicaltrials.gov/study/NCT06276946"},{"conditions":["Taste, Altered","Xerostomia","Neoplasms"],"countries":["Ireland"],"enrollment":120,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06287294","official_title":"An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer","phases":[],"primary_completion":"2025-12-31","sponsor":"Our Lady's Hospice and Care Services","start":"2023-08-30","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer","url":"https://clinicaltrials.gov/study/NCT06287294"},{"conditions":["Salivary Gland Neoplasm Duct"],"countries":["China"],"enrollment":37,"has_results":false,"interventions":["DRUG: Rezvilutamide","DRUG: Leuprolide Acetate"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06348264","official_title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial","phases":["PHASE2"],"primary_completion":"2029-03-30","sponsor":"Peking University First Hospital","start":"2024-10-10","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","url":"https://clinicaltrials.gov/study/NCT06348264"},{"conditions":["Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Metastatic Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Head and Neck Carcinoma","Head and Neck Neoplasm","Salivary Gland Neoplasms","Thyroid Gland Neoplasm"],"countries":["United States"],"enrollment":560,"has_results":false,"interventions":["OTHER: Non-Interventional Study"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06356272","official_title":"Oropharynx (OPX) Biomarker Trial","phases":[],"primary_completion":"2029-11-30","sponsor":"Mayo Clinic","start":"2019-11-15","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Oropharynx (OPX) Biomarker Trial","url":"https://clinicaltrials.gov/study/NCT06356272"},{"conditions":["Gynecologic Disease","Gynecologic Cancer","Endometriosis","Ovarian Cancer","Cyst Ovary","Fibroid","Cervical Cancer","Uterine Cancer"],"countries":["France"],"enrollment":2500,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Saliva sample"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06392997","official_title":"Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology","phases":[],"primary_completion":"2026-12","sponsor":"ZIWIG","start":"2024-12-05","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology","url":"https://clinicaltrials.gov/study/NCT06392997"},{"conditions":["Esophageal Carcinoma Salivary Gland Type","Radiotherapy"],"countries":["China"],"enrollment":200,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06393140","official_title":"The Study on the Mechanism of Radiotherapy-elicited Immune Response","phases":[],"primary_completion":"2026-07-20","sponsor":"Fudan University","start":"2022-07-01","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"The Study on the Mechanism of Radiotherapy-elicited Immune Response","url":"https://clinicaltrials.gov/study/NCT06393140"},{"conditions":["Sjogren's Syndrome","Pediatric ALL"],"countries":["China"],"enrollment":15,"has_results":false,"interventions":["DRUG: Rituximab","DRUG: Belimumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06410833","official_title":"Effectiveness of Belimumab After Rituximab in Resistant Primary Juvenile Sjogren's Syndrome","phases":["PHASE4"],"primary_completion":"2025-12-31","sponsor":"Peking Union Medical College Hospital","start":"2024-03-09","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Belimumab After Rituximab in Resistant Primary Juvenile SS","url":"https://clinicaltrials.gov/study/NCT06410833"},{"conditions":["Radiation-induced Xerostomia"],"countries":["Egypt"],"enrollment":40,"has_results":false,"interventions":["BIOLOGICAL: Hibiscus Sabdariffa"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06413550","official_title":"The Efficacy of Hibiscus Sabdariffa L. Mouth Rinse in Head and Neck Cancer Patients With Xerostomia: A Randomized, Placebo-Controlled Clinical Trial","phases":["NA"],"primary_completion":"2025-01","sponsor":"Ain Shams University","start":"2024-04-01","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"The Efficacy of Hibiscus Sabdariffa in Xerostomia","url":"https://clinicaltrials.gov/study/NCT06413550"},{"conditions":["Parotid Cancer"],"countries":["United Kingdom"],"enrollment":97,"has_results":false,"interventions":["RADIATION: Proton Beam Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06421649","official_title":"An Evaluative Commissioning Study to Investigate the Role of Adjuvant Proton Beam Radiotherapy in Patients With Localised Parotid Carcinoma","phases":["NA"],"primary_completion":"2029-09-01","sponsor":"The Christie NHS Foundation Trust","start":"2025-09-05","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Investigating the Role of Adjuvant Proton Beam Therapy in Patients With Parotid Carcinoma","url":"https://clinicaltrials.gov/study/NCT06421649"},{"conditions":["Head and Neck Cancer"],"countries":["Switzerland"],"enrollment":150,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Repetitive (semi-)objective and subjective taste, smell, and saliva analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06444776","official_title":"Therapy-Associated Saliva and Taste Change Evaluation (TASTE) in Head & Neck Cancer","phases":[],"primary_completion":"2025-10","sponsor":"Sonja Stieb, MD","start":"2022-12-19","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Therapy-Associated Saliva and Taste Change Evaluation (TASTE) in Head & Neck Cancer Patients Undergoing Radiotherapy","url":"https://clinicaltrials.gov/study/NCT06444776"},{"conditions":["Locally Advanced Salivary Gland Carcinoma"],"countries":["Germany"],"enrollment":100,"has_results":false,"interventions":["PROCEDURE: simultaneous postoperative radiochemotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06464198","official_title":"Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region","phases":[],"primary_completion":"2036-06","sponsor":"University of Erlangen-Nürnberg Medical School","start":"2024-06-01","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region","url":"https://clinicaltrials.gov/study/NCT06464198"},{"conditions":["Head and Neck Cancer","Xerostomia"],"countries":["Hong Kong"],"enrollment":126,"has_results":false,"interventions":["BEHAVIORAL: Self-administered acupressure","OTHER: Oral health education"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06465628","official_title":"Effect of Self-administered Acupressure for Improving Xerostomia in Head and Neck Cancer Patients: a Randomized Controlled Trial","phases":["NA"],"primary_completion":"2026-12-31","sponsor":"The University of Hong Kong","start":"2024-12-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Acupressure on Xerostomia in Head and Neck Cancer Patients","url":"https://clinicaltrials.gov/study/NCT06465628"},{"conditions":["Advanced Solid Tumor"],"countries":[],"enrollment":60,"has_results":false,"interventions":["DRUG: Neratinib tablets"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06519110","official_title":"A Single-arm, Open-label, Multicenter Phase II Clinical Study of Neratinib Tablets Monotherapy in the Treatment of Advanced Solid Tumors With HER2 Mutations","phases":["PHASE2"],"primary_completion":"2026-02-14","sponsor":"Convalife (Shanghai) Co., Ltd.","start":"2024-08-10","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations","url":"https://clinicaltrials.gov/study/NCT06519110"},{"conditions":["Head Neck Cancer","Xerostomia Following Radiotherapy"],"countries":["Canada"],"enrollment":50,"has_results":false,"interventions":["DRUG: OnabotulinumtoxinA","DRUG: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06530524","official_title":"Pretherapy Botulinum Toxin to Reduce Radiation-related Xerostomia in Head and Neck Cancer","phases":["PHASE2"],"primary_completion":"2026-10-01","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","start":"2024-10-01","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery","url":"https://clinicaltrials.gov/study/NCT06530524"},{"conditions":["ORR,OS,PFS"],"countries":["China"],"enrollment":10,"has_results":false,"interventions":["BIOLOGICAL: CD38/CS1 injection"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06574958","official_title":"Professor of Medicine Second Hospital of Shandong University","phases":["EARLY_PHASE1"],"primary_completion":"2025-01-15","sponsor":"The Second Hospital of Shandong University","start":"2024-04-30","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Clinical Study of CD38\\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06574958"},{"conditions":["Bone Cancer","Brain Cancer","Colorectal Cancer","Esophagus Cancer","Lymphoma","Salivary Gland Cancer","Head and Neck Cancer","Liver Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Small Intestine Cancer","Stomach Cancer","Urinary Bladder Cancer","Anal Cancer","Blood Cancer","Breast Cancer","Cervical Cancer","Lung Cancer","Kidney Cancer","Penile Cancer","Skin Cancer","Testicular Cancer","Thyroid Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer"],"countries":["United States"],"enrollment":33,"has_results":false,"interventions":["OTHER: Standard assistance","OTHER: Enhanced assistance"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06582849","official_title":"Enhanced Assistance During Radiotherapy for Unmet Essential Needs (EARN): a Single Center Hybrid Type 1 Efficacy-implementation Study","phases":["NA"],"primary_completion":"2025-08-08","sponsor":"Washington University School of Medicine","start":"2024-10-04","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Enhanced Assistance During Radiotherapy for Unmet Essential Needs","url":"https://clinicaltrials.gov/study/NCT06582849"},{"conditions":["Striae Distensae"],"countries":[],"enrollment":20,"has_results":false,"interventions":["DEVICE: pulsed dye laser","DEVICE: Carboxytherapy"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT06591208","official_title":"Study the Effect of Pulsed Dye Laser Versus Carboxytherapy in the Treatment of Striae Rubra","phases":["NA"],"primary_completion":"2025-01","sponsor":"Cairo University","start":"2024-09-11","status":"UNKNOWN","study_type":"INTERVENTIONAL","title":"Study the Effect of Pulsed Dye Laser Versus Carboxytherapy in the Treatment of Striae Rubra","url":"https://clinicaltrials.gov/study/NCT06591208"},{"conditions":["Rheumatoid Arthritis (RA","Psoriatic Arthritis (PsA"],"countries":["Italy"],"enrollment":178,"has_results":false,"interventions":["DRUG: Upadacitinib 15 MG [Rinvoq]"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06630715","official_title":"Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis. OPTimising IMAging For The Use In The Follow-Up Of Arthritis: The OPTIMA Study","phases":[],"primary_completion":"2025-12","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","start":"2024-07-23","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.","url":"https://clinicaltrials.gov/study/NCT06630715"},{"conditions":["Ovarian Cancer","Ovarian Mass","Ovarian Cysts","Fallopian Tube Neoplasms","Adnexal Carcinoma","Adnexal Cyst","Adnexal Masses"],"countries":["United Kingdom"],"enrollment":25,"has_results":false,"interventions":["PROCEDURE: MIRRORS-FROZEN Protocol.","PROCEDURE: Standard open surgery"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT06638593","official_title":"MIRRORS-FROZEN - A Pilot Randomised Controlled Trial (RCT) Comparing Open Vs Robotic Surgery in the Management of Women With Complex Pelvic Adnexal Masses ≤ 8cm.","phases":["NA"],"primary_completion":"2026-12-01","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","start":"2024-09-23","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women With Complex Pelvic Adnexal Masses ≤ 8cm.","url":"https://clinicaltrials.gov/study/NCT06638593"},{"conditions":["Urachal Cancer","Parathyroid Carcinoma","Fibrolamellar Carcinoma","Angiosarcoma","Secretory Carcinoma of Breast","Anal Neoplasms","Metaplastic Breast Carcinoma","Translocation Renal Cell Carcinoma","Carcinosarcoma","Small Intestine Neoplasms","Cholangiocarcinoma","Sertoli-Leydig Cell Tumor","Adenoid Cystic Carcinoma","Mesothelioma","Neuroblastoma","Adrenal Gland Neoplasms","Penile Neoplasms","Apocrine Carcinoma","Fibrosarcoma","Cancer of Unknown Primary","Hemangioblastoma","Thyroid Neoplasms","Hepatoblastoma","Fallopian Tube Neoplasms","Leiomyosarcoma","Vaginal Neoplasms","Neurofibrosarcoma","Gallbladder Neoplasms","Osteosarcoma","Biliary Tract Neoplasms","Clear Cell Endometrial Cancer","Yolk Sac Tumor","Vulvar Neoplasms","Kaposi Sarcoma","Ovarian Epithelial Cancer","Soft Tissue Sarcoma","Urethral Neoplasms","Granulosa Cell Tumor","Primitive Neuroectodermal Tumor","Neuroendocrine Tumors","Trophoblastic Tumor"],"countries":["Brazil"],"enrollment":28,"has_results":false,"interventions":["DRUG: Nivolumab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06638931","official_title":"Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors","phases":["PHASE2"],"primary_completion":"2027-07","sponsor":"Instituto do Cancer do Estado de São Paulo","start":"2024-07-16","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Agnostic Therapy in Rare Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06638931"},{"conditions":["Cutaneous Metastasis","Cutaneous Malignant Mixed Tumor","Bleomycin Adverse Reaction","Electrochemotherapy"],"countries":["Denmark"],"enrollment":55,"has_results":false,"interventions":["DRUG: Bleomycin"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06647342","official_title":"Randomised Controlled Clinical Trial Investigating the Effect of Reduced Bleomycin in Elechtrochemotherapy Treatment on Patients With Cutaneous Malignancies (The BLESS Trial)","phases":["PHASE4"],"primary_completion":"2027-03-31","sponsor":"Julie Gehl","start":"2024-10-29","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"The Effect of Reduced Bleomycin in Electrochemotherapy Treatment","url":"https://clinicaltrials.gov/study/NCT06647342"},{"conditions":["Pheochromocytoma/Paraganglioma","Rhabdomyosarcoma","Paget Disease, Extramammary","Renal Angiomyolipoma","Perivascular Epithelioid Cell Tumor, Malignant","Sarcoma","Urachal Cancer","Neuroendocrine Cancer","Basal Cell Carcinomas","Sarcomatoid Carcinoma","Penile Cancer","Adrenal Cortical Cancer","Germ Cell Cancer Metastatic","Non-Clear Cell Renal Cell Carcinoma","Prostate Cancers","Clear Cell Renal Cancer","Urothelial Carcinoma","Kidney Cancer","Rare Tumors"],"countries":["China"],"enrollment":400,"has_results":false,"interventions":["DRUG: Ivocizumab"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT06683846","official_title":"Ivonescimab (PD-1/VEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study","phases":["PHASE2"],"primary_completion":"2027-11-30","sponsor":"Fudan University","start":"2024-11-20","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","url":"https://clinicaltrials.gov/study/NCT06683846"},{"conditions":["Paget Disease, Extramammary","Rhabdomyosarcoma","Testicular Cancer","Penile Cancer","Urachal Cancer"],"countries":["China"],"enrollment":100,"has_results":false,"interventions":["DRUG: Albumin-paclitaxel Injection"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT06684327","official_title":"Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors","phases":["PHASE2"],"primary_completion":"2026-12-30","sponsor":"Fudan University","start":"2024-11-30","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors","url":"https://clinicaltrials.gov/study/NCT06684327"},{"conditions":["Salivary Gland Cancers","Patient Derived Organoid","Drug Sensitive Test in Vitro"],"countries":["China"],"enrollment":40,"has_results":false,"interventions":["OTHER: No Intervention: Observational Cohort"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06686979","official_title":"Consistency Evaluation of Drug Efficacy Between Clinical Systemic Treatment and Drug Sensitive Test Based on Patient-derived Organoid in Patients With Recurrent/Metastatic Salivary Gland Cancer: A Prospective, Multicenter, Observational Study","phases":[],"primary_completion":"2027-06-30","sponsor":"Huashan Hospital","start":"2025-03-26","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"PDO Based Drug Sensitive Test in R/M SGC","url":"https://clinicaltrials.gov/study/NCT06686979"},{"conditions":["Adnexal Mass","Adnexal Tumor","Adnexal Cyst","Adnexal Masses in Young Girls and Adolescents"],"countries":["Belgium"],"enrollment":1000,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Group 2: Conservative management (follow-up)","PROCEDURE: Group 1: Surgical management"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06693596","official_title":"Masses in Young Patients - International Ovarian Tumour Analysis: Prospective Validation and Comparison of Simple Rules, Benign Descriptors and ADNEX Models for Discrimination Between Benign and Malignant Adnexal Masses in Young Girls and Adolescents MY-IOTA","phases":[],"primary_completion":"2026-07-21","sponsor":"Universitaire Ziekenhuizen KU Leuven","start":"2024-11-20","status":"UNKNOWN","study_type":"OBSERVATIONAL","title":"Masses in Young Patients - International Ovarian Tumour Analysis (MY-IOTA)","url":"https://clinicaltrials.gov/study/NCT06693596"},{"conditions":["Breast Cancer","Gastric Cancer","Esophageal Cancer","Gastroesophageal Cancer","Colorectal Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Ovarian Cancer","Urothelial Carcinoma","Salivary Gland Cancer","Pancreatic Cancer","HER-2 Protein Overexpression"],"countries":["Georgia","South Korea","Spain","United States"],"enrollment":200,"has_results":false,"interventions":["DRUG: Zanidatamab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06695845","official_title":"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)","phases":["PHASE2"],"primary_completion":"2026-12-31","sponsor":"Jazz Pharmaceuticals","start":"2025-01-14","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","url":"https://clinicaltrials.gov/study/NCT06695845"},{"conditions":["Xerostomia Due to Radiotherapy (Disorder)"],"countries":["China"],"enrollment":100,"has_results":false,"interventions":["RADIATION: Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06700863","official_title":"Screening of Diagnostic Biomarkers and Related Mechanisms for Radiation-induced Xerostomia","phases":[],"primary_completion":"2026-07-01","sponsor":"The First Affiliated Hospital with Nanjing Medical University","start":"2024-05-17","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Screening of Biomarkers and Related Mechanisms for RIX","url":"https://clinicaltrials.gov/study/NCT06700863"},{"conditions":["Sjogren Syndrome","Malignant Tumors","Arterial Disease"],"countries":["Netherlands"],"enrollment":20,"has_results":false,"interventions":["DEVICE: Multispectral optoacoustic tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06740175","official_title":"The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases: a Phase 1 Explorative Imaging Study (FOMO-study)","phases":["NA"],"primary_completion":"2021-10-14","sponsor":"University Medical Center Groningen","start":"2020-04-07","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases","url":"https://clinicaltrials.gov/study/NCT06740175"},{"conditions":["Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy"],"countries":[],"enrollment":45,"has_results":false,"interventions":["DEVICE: IVIM Imaging MRF Imaging"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06751381","official_title":"A Prospective Study on Monitoring Salivary Gland Injury in Nasopharyngeal Carcinoma Patients After Radiotherapy Using Multi-Modal Radiomics","phases":[],"primary_completion":"2026-06-06","sponsor":"Hainan Medical College","start":"2025-01-20","status":"NOT_YET_RECRUITING","study_type":"OBSERVATIONAL","title":"Monitoring Salivary Gland Injury in Nasopharyngeal Carcinoma Patients After Radiotherapy Using Multi-Modal Radiomics","url":"https://clinicaltrials.gov/study/NCT06751381"},{"conditions":["Advanced Solid Tumors","HER2 Mutation"],"countries":["Australia","Canada","China","Denmark","France","Italy","Japan","South Korea","Spain","Switzerland","United States"],"enrollment":111,"has_results":false,"interventions":["DRUG: BAY2927088"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06760819","official_title":"A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations","phases":["PHASE2"],"primary_completion":"2029-02-02","sponsor":"Bayer","start":"2025-02-13","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","url":"https://clinicaltrials.gov/study/NCT06760819"},{"conditions":["Xerostomia, Radiation-induced Parotid Damage,Predictivevalue,Head and Neck Cancer"],"countries":[],"enrollment":20,"has_results":false,"interventions":["OTHER: IVIM Imaging MRF Imaging"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06792526","official_title":"Monitoring Salivary Gland Damage After Radiotherapy in Patients with Head and Neck Cancer Using Multimodal Radiomics","phases":[],"primary_completion":"2025-07-20","sponsor":"Hainan People's Hospital","start":"2025-01-20","status":"NOT_YET_RECRUITING","study_type":"OBSERVATIONAL","title":"Prospective Study on Monitoring Parotid Gland Injury After Radiotherapy for Head and Neck Tumors Using Multimodal Radiomics","url":"https://clinicaltrials.gov/study/NCT06792526"},{"conditions":["Salivary Gland Cancer","Advanced Salivary Gland Carcinoma","Metastatic Salivary Gland Cancer","Adenoid Cystic Carcinoma"],"countries":["United States"],"enrollment":35,"has_results":false,"interventions":["DRUG: Ivonescimab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06805617","official_title":"A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)","phases":["PHASE2"],"primary_completion":"2027-07-01","sponsor":"Dana-Farber Cancer Institute","start":"2025-02-26","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT06805617"},{"conditions":["Radiotherapy Side Effect","Xerostomia Due to Radiotherapy","Xerostomia Due to Radiotherapy (Disorder)"],"countries":["Egypt"],"enrollment":260,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06851572","official_title":"Prevalence of Late Xerostomia and Hyposalivation with Associated Risk Factors in Survivors of Head and Neck Cancer After Radiotherapy: a Multi-centric Cross-sectional Study","phases":[],"primary_completion":"2024-03-01","sponsor":"Ain Shams University","start":"2023-03-20","status":"COMPLETED","study_type":"OBSERVATIONAL","title":"Prevalence of Late Xerostomia and Hyposalivation with Associated Risk Factors in Survivors of Head and Neck Cancer After Radiotherapy: a Multi-centric Cross-sectional Study","url":"https://clinicaltrials.gov/study/NCT06851572"},{"conditions":["Salivary Gland Cancer","Thyroid Cancer"],"countries":["Singapore"],"enrollment":32,"has_results":false,"interventions":["DRUG: Sacituzumab govitecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT06923826","official_title":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) - A Phase 2 Multi-centre Trial","phases":["PHASE2"],"primary_completion":"2030-04","sponsor":"National University Hospital, Singapore","start":"2025-04-15","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)","url":"https://clinicaltrials.gov/study/NCT06923826"},{"conditions":["Congenital Cataract","Tooth Abnormalities","Ocular Pathologies"],"countries":["Italy"],"enrollment":5,"has_results":false,"interventions":["GENETIC: Whole Genome Sequencing","OTHER: Cephalometric tracing"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT06950619","official_title":"A Clinical Investigation Into the Co-occurrence of Dental Anomalies With Ocular and Cutaneous Features","phases":["NA"],"primary_completion":"2027-04","sponsor":"University of Pavia","start":"2026-02","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Associations Between Dental Anomalies and Ocular, Cutaneous and Skin Appendages Features","url":"https://clinicaltrials.gov/study/NCT06950619"},{"conditions":["Paraganglioma/ Phaeochromocytoma","Melanoma and Other Malignant Neoplasms of Skin","Gastrointestinal Stromal Tumor (GIST)","Adrenocortical Tumor","Pancreatic Tumors","Esthesioneuroblastoma, Olfactory","Mesothelioma","Nasopharyngeal Carcinoma (NPC)","NUT Carcinoma","Pleuropulmonary Blastoma","Salivary Gland Tumors","Thymic Tumors","Thyroid Carcinoma","Appendiceal Cancers"],"countries":["Italy"],"enrollment":6250,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07072143","official_title":"The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.","phases":[],"primary_completion":"2049-01-06","sponsor":"Azienda Ospedaliera di Padova","start":"2025-01-25","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"An International Study on Pediatric Patients With Rare Tumors.","url":"https://clinicaltrials.gov/study/NCT07072143"},{"conditions":["Anal Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Cholangiocarcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Lung Carcinoma","Malignant Adrenal Gland Neoplasm","Malignant Brain Neoplasm","Malignant Neoplasm of Unknown Primary","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Malignant Uterine Neoplasm","Neuroendocrine Neoplasm","Ovarian Carcinoma","Pancreatic Carcinoma","Penile Carcinoma","Pleural Carcinomatosis","Primary Peritoneal Carcinoma","Prostate Carcinoma","Salivary Gland Carcinoma","Sarcoma","Skin Carcinoma","Solitary Fibrous Tumor","Thymus Carcinoma","Thyroid Gland Carcinoma","Thyroid Gland Medullary Carcinoma","Urothelial Carcinoma","Vaginal Carcinoma"],"countries":["United States"],"enrollment":30,"has_results":false,"interventions":["PROCEDURE: Computed Tomography","OTHER: Fludeoxyglucose F-18","RADIATION: Gallium Ga 68 FAPi-46","PROCEDURE: Positron Emission Tomography"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07118176","official_title":"PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients","phases":["PHASE1"],"primary_completion":"2026-06-23","sponsor":"Jonsson Comprehensive Cancer Center","start":"2025-08-01","status":"ACTIVE_NOT_RECRUITING","study_type":"INTERVENTIONAL","title":"Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers","url":"https://clinicaltrials.gov/study/NCT07118176"},{"conditions":["Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer"],"countries":["United States"],"enrollment":100,"has_results":false,"interventions":["DRUG: Trastuzumab deruxtecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07124000","official_title":"Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","phases":[],"primary_completion":"2028-03-30","sponsor":"AstraZeneca","start":"2025-09-18","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"DESTINY-PANTUMOUR04","url":"https://clinicaltrials.gov/study/NCT07124000"},{"conditions":["Xerostomia Due to Radiotherapy (Disorder)"],"countries":["China"],"enrollment":50,"has_results":false,"interventions":["RADIATION: Radiation Therapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07170358","official_title":"Screening of Diagnostic Biomarkers and Related Mechanisms for Radiation-induced Xerostomia","phases":[],"primary_completion":"2026-12-01","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","start":"2024-05-17","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Screening of Biomarkers and Related Mechanisms for RIX","url":"https://clinicaltrials.gov/study/NCT07170358"},{"conditions":["Parotid Tumors","Parotidectomy"],"countries":["Egypt"],"enrollment":120,"has_results":false,"interventions":["PROCEDURE: Superficial parotidectomy","PROCEDURE: Intracapsular parotidectomy (ICP)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07185542","official_title":"Function-Preserving Surgery for Parotid Tumors: Intracapsular Versus Superficial Parotidectomy; A Randomized Clinical Trial.","phases":["NA"],"primary_completion":"2025-05-01","sponsor":"Al-Azhar University","start":"2024-05-01","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Function-Preserving Surgery for Parotid Tumors: Intracapsular Versus Superficial Parotidectomy; A Randomized Clinical Trial.","url":"https://clinicaltrials.gov/study/NCT07185542"},{"conditions":["Immune-Related Adverse Events","Lupus Erythematosus, Systemic","Sjogren Syndrome","Systemic Sclerosis (SSc)","Inflammatory Myopathies","Solid Tumors"],"countries":["Spain"],"enrollment":300,"has_results":false,"interventions":["DRUG: Immune Checkpoint Inhibitors"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07249060","official_title":"Interferon Signature in Cancer Patients Treated With Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies: A Multicenter, Prospective, Observational Cohort Study Comparing Cancer Patients and Non-Cancer Patients With Systemic Autoimmune Diseases","phases":[],"primary_completion":"2026-12","sponsor":"Hospital Universitario Araba","start":"2024-01-08","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients","url":"https://clinicaltrials.gov/study/NCT07249060"},{"conditions":["Hepatocellular Carcinoma"],"countries":["Italy"],"enrollment":200,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Contrast-Enhanced Ultrasound"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07272083","official_title":"Application of the New Diagnostic Criteria CEUS (Contrast-Enhanced Ultrasound) LI-RADS (Liver Imaging Reporting and Data System) TRA (Nonradiation Treatment Response Assessment) in the Evaluation Response to Ablation Treatment (Radiofrequency or Microwave Ablation) of Hepatocellular Carcinoma (HCC) Nodules.","phases":[],"primary_completion":"2028-12-01","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","start":"2025-12-01","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules","url":"https://clinicaltrials.gov/study/NCT07272083"},{"conditions":["Xerostomia Due to Hyposecretion of Salivary Gland","Xerostomia Due to Radiotherapy","Sjögren´s Syndrome"],"countries":[],"enrollment":100,"has_results":false,"interventions":["DRUG: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","DRUG: Placebo"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07290946","official_title":"Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors","phases":["PHASE2"],"primary_completion":"2027-06","sponsor":"Christian von Buchwald","start":"2025-12","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors","url":"https://clinicaltrials.gov/study/NCT07290946"},{"conditions":["Oral Squamous Cell Carcinoma (OSCC)","Postoperative Pain","Postoperative Oral Mucositis","Free Flap Reconstruction","Oral Cancer"],"countries":["Taiwan"],"enrollment":36,"has_results":false,"interventions":["OTHER: Hydrogen Water Oral Care","OTHER: Water Oral Care"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07306546","official_title":"Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer","phases":["NA"],"primary_completion":"2027-10-31","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","start":"2025-12-16","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer","url":"https://clinicaltrials.gov/study/NCT07306546"},{"conditions":["Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis"],"countries":["Cambodia"],"enrollment":10000,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07358910","official_title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phases":[],"primary_completion":"2026-04-16","sponsor":"Institut Pasteur du Cambodge","start":"2025-12-18","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","url":"https://clinicaltrials.gov/study/NCT07358910"},{"conditions":["Head & Neck Cancer","Head & Neck Squamous Cell Carcinoma","Periodontal Disease","Xerostomia"],"countries":["Egypt"],"enrollment":100,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07394842","official_title":"Longitudinal Effects of Head and Neck Radiotherapy on Periodontal and Dental Oral Health: A Prospective Cohort Study","phases":[],"primary_completion":"2026-02-01","sponsor":"Ain Shams University","start":"2025-02-01","status":"ACTIVE_NOT_RECRUITING","study_type":"OBSERVATIONAL","title":"Longitudinal Oral Health Changes After Head and Neck Radiotherapy","url":"https://clinicaltrials.gov/study/NCT07394842"},{"conditions":["Squamous Cell Carcinoma of the Oral Cavity and Oropharynx"],"countries":["France"],"enrollment":70,"has_results":false,"interventions":["RADIATION: Coplanar External Beam Radiotherapy","RADIATION: Non-Coplanar External Beam Radiotherapy"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07413627","official_title":"A Randomized Pilot Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers","phases":["NA"],"primary_completion":"2028-02-28","sponsor":"Centre Georges Francois Leclerc","start":"2026-04-01","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers","url":"https://clinicaltrials.gov/study/NCT07413627"},{"conditions":["Salivary Gland Carcinomas"],"countries":["China"],"enrollment":90,"has_results":false,"interventions":["DRUG: MRG 003","DRUG: Pucotenlimab"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07464366","official_title":"The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study","phases":["PHASE2"],"primary_completion":"2028-05-30","sponsor":"Ji Dongmei","start":"2026-03-19","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study","url":"https://clinicaltrials.gov/study/NCT07464366"},{"conditions":["Oral Mucositis","Chemotherapy-induced Oral Mucositis","Head and Neck Neoplasms"],"countries":["Italy"],"enrollment":50,"has_results":false,"interventions":["DEVICE: Gas Ozone Therapy","OTHER: Biomimetic Oral Care Regimen"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07491536","official_title":"Combined Gas Ozone Therapy and Biomimetic Oral Care in the Management of Radio- and Chemotherapy-Induced Oral Mucositis: A Randomized Controlled Clinical Trial","phases":["NA"],"primary_completion":"2026-12-01","sponsor":"University of Pavia","start":"2026-03-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis","url":"https://clinicaltrials.gov/study/NCT07491536"},{"conditions":["Adenoid Cystic Carcinoma of the Salivary Gland","Adenoid Cystic Carcinoma of the Head and Neck"],"countries":["Italy"],"enrollment":114,"has_results":false,"interventions":["OTHER: Standard of Care (Investigator Choice)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07507578","official_title":"A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma (MAPPING-ACC)","phases":[],"primary_completion":"2028-04-30","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","start":"2025-03-01","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma","url":"https://clinicaltrials.gov/study/NCT07507578"},{"conditions":["Parotid Gland Tumor","Facial and Neck Rhytides"],"countries":[],"enrollment":20,"has_results":false,"interventions":["DEVICE: Non-invasive facial nerve monitoring patch"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07523373","official_title":"A Prospective Comparative Study Comparing Wireless Dry Electrode Patch and Standard EMG Monitoring for Intraoperative Facial Nerve Monitoring","phases":["NA"],"primary_completion":"2027-02-18","sponsor":"Sheba Medical Center","start":"2026-05-01","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch","url":"https://clinicaltrials.gov/study/NCT07523373"},{"conditions":["Adenoid Cystic Carcinoma of the Head and Neck","SBRT","Antibody-drug Conjugates"],"countries":[],"enrollment":40,"has_results":false,"interventions":["DRUG: Becotatug Vedotin","RADIATION: SBRT","DRUG: Becotatug Vedotin or Sacituzumab Tirumotecan"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07579598","official_title":"Antibody-Drug Conjugate Plus Stereotactic Body Radiotherapy in Recurrent or Metastatic Salivary Gland Carcinoma - A Phase II Exploratory Study","phases":["PHASE2"],"primary_completion":"2026-12-31","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2026-05-01","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT07579598"},{"conditions":["Thyroid Cancer","Thyroid and Parathyroid Surgery","Hyperthyreosis and Goiter","Surgical Stress Response"],"countries":["Croatia"],"enrollment":48,"has_results":false,"interventions":["OTHER: bilateral ultrasound guided intermediate cervical plexus block with 0,25% levobupivacaine"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07600580","official_title":"The Association Between Bilateral Intermediate Cervical Plexus Block and Salivary and Serum Biomarkers of Surgical Stress Response During Total Thyroidectomy","phases":["PHASE4"],"primary_completion":"2027-02-03","sponsor":"University Hospital Dubrava","start":"2024-05-13","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response","url":"https://clinicaltrials.gov/study/NCT07600580"},{"conditions":["Parotid Neoplasms","Post-operative Complications","Seroma as Procedural Complication"],"countries":["Sweden"],"enrollment":600,"has_results":false,"interventions":["PROCEDURE: Active wound drainage (Standard of Care)","PROCEDURE: Omission of active wound drain"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07620184","official_title":"A Prospective, Randomized, Multicenter Non-Inferiority Trial Evaluating the Safety of Parotidectomy Without Active Surgical Drainage (Svenska Nationella Parotisstudien)","phases":["NA"],"primary_completion":"2030-12","sponsor":"Uppsala University Hospital","start":"2026-05-06","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Swedish National Parotidectomy Study (SNaPs): Drainless Versus Standard Surgery","url":"https://clinicaltrials.gov/study/NCT07620184"},{"conditions":["Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma","Paranasal Sinus Neoplasms","Nasopharyngeal Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Hypopharyngeal Cancer","Carcinoma of Larynx","Oral Squamous Cell Carcinoma","Salivary Gland Cancer","Adenoid Cystic Carcinoma","Prostate Cancer","Metastatic Castration Resistant Prostate Cancer"],"countries":["United States"],"enrollment":120,"has_results":false,"interventions":["DRUG: SX-682","DRUG: DTX"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07667400","official_title":"Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer","phases":["PHASE1","PHASE2"],"primary_completion":"2036-10-01","sponsor":"National Cancer Institute (NCI)","start":"2026-11-15","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT07667400"},{"conditions":["Xerostomia","Head Cancer","Neck Cancer","Nasopharyngeal Carcinoma (NPC)","Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma"],"countries":["Singapore"],"enrollment":50,"has_results":false,"interventions":["PROCEDURE: Acupuncture"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07674706","official_title":"A Pilot Randomised Trial Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","phases":["NA"],"primary_completion":"2029-06","sponsor":"National University Hospital, Singapore","start":"2026-06","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","url":"https://clinicaltrials.gov/study/NCT07674706"},{"conditions":["Adenoid Cystic Carcinoma of the Salivary Gland","Recurrence","Metastatic Disease"],"countries":["France"],"enrollment":51,"has_results":false,"interventions":["DRUG: Zanzalintinib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07682675","official_title":"ZANACC: Phase 2 Non-randomized Single Arm Study Evaluating Zanzalintinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck","phases":["PHASE2"],"primary_completion":"2029-04","sponsor":"UNICANCER","start":"2026-10","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT07682675"},{"conditions":["HNSCC","OSCC","OPSCC","Ivonescimab"],"countries":["China"],"enrollment":20,"has_results":false,"interventions":["DRUG: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07686575","official_title":"Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma","phases":[],"primary_completion":"2026-10-30","sponsor":"Zhujiang Hospital","start":"2026-01-26","status":"ACTIVE_NOT_RECRUITING","study_type":"OBSERVATIONAL","title":"Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT07686575"},{"conditions":["Oral Squamous Cell Carcinoma (OSCC)"],"countries":["Italy"],"enrollment":38,"has_results":false,"interventions":["OTHER: Saliva Collection and Biomarker Analysis"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07692360","official_title":"Salivary Interleukin-6 Levels and Interleukin Gene Polymorphisms for the Biological Stratification of Locoregional Progression in Oral Squamous Cell Carcinoma (OSCC): A Multicentre Observational Cross-Sectional Study","phases":[],"primary_completion":"2028-05-31","sponsor":"University of Pavia","start":"2026-09-01","status":"NOT_YET_RECRUITING","study_type":"OBSERVATIONAL","title":"Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT07692360"},{"conditions":["Head and Neck Neoplasms","Xerostomia","Cancer-related Fatigue","Pain"],"countries":["Taiwan"],"enrollment":180,"has_results":false,"interventions":["PROCEDURE: True Foot Reflexology","PROCEDURE: Sham Foot Reflexology","DEVICE: True ta-VNS","DEVICE: Sham ta-VNS","PROCEDURE: True Auricular Acupressure","PROCEDURE: Sham Auricular Acupressure","OTHER: Usual Care"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07711626","official_title":"Efficacy of Foot Reflexology and Transcutaneous Auricular Vagus Nerve Stimulation on Pain, Xerostomia, Fatigue, Sleep, and Treatment-Related Symptoms in Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy: A Randomized, Single-Blind, Sham-Controlled Trial","phases":["NA"],"primary_completion":"2028-12-31","sponsor":"Tzu Chi University","start":"2026-07-13","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT","url":"https://clinicaltrials.gov/study/NCT07711626"},{"conditions":["Sebaceous Gland Carcinoma"],"countries":["China"],"enrollment":25,"has_results":false,"interventions":["DRUG: Sintilimab","DRUG: disitamab vedotin"],"names_myoepithelial":false,"names_skin_adnexal":true,"nct_id":"NCT07740993","official_title":"A Single-Arm, Prospective Clinical Study of Sintilimab Combined With Disitamab Vedotin as Neoadjuvant Therapy for Locally Advanced Eyelid Sebaceous Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2027-10-01","sponsor":"West China Hospital","start":"2026-08-01","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT07740993"},{"conditions":["NSCLC Patients With EGFR Activating Mutation","Adenoid Cystic Carcinoma Metastatic","Adenoid Cystic Carcinoma of the Head and Neck"],"countries":["India"],"enrollment":30,"has_results":false,"interventions":["DRUG: JBI-778"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07755397","official_title":"A Phase 1, Multicenter, Open-Label, Dose-Escalation/Consolidation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Orally Administered JBI-778 in EGFR Mutated Lung Cancer Patients With or Without Brain Metastasis, Isocitrate Dehydrogenase (IDH) Mutated WHO Grade 3/4 Recurrent Glioma and Adenoid Cystic Carcinoma (ACC)","phases":["PHASE1"],"primary_completion":"2028-03","sponsor":"Jubilant Therapeutics India Limited","start":"2024-08-26","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor","url":"https://clinicaltrials.gov/study/NCT07755397"},{"conditions":["Adnexal Masses"],"countries":["Italy"],"enrollment":12000,"has_results":false,"interventions":[],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07793201","official_title":"Machine Learning Algorithms Incorporating Radiomic Ultrasound Features for Clinical Precision in Diagnosing Adnexal Tumors and Optimizing Patient Management: a Multicenter IOTA Study","phases":[],"primary_completion":"2028-01","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","start":"2026-09","status":"NOT_YET_RECRUITING","study_type":"OBSERVATIONAL","title":"Machine Learning Algorithms Incorporating Radiomic Ultrasound Features","url":"https://clinicaltrials.gov/study/NCT07793201"},{"conditions":["Xerostomia","Head and Neck Squamous Cell Carcinoma"],"countries":["United States"],"enrollment":10,"has_results":false,"interventions":["DRUG: Dexamethasone 4mg/mL","DRUG: Dexamethasone 10mg/mL"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07802977","official_title":"Intraglandular Salivary Corticosteroid Injections to Prevent Radiation-Induced Xerostomia: A Pilot Study","phases":["PHASE1"],"primary_completion":"2022-07-30","sponsor":"University of California, Davis","start":"2020-07-02","status":"COMPLETED","study_type":"INTERVENTIONAL","title":"Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia","url":"https://clinicaltrials.gov/study/NCT07802977"},{"conditions":["Parotid Neoplasm","Bupivacaine","Dexamethasone"],"countries":["France"],"enrollment":10,"has_results":false,"interventions":["DRUG: Intraparotid injection of bupivacaine/ dexamethasone"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07812259","official_title":"Evaluation of the Clinical Tolerance of an Intraparotid Injection of Bupivacaine, Combined With Dexamethasone, After Parotidectomy for Benign Tumor - A Single-center Prospective Cohort Study.","phases":["EARLY_PHASE1"],"primary_completion":"2027-06","sponsor":"Centre Hospitalier Universitaire de Nīmes","start":"2026-05-18","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Clinical Tolerance of an Intraparotid Injection of Bupivacaine, Combined With Dexamethasone, After Parotidectomy for Benign Tumor","url":"https://clinicaltrials.gov/study/NCT07812259"},{"conditions":["Salivary Gland Carcinoma"],"countries":["China"],"enrollment":36,"has_results":false,"interventions":["DRUG: abiraterone combined with dalpiciclib"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07815522","official_title":"A Prospective, Open-Label, Single-Arm, Phase II Clinical Study of Abiraterone Combined With Dalpiciclib in Patients With HER-2-Negative, AR-Positive Recurrent/Metastatic Salivary Gland Carcinoma","phases":["PHASE2"],"primary_completion":"2028-10-01","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","start":"2026-10-01","status":"RECRUITING","study_type":"INTERVENTIONAL","title":"Abiraterone With Dalpiciclib in Salivary Gland Carcinoma","url":"https://clinicaltrials.gov/study/NCT07815522"},{"conditions":["Oral Potentially Malignant Disorders","Oral Lichen Planus","Oral Leukoplakia","Oral Squamous Cell Carcinoma","Smoking"],"countries":["Egypt"],"enrollment":250,"has_results":false,"interventions":["DIAGNOSTIC_TEST: Salivary IL-8 and Serum IL-6 Measurement"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07915570","official_title":"Diagnostic Performance of Salivary Interleukin-8 and Serum Interleukin-6 for Oral Potentially Malignant Disorders: Effect Modification by Smoking Status - A Cross-Sectional Study","phases":[],"primary_completion":"2026-12-30","sponsor":"British University In Egypt","start":"2026-10-01","status":"RECRUITING","study_type":"OBSERVATIONAL","title":"Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers","url":"https://clinicaltrials.gov/study/NCT07915570"},{"conditions":["Salivary Gland Cancers","Adenoid Cystic Carcinoma of the Salivary Gland"],"countries":["Brazil"],"enrollment":64,"has_results":false,"interventions":["BIOLOGICAL: Sacituzumab Tirumotecan (Sac-TMT)"],"names_myoepithelial":false,"names_skin_adnexal":false,"nct_id":"NCT07928193","official_title":"Phase 2 Study of Sacituzumab Tirumotecan (Sac-TMT) in Salivary Gland Cancers - Saint-Tropez (LACOG 1824) Trial","phases":["PHASE2"],"primary_completion":"2030-04","sponsor":"Latin American Cooperative Oncology Group","start":"2027-03","status":"NOT_YET_RECRUITING","study_type":"INTERVENTIONAL","title":"Sac-TMT in Salivary Gland Cancers","url":"https://clinicaltrials.gov/study/NCT07928193"}]